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1 INTRODUCTION 
1.1 Targeted therapies in cancer treatment 
1.1.1 General considerations 
The treatment of cancer is one of the fastest approaching medical fields and subject to 
constant change. In 2015 alone, 20 new drugs were approved by the US Food and 
Drug Administration (FDA) for various cancer types, mostly addressing new 
therapeutic targets [1]. However, conventional cytotoxic drugs were, and still are in 
some indications, the backbone of cancer therapy. After a major breakthrough in the 
mid of the 20th century, where it could be shown that the combination of several 
cytotoxic drugs can be highly beneficial for the patient, chemotherapeutic regimens as 
we know them today were developed and further enhanced over the course of time [2]. 
While efficient in some patients, the outcome of chemotherapy can be highly variable. 
Due to their lack of specificity for tumor cells, cytotoxic drugs are usually associated 
with often severe adverse events (AE) [3]. A better understanding of carcinogenesis 
and tumor pathophysiology led to the development of several new classes of drugs 
which aimed to improve the major shortcomings of conventional chemotherapies. 
Despite their often highly different modes of action these new drugs are gathered under 
the term targeted therapy. 
Targeted therapy comprises all treatment approaches which aim to specifically 
intervene in defined processes related to carcinogenesis. Due to their higher 
specificity, those therapies should, in contrast to the conventional cytotoxic drugs, 
ideally increase efficacy and lower the risk of developing typical AE such as nausea, 
alopecia and myelosuppression [4]. Targeted therapies can be subdivided based on 
their mechanism or chemical and/or biological structure. The National Cancer Institute 
of the United States (NCI) defines the following categories: 
− Hormone therapies 
− Signal transduction inhibitors 
− Gene expression modulators 
− Apoptosis inducers 
− Angiogenesis inhibitors 
2  Introduction 
   
− Immunotherapies 
− Monoclonal antibodies that deliver toxic molecules 
The first drug labeled as targeted cancer therapy was the monoclonal antibody 
rituximab which selectively binds the CD20 antigen on the cell surface. Rituximab was 
approved in 1997 for patients with B-cell non-Hodgkin lymphoma no longer responding 
to any other treatment options [5]. 
In 2015, targeted therapies accounted for almost 50% of all cancer therapy costs 
worldwide [6]. An analysis in Germany, France, Italy, Spain and UK showed that 
between 500,000 and 600,000 patients were treated with targeted therapies of any 
kind at time of data acquisition (2014). This accounts for 32% of all cancer drugs used 
in the respective countries [7]. As shown in Figure 1.1, Germany is the leading country 
concerning the use of targeted therapies with a share of more than one third of all 
cancer treatments. Currently, over 80 substances associated with targeted therapy are 
approved by the FDA and European Medicine Agency (EMA), with more potential 
candidates currently in clinical trials [8].  
 
  
 
Fig. 1.1:  Results of the OncoView study by Cegedim Strategic Data [7]. 
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1.1.2 Angiogenesis inhibition 
One of the most promising mechanisms identified for potential drug targets was tumor 
angiogenesis. The therapeutic value of angiogenesis in cancer therapy was first 
mentioned by Judah Folkman in 1971 [9]. Angiogenesis is necessary for several 
physiological processes, such as wound healing or during pregnancy, but is also 
involved in disease development, e.g. ischemia, rheumatoid arthritis and cancer [10]. 
More precisely, angiogenesis is the process of sprouting new vessels from existing 
ones. Angiogenesis has to be differentiated from vasculogenesis, which describes the 
development of entirely new vessels from angioblasts or other progenitor cells, as it 
happens during embryogenesis (Figure 1.2) and intussusception. The latter is the term 
for vessels which are divided by endoluminal migration of endothelial cells resulting in 
two or more new vessels [11]. 
Similar mechanisms are triggered by a tumor once it reaches a critical size, usually 
about ≥ 2 mm. Up to this point, neoplasms are able to cover all nutritional needs by 
passive diffusion [11]. Thus, the main triggers for tumor induced angiogenesis are 
hypoxia and nutrient deficiency. By release of pro-angiogenic factors, such as vascular 
endothelial growth factor (VEGF), the tumor shifts the balance towards increased 
angiogenesis. This process is often referred to as the “angiogenic switch” [10,11]. In 
context of tumor-induced angiogenesis the term “vascular mimicry” was established: 
Tumor cells are able to differentiate into endothelial-like cells and can be part of 
existing vessels or form entirely new ones (Figure 1.2). However, tumor induced 
angiogenesis results in comparatively chaotic structures which often provide only 
irregular supply. In the worst case this can lead to necrosis in tumor areas with critical 
nutrient shortage over a certain period of time [10,11]. 
Angiogenesis is a multifactorial process with a high number of signaling pathways 
involved, of which some, like the mTOR or VEGF pathways, proved to be therapeutic 
targets. Naturally, targeting only isolated pathways or proteins, increases the risk for 
development of resistance to the respective therapies. Currently two main modes of 
resistance are discussed [12,13]: The concept of adaptive or evasive resistance 
describes the first mechanism, which is a direct reaction to the anti-angiogenic 
treatment as alternative signaling pathways are activated and more pro-angiogenic 
cells are recruited from the bone marrow. 
  
4  Introduction 
   
 
Furthermore, an increased tight pericyte count is observed, which can serve as 
protection for tumor blood vessels. A more aggressive migration of tumor cells in non-
tumor tissue can also be a result of inhibition of angiogenesis. The second mode of 
resistance describes the already existing indifference or non-responsiveness of a 
tumor to antiangiogenic drugs even before starting the treatment. Thus, the optimal 
combination and sequence of anti-angiogenic treatments are still under discussion and 
the basis of several studies [14,15]. 
 
The VEGF pathway 
The VEGF pathway is critically important to (tumor-) angiogenesis and a target of 
various drugs, including VEGF antibodies and tyrosine-kinase inhibitors (TKI). Most 
research has concentrated on this pathway. The most crucial receptors and their 
respective ligands are shown in Figure 1.3.  
Fig. 1.2: Different mechanism of sprouting angiogenesis and vasculogenesis [10]. 
EC = Endothelial cells, ECM = Extracellular matrix, EPC = Endothelial 
progenitor cells, MMP = Matrix metalloprotease, VEGF = Vascular 
endothelial growth factor, sVEGFR-2 = Soluble vascular endothelial 
growth factor receptor 
Introduction  5 
 
   
 
Signaling is mediated via different VEGF homologs which can be further subdivided in 
several isoforms. Depending on receptor specificity and affinity these growth factors 
trigger different effects. VEGF-A, which is often referred to as VEGF, is one of the most 
important ligands. In animal studies it could be shown that VEGF-A deficient mice are 
not capable of surviving due to its crucial role in angio- and vasculogenesis [16]. Angio- 
and vasculogenesis are mainly regulated via vascular endothelial growth factor 
receptor (VEGFR) -1 and -2 which are expressed ubiquitously on endothelial cells, with 
VEGFR-2 being the most common one. VEGFR-3 is primarily expressed in lymphatic 
endothelial cells. Hence, it serves as a mediator in lymphangiogenesis. In addition to 
the receptor tyrosine kinases VEGFR-1 to 3, neuropilin (NRP) -1 and -2 have been 
identified as co-receptors. These are highly specific for one isoform of VEGF (VEGF165) 
and can increase the affinity of VEGF to its other receptors [11,17].  
  
 
Fig. 1.3: VEGF receptor signaling pathway (modified from [17] and [18]). 
VEGF(R) = Vascular endothelial growth factor (receptor),  
NRP = Neuropilin 
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Effects mediated by VEGF through binding the respective receptors include increased 
vessel permeability, activation of endothelial cells, increased endothelial proliferation 
and endothelial invasion and migration [19]. Furthermore, it was shown that VEGF 
regulates blood pressure via promotion of NO-synthase expression and NO activity 
mainly via VEGFR-2 [20,21]. 
A key factor for VEGF expression is hypoxia. Hypoxia triggers the dimerization of 
hypoxia inducible factor-1 α and β (HIF-1) which results in an increased transcription 
of VEGF. HIF-1 originates from the so called “Von Hippel-Lindau” (VHL) tumor 
suppressor gene. VHL has a crucial role in renal cell carcinoma as patients with 
mutations in the VHL gene are likely to develop this malignancy (Section 1.2 and Figure 
1.4). Other important regulators include various oncogenes such as p53 or 
transcription factors [17]. 
 
 
  
 
Fig. 1.4: Effects of the VHL gene product on angiogenesis under normal conditions  
and in case of hypoxia (modified from [18]).  
HIF = Hypoxia-inducible factor, VHL = Von Hippel-Lindau, PDGF = Platelet-
derived growth factor, VEGF = Vascular endothelial growth factor 
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Soluble VEGF receptors 
Soluble forms of all three VEGF receptors have been identified, however their exact 
physiological function is not yet fully understood [22–24]. In general, these soluble 
receptors are able to bind VEGF and its variants to a comparable degree or with an 
even higher affinity as the membrane-bound forms. This led to the assumption that 
sVEGF receptors fulfill regulative tasks in angio- and lymphangiogenesis. Among all 
three soluble receptors sVEGFR-1 is the best investigated. It could be shown that it 
has crucial physiological roles in e.g. embryogenesis and corneal avascularity and is 
also involved in numerous pathological processes, such as the development of 
preeclampsia during pregnancy [25,26]. Interestingly, one of the main functions of the 
soluble isoform of VEGFR-2 seems to be the regulation of lymphangiogenesis as a 
splice variant is binding VEGF-C with a high affinity [27]. sVEGFR-2 has been 
investigated in various tumor entities regarding its role in cancer development and 
during angiogenesis. In this context, it was also observed that sVEGFR-2 plasma 
concentrations are downregulated as reaction to antiangiogenic therapies [24,28]. The 
important role of sVEGFR-3 in corneal alymphaticity suggests regulatory functions in 
lymphangiogenesis [29]. Similar to sVEGFR-2, sVEGFR-3 plasma concentrations 
decrease under antiangiogenic treatment and are therefore heavily investigated as 
potential biomarkers for therapies targeting the VEGF pathway [30–32]. 
 
Drugs targeting tumor angiogenesis 
In 2004, bevacizumab (Avastin®, Roche), the first drug in the class of angiogenesis 
inhibitors, was authorized by the FDA for treatment of colorectal cancer patients. 
Bevacizumab targets VEGF-A which is an important mediator in the VEGF pathway 
(as described above). However, bevacizumab is usually applied in addition to 
conventional cytotoxic drugs, depending on the indication [33]. A distinct feature of 
bevacizumab is an increased efficacy in glioblastoma patients when applied as single 
agent, which led to the approval for this indication in 2009 by the FDA [34]. In the years 
thereafter several drugs with different targets in the VEGF pathway were approved. 
One of the more important subclasses of antiangiogenic treatments are the multi-
tyrosine kinase inhibitors (TKI). While imatinib (Glivec®) is considered as the first TKI, 
the first drug specifically targeting VEGFR-1 and 2 was sorafenib (Nexavar®) in 2006 
[35,36]. Sorafenib was shortly followed by several other VEGF-specific TKI including 
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sunitinib and pazopanib, which are described in more detail later (Sections 1.1.3 and 
1.1.4). 
Another important class of angiogenesis inhibitors include the “mammalian target of 
rapamycin” (mTOR) -inhibitors everolimus (Afinitor®) and temsirolimus (Torisel®) [37]. 
The mTOR is a serine/threonine kinase with a crucial regulative role for cell growth, 
proliferation and also angiogenesis [38]. By inhibition of the mTOR complex 1 
(mTORC1) (Figure 1.7) the transcription and translation of several proteins important 
for cell proliferation is hindered. Of particular importance is the decreased translation 
of HIF-1α resulting in lower VEGF plasma levels and consequently to an impaired 
angiogenesis [38,39]. 
 
Adverse events associated with antiangiogenic treatment 
Whereas antiangiogenic agents in general have moderate toxicity compared to most 
conventional cytotoxic drugs, angiogenesis inhibition can still result in therapy-limiting 
adverse events.  
Hypertension is one of the most often reported adverse events under antiangiogenic 
treatment [40–43]. Mechanistically, increased blood pressure is a result of reduced 
vasodilatation as VEGF triggers the release of NO and prostaglandin I2 (PGI2) under 
normal conditions. Additionally an effect on baroreceptors is discussed since it could 
be shown in animal experiments that an infusion with VEGF reduces the relevant 
signaling pathways resulting in a decreased blood pressure. However, the mechanism 
of this effect is still unknown. A long-term consequence of angiogenesis inhibition is 
the density reduction of smaller vessels and capillaries (“rarefaction”) which can also 
lead to hypertension due to increased vascular resistance [44]. In a more recent study 
in patients treated with sunitinib, increased levels of the highly potent vasoconstrictor 
endothelin-1 were observed, which may contribute to the increase of blood  
pressure [45]. 
Hematologic toxicity such as anemia, leukopenia or thrombocytopenia is commonly 
observed in sunitinib patients and, with a lower frequency, also in pazopanib and 
sorafenib treated patients [36,46,47]. The exact mechanism of these adverse events 
is not known. However, as VEGF receptors are commonly expressed on hematopoietic 
progenitor cells inhibition of these might prevent the maturation process [44,48]. 
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Kumar et al. investigated the different kinase selectivity of sunitinib, pazopanib and 
sorafenib with the result that the latter ones show a lower activity against the KIT (stem 
cell factor)-receptor (cKIT) and Fms-like tyrosine kinase 3 (FLT-3). As both receptors 
are factors in the genesis of hematopoietic cells, this might serve as an explanation for 
the frequency disparity [48]. 
Hypothyroidism was reported by various studies as a common adverse event under 
sunitinib treatment independent of tumor entity [49,50]. In a review from 2011 by Wolter 
et al. three prospective clinical trials in renal cell carcinoma (RCC) patients treated with 
pazopanib were evaluated with respect to reported hypothyroidism. Here, the 
incidence was comparably low with only 4% (26 of 578 patients) [51]. Similarly, other 
TKI, such as sorafenib, show also lower rates of thyroid dysfunction compared to 
sunitinib [52,53]. In a meta-analysis from 2014 12 studies with patients treated with 
sunitinib, axitinib or cediranib were investigated. However, no statistically significant 
difference between sunitinib and cediranib regarding hypothyroidism incidence was 
found. A comparison between axitinib and sunitinib was not possible due to low patient 
numbers in the axitinib group [54]. As a result, the mechanism of TKI-induced thyroid 
dysfunction was mainly investigated for sunitinib. Though, the mode of action of this 
adverse event is not yet fully understood, direct toxic effects of sunitinib leading to 
shrinkage of thyroid tissue are amongst the most popular theories [55]. 
 
1.1.3  Sunitinib 
Sunitinib was first authorized by the FDA and EMA in 2006 under the label Sutent® 
[46]. Initially, marketing authorization was granted for gastro-intestinal stroma tumors 
(GIST) as well as renal cell carcinomas. In a phase III study with 312 imatinib-resistant 
GIST patients it was shown that median time-to-progression (TTP) was significantly 
increased in patients treated with sunitinib (4 weeks on and 2 weeks off treatment) 
compared to placebo (26.6 weeks vs 6.4 weeks) [56]. Similar results were shown in 
the authorization study including 750 treatment-naïve patients with metastasized renal 
cell carcinoma (mRCC) receiving 50 mg sunitinib daily in a 4/2 schedule, with 4 weeks 
continuous dosing and two weeks off treatment. Median progression-free survival 
(PFS) was significantly increased compared to the standard treatment with interferon 
(IFN)-α (11.1 months vs 4.1 months) [57]. Since 2010 sunitinib is also approved for 
patients with non-resectable or metastasized pancreatic neuroendocrine tumors 
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(pNET) [46]. While in general more tolerated than conventional cytotoxic drugs 
sunitinib still may cause severe adverse events. As mentioned in Section 1.1.2 most 
common adverse events (1 in 10 patients) include, amongst others, hypertension, 
hypothyroidism, fatigue and myelosuppression [46]. 
Pharmacologically, sunitinib is an inhibitor of several receptor-tyrosine kinases which 
are associated with angiogenesis and the growth of metastases. Sunitinib inhibits 
platelet-derived growth factor (PDGF) receptor α and β, VEGF receptor 1-3, cKIT,  
FLT-3 receptor, colony stimulating factor 1 (CSF 1) receptor as well as the “rearranged 
during transfection” (RET) receptor [46,58]. 
 
 
As shown in Figure 1.5, sunitinib is primarily metabolized by cytochrome P450 3A4 
which leads to the active metabolite N-desethyl-sunitinib (SU12662). The metabolite 
shows similar pharmacodynamic and pharmacokinetic effects and is responsible for 
23 to 27% of total drug exposure. The volume of distribution is about 2230 L, the 
elimination half-life approximately 40 to 60 h for sunitinib and 80 to 110 h for the active 
metabolite. Plasma protein binding is reported with 95% for sunitinib and 90% for 
 
Fig. 1.5: Chemical structure of sunitinib and its active metabolite SU12662 with 
molecular weights. Sunitinib is a pyrrole class tyrosine kinase inhibitors. 
SU12662 is formed by oxidative elimination of one ethyl group. 
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SU12662, respectively. With 50 to 72% feces is the main route of excretion for 
sunitinib, while up to 20% can be found in urine [46,59]. 
As mentioned above, sunitinib is usually administered once daily in cycles of 6 weeks 
with 4 weeks on and 2 weeks off treatment. Depending on the indication the dose 
varies between 25 and 50 mg daily [46]. Although other regimens such as a 2/1 or 
continuous treatments were tested in smaller studies, there is still no evidence of a 
superiority compared to the standard schedule. However, Kalra et al. pointed out that 
no valuable studies which directly compared different schedules except a comparison 
between the classical 4/2 scheme and continuously dosing are available. Here, only a 
small benefit with respect to toxicity could be observed [60]. 
 
1.1.4 Pazopanib 
Marketing authorization for pazopanib was granted in the United States in 2009 
followed by a European-wide approval by the EMA in 2010. Besides first-line therapy 
for advanced RCC pazopanib is also indicated in soft tissue sarcomas [47]. In the 
authorization study for mRCC with 435 patients it could be shown, that pazopanib 
improved progression-free survival compared to placebo significantly (median PFS: 
9.2 vs 4.2 months) when applied in a dose of 800 mg continuously. Furthermore, a 
subgroup analysis revealed, that also patients pretreated with cytokines can benefit 
compared to placebo (median PFS: 7.4 vs 4.2 months) [61]. For pretreated metastatic 
soft-tissue sarcoma, 372 patients randomized to a pazopanib and a placebo group 
were compared in a phase III trial. Median PFS was significantly higher under daily 
administration of 800 mg pazopanib compared to placebo (median PFS: 4.6 vs 1.6 
months) [62]. Most common adverse events under pazopanib treatment include 
hypertension, myelosuppression and fatigue [47]. 
The pharmacological properties of pazopanib are comparable with sunitinib: as an oral 
multi-tyrosine kinase inhibitor pazopanib targets VEGF receptor -1, -2 and -3, PDGFR-
α and -β as well as c-KIT. 
Pazopanib is primarily metabolized by CYP3A4 and partly by CYP1A2 and CYP2C8. 
There are 4 metabolites which only contribute for 6% of the overall exposure. In-vivo 
binding to human plasma proteins is higher than 99% which results in a low volume of 
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distribution. Excretion is primarily via feces with renal elimination accounting for only  
< 4%. The elimination half-life is stated with 30.9 h [47,59]. 
Oral absorption of pazopanib is most likely limited by solubility as doses above 800 mg 
do not lead to a proportional increase in steady-state concentrations [63]. However, it 
was shown that crushing the tablet before administration can increase rate and extent 
of absorption [64]. Furthermore, pazopanib bioavailability is dependent on food intake: 
compared to fasted state fed condition increases the area under the plasma 
concentration-time curve (AUC) and the maximum observed plasma concentration 
(Cmax) by almost two-fold. A difference between high or low-fat meals was not observed 
[65]. 
In contrast to sunitinib the normal dosing schedule does not include a treatment-free 
interval and it is applied continuously in doses ranging between 400 mg and 800 mg 
on a daily basis [47]. The chemical structure of pazopanib is shown in Figure 1.6. 
 
 
1.2 Metastasized renal cell carcinoma  
1.2.1 Definition and classification 
Kidney cancer of any type is currently the 12th most common cancer worldwide with 
337 860 new cases in 2012 [66]. Renal cell carcinomas (RCC) account for over 90% 
of all renal malignancies [67]. However, incidences highly vary between gender and 
age groups. Of all new cases in 2012 46.8% were registered in patients above 65 years 
[66]. When considering genders separately males are more affected than females at a 
ratio of almost 2:1 (63.3% vs 36.7%). Furthermore, differences between nations and 
ethnicities can be observed, as most cases occur in well-developed countries, mainly 
North America and Europe. This is in accordance with life-style related risk factors, 
 
Fig. 1.6: Chemical structure of pazopanib with molecular weight.  
Pazopanib belongs to the pyrimidine class tyrosine kinase inhibitors. 
Introduction  13 
 
   
which include, amongst others, obesity, smoking and hypertension [67–69]. Beside 
these extrinsic aspects, several hereditary and genetic risk factors have been identified 
[69]. 
The World Health Organization (WHO) classification of RCCs differentiates between 
numerous histological subtypes [70]: most common are clear-cell, papillary and 
chromophobe entities. Clear cell carcinomas (ccRCC) account for the majority of all 
RCCs (70 – 80%). Usually ccRCC arise sporadic, though genetic dispositions such as 
the VHL disease can trigger the development of carcinomas (Figure 1.4). As a 
consequence the incidence of certain tumor types is increased in these patients. 
Seemingly VHL plays also an important role in non-hereditary malignancies as 18-82% 
of all sporadic ccRCC show somatic mutations in the VHL gene [71]. 
Beside pathological differences, the defined RCC subtype provides value as 
prognostic marker. Patients diagnosed with ccRCC seem to have a significantly worse 
prognosis compared to the other two subtypes [18,67,71].  
 
1.2.2 Treatment options 
Localized renal cell carcinomas are best treated with surgical interventions. The 
newest guideline suggests that nephron-sparing surgeries provide the same benefit for 
the patients as radical nephrectomies. However, in mRCC cytoreductive surgeries are 
no longer curative and have, in most cases, only palliative use [67,68]. 
Conventional chemotherapies show only moderate to no effect in mRCC patients. The 
only agent of this category which is still mentioned in the guidelines is fluorouracil in 
combination with interleukin-2. Until the first antiangiogenic treatments emerged, 
immunotherapy using interferon-α or interleukin-2 was the gold standard. Nowadays 
these agents are rarely used, as the risk-benefit balance and response rates are worse 
than those of modern targeted therapy. The decision which agent to use as initial 
treatment was usually based on the so called Memorial Sloan Kettering Cancer Center 
(MSKCC) score, which includes the Karnofsky performance score, hemoglobin, 
calcium (corrected), time of diagnosis until first-line therapy and LDH [67,68]. As this 
score was developed when patients were treated mainly with immunotherapy, a 
validated score was needed for the newer targeted agents. This is available with the 
Heng Score [72]. A comparison of both scores is shown in Table 1.1.  
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Tab. 1.1:  Comparison between MSKCC and Heng Score [73] 
MSKCC Score Heng Score 
− Karnofsky-Score < 80% − Karnofsky-Score < 80% 
− Hemoglobin < reference value − Hemoglobin < reference value 
− Calcium1 > 10 mg/dL − Calcium* > 10 mg/dL 
− Time from diagnosis to therapy < 
12 month 
− Time from diagnosis to therapy < 
12 month 
− LDH > 1.5 fold increase 
compared to reference value 
− Neutrophilic granulocytes > 
reference value 
 − Thrombocytes > reference value 
1Corrected for serum albumin 
Each risk factor accounts for one point, if the criteria is fulfilled. Dependent on the 
number of points the patient can be assigned to a risk group: favorable (0 points), 
intermediate (1-2 points) or poor (3-6 points). This stratification is then used for therapy 
choice.  
Second- and third-line therapies are then chosen based on the previous treatment 
option. For instance, patients who received a TKI as first-line therapy are usually 
treated with nivolumab or cabozantinib. Second choice are the TKIs axitinib and 
sorafenib as well as the mTOR inhibitor everolimus. On the other hand a first-line 
therapy with immunological agents qualifies for a second-line with the TKIs axitinib, 
sorafenib or pazopanib. An overview of the respective targets of all relevant targeted 
agents is given in Figure 1.7. 
 
Pazopanib versus Sunitinib 
Both agents are indicated for first-line therapy of mRCC and their efficacy seems to be 
largely equivalent. In a phase IV study with 1110 clear cell mRCC patients it was shown 
that PFS was comparable between both drugs when administered in their standard 
regimen and that pazopanib is non-inferior to sunitinib (Hazard ratio (HR): 1.05; 
Confidence interval (CI) 90%: 0.9 – 1.22). With respect to adverse events pazopanib 
proved to be superior to sunitinib with lower incidences of fatigue (63% vs 55%), hand-
foot syndrome (50% vs 29%) and thrombocytopenia (78% vs 41%) [74]. The so called 
PISCES study investigated patient-reported outcomes in a double-blind, cross-over 
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approach using health-related quality of life as endpoint. Patients were either treated 
with pazopanib or sunitinib for 10 weeks followed by a two weeks wash-out period and 
the switched consecutive treatment for another 10 weeks. In the final intention-to-treat 
analysis 114 of 169 initially recruited mRCC patients were considered. Here, 70% 
preferred pazopanib over sunitinib. Patients’ preference was mainly influenced by a 
higher overall quality of life and decreased incidence of adverse events in the 
pazopanib group [75]. 
 
 
1.3 Biomarkers 
1.3.1 Definitions and general considerations 
According to the NCI a biomarker is defined as “a biological molecule found in blood, 
other body fluids, or tissues that is a sign of a normal or abnormal process, or condition 
or disease. A biomarker may be used to see how well the body responds to a treatment 
 
Fig. 1.7: Relevant therapeutic pathways and targets in renal cell carcinoma  
(modified from [18]).  
HIF = Hypoxia inducible factor, VHL = Von Hippel-Lindau, PDGF(R) = 
Platelet derived growth factor (receptor), VEGF(R) = Vascular endothelial 
growth factor (receptor) 
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for a disease or condition.” [4]. The “Biomarkers Definitions Working Group” provides 
a slightly broader definition and includes all objectively quantifiable characteristics 
which can be used as “an indicator of normal biological processes, pathogenic 
processes, or pharmacological responses to a therapeutic intervention” [76].  
Medical biomarkers can be further categorized depending on the type of application. 
A diagnostic biomarker is used for a more detailed diagnosis and discrimination of 
subtypes of a specific disease e.g. a tumor types. Prognostic biomarkers provide 
information on the outcome of a disease independent of treatment, while a predictive 
marker is usually used to estimate the therapy outcome for a patient [76]. Under certain 
circumstances biomarkers can serve as surrogate for clinical endpoints. Per definition 
all surrogate endpoints are biomarkers, but not all biomarkers are surrogate endpoints. 
A surrogate endpoint is therefore a biomarker allowing to draw conclusions on a clinical 
endpoint e.g. survival [4,76]. Surrogate endpoints are of great value for clinical drug 
development as they often allow faster approval and reduced time and cost expenses. 
Between 2008 and 2012, 56 cancer drugs were approved by the FDA with 36 (67%) 
using a surrogate endpoint in the authorization studies [77]. 
 
1.3.2 Biomarkers for cancer treatments 
While targeted drugs are a major improvement over the previously used cytotoxic 
therapies, the decision which agent or dose might provide the most benefit for the 
individual patient is still mostly based on empirical knowledge. Up to now there are only 
few valuable objective methods to differentiate non-responders from responders for 
certain targeted therapies. Hence, considerable effort has been put in the search for 
predictive biomarkers. Of particular interest is the genetic profile of the patient and the 
tumor. 
Pharmacogenetics and pharmacogenomics are often interchangeably used as there is 
no universally accepted definition; however, the term pharmacogenetics is mostly 
applied to describe the differences in drug effects among individual patients with 
respect to the presence of different gene variants in form of single nucleotide 
polymorphisms (SNPs). In contrast, the focus of pharmacogenomics is the so called 
compound variability. Particularly, this means the investigation of drug effects on gene 
expression and their usage for drug discovery [78]. Currently, there are only few 
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examples for pharmacogenetically-guided therapy decisions in cancer treatment, the 
most prominent one being the monoclonal antibody trastuzumab (Herceptin®, Roche). 
Trastuzumab is directed against the human epidermal growth factor receptor 2 (HER2) 
and highly effective in breast cancer patients with a HER2 overexpression in 
combination with chemotherapy. Hence, determination of the HER2 genotype prior to 
therapy start is obligatory [79,80]. At present, the FDA lists 204 drugs with 
pharmacogenetics biomarkers in drug labeling with 71 only in the field of oncology. 
However, most recommendations are not required and only optional which potentially 
hinders the implementation in clinical practice [81]. 
Beside genetic biomarkers, pharmacokinetic disposition (Section 1.4.3) or 
pharmacodynamic response to a drug are investigated for their predictive potential for 
efficacy or toxicity. In case of TKI there is already a wide spectrum of possible 
biomarkers. Most of them can be considered as TKI class effects which were or 
currently are investigated in various tumor types for their predictive performance. For 
instance, the plasma concentrations of sVEGFR-2 and -3, circulating endothelial cells 
and the increase of blood pressure which would all fulfill the criteria as easy-to-
measure surrogates for efficacy or toxicity [28,82,83]. However, despite some 
promising results there is still no biomarker of this kind recommended for any 
angiogenesis inhibitor [67,68,81]. 
 
1.4 Pharmacometrics 
1.4.1 General considerations 
Pharmacometrics is an interdisciplinary field combining aspects of pharmacology with 
statistics and computer sciences. General aim of this discipline is to quantify the 
pharmacological response of a drug and to use the resulting mathematical models for 
further exploration and extrapolation [84]. Originally, pharmacometrics developed from 
the field of pharmacokinetics (PK) which can now be seen as the “fundament” of 
pharmacometric research. Pharmacokinetics itself deals with all processes involved in 
the fate of a drug once it is administered. These are often referred as LADME which is 
the abbreviation for Liberation, Absorption, Distribution, Metabolism and Excretion. In 
lay terms, this is explained as “what the body does to the drug” whereas 
pharmacodynamics (PD) describes “what the drug does to the body”. Pharmacokinetic 
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research usually consists of the analysis of plasma concentration-time data of a drug. 
Here, two basic methods can be used. In case of dense sampling, thus many 
informative data points, a non-compartmental analysis (NCA) is a feasible approach. 
In essence, a NCA is a statistical evaluation of the data without any prior assumptions. 
This allows the calculation of important pharmacokinetic parameters such as AUC, 
Cmax and the drugs half-life [85]. However, if not enough data points are available this 
method becomes unreliable. Alternatively, a model-based analysis can be conducted. 
By choosing a mathematical model to describe the underlying data it is possible to 
generate reliable estimates of key pharmacokinetic parameters [84–86]. Similar 
principles apply for pharmacodynamic data analysis. Whereas a model-independent 
approach is also possible, model-based evaluations are far more common with often 
classical linear or Emax models as basis for dose-response relationships [85]. 
 
 
However, these methods are limited to single or small cohorts of patients as each 
individual has to be evaluated separately. To overcome this limitation, population 
PK/PD is a common approach to analyze large patient groups and quantify inter-
individual differences (Section 1.4.2). Another field that evolved from basic 
pharmacokinetics is the so called physiologically-based pharmacokinetics (PBPK). In 
contrast to population pharmacokinetics, where an appropriate model is chosen based 
 
Fig. 1.8: General implementation of pharmacometric approaches in drug 
development. 
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on the underlying data, PBPK models feature important physiological processes and 
include the physicochemical properties of the drug. Therefore PBPK is referred to as 
a “bottom-up” approach, while population PK/PD is a “top-down” analysis [87]. The 
general concept of pharmacometric analyses in drug development is presented in 
Figure 1.8. 
 
1.4.2 Principles of population pharmacokinetics and –dynamics 
The term population pharmacokinetics was originally established by Lewis Sheiner and 
Stuart Beal who are considered as pioneers in this field. The software package 
NONMEM® which they originally developed (Non-linear Mixed Effects modeling) is still 
the gold standard for population analysis pharmaceutical industry and academia [88]. 
A detailed methodological description can be found in Section 3.8.1. 
Classical methods to cope with population pharmacokinetic data comprise the naïve 
pooling as well as the two-stage approach. Naïve pooling is the simplest method of, 
but also the least preferable, since the individual data from all patients is pooled and 
analyzed in one step. The result is a mean response without taking variability among 
patients into account. This method can be useful when the overall variability is small, 
for example in preclinical data from standardized animals [84]. The two-stage approach 
uses the individual estimates from each patient to calculate population parameters. In 
the first stage a pharmacokinetic model of choice is fitted to each individual’s data. 
From these data a population mean as well as a variance can be calculated for each 
parameter [84]. 
With non-linear mixed effects (NLME) models it is possible to analyze all patients in 
one step and to obtain mean population estimates of the PK/PD parameters of interest 
as well as the variability. This allows the evaluation of large data sets with sparse 
sampling without relying on separate individual estimations for each patient [86,89]. 
Population PK/PD models are not only useful for descriptive analyses, but may also 
allow extrapolation based on the underlying data to investigate e.g. dosing regimens 
which were not part of the original study. By linking PK/PD models with models for 
clinical outcome it is further possible to simulate whole clinical trials and use the results 
as guidance for study planning. This so called “model-informed drug development” can 
be applied to every phase of clinical (or pre-clinical) drug development and is gaining 
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importance in pharmaceutical industry [90,91]. Moreover, population PK/PD models 
can serve as basis for dose individualization and help identifying clinically relevant 
influential factors on PK and PD. 
 
1.4.3 PK/PD dose individualization in oncology 
The NCI defines personalized medicine as “a form of medicine that uses information 
about a person’s genes, proteins, and environment to prevent, diagnose, and treat 
disease. In cancer, personalized medicine uses specific information about a person’s 
tumor to help diagnose, plan treatment, find out how well treatment is working, or make 
a prognosis” [4]. Hence, dose individualization can be considered as a part of 
personalized treatment, as the best drug from a therapeutic perspective needs to be 
adapted to the inter-individual differences in pharmacokinetic and pharmacodynamic 
response of a patient. 
For dose individualization it is therefore possible to target a pharmacokinetic parameter 
correlating with pharmacodynamics or, if feasible, by using a pharmacodynamic 
parameter. 
 
Therapeutic drug monitoring 
The term therapeutic drug monitoring (TDM) refers to a specific method of 
pharmacokinetic dose individualization. Here, the dose is adapted based on a 
pharmacokinetic target quantifying drug exposure in the patient, e.g. the plasma 
concentration or the area under the concentration-time curve (AUC) of a specific drug. 
More precisely, TDM is a pharmacokinetic dose adaption with feedback mechanism, 
as the target parameter is controlled in defined intervals over the course of the therapy. 
This allows a precise correction of the dose if needed. To keep the additional burden 
for the patients to a minimum only very few samples are collected for dose calculation 
[92]. This is possible due to the use of the so called Bayes method of conditional 
probability, which is implemented in almost all modern TDM software programs and is 
described in more detail in Section 3.8.4 [93]. Particularly, this means an existing 
pharmacokinetic model with known mean response and known variability is used to 
estimate individual parameters under the condition of a given pharmacokinetic target 
like the plasma concentration of the respective drug and other influential factors. The 
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individual parameters can then be used to simulate concentration-profiles and to 
optimize dose strength and interval. 
As this method is quite costly and time-consuming, it is not viable for all drugs. Major 
requirements include a known quantitative relationship between pharmacokinetics and 
-dynamics, a narrow therapeutic index and a high inter- and intraindividual  
variability [94]. 
 
Applications in oncology  
While the criteria for PK/PD dosing, more precisely TDM, are fulfilled by a lot of 
anticancer drugs, it is not a commonly used approach in oncology [95,96]. Although it 
has already been proved to have a weak correlation in most cases, body surface area 
(BSA) is still one of the most used parameters for dose adjustment of cytotoxic drugs. 
However, only 30% of inter-individual variability can be explained by BSA [3]. 
Prominent examples of anticancer drugs where pharmacokinetic methods for dose 
adaptations are used include carboplatin and fluorouracil (5-FU). For carboplatin an 
empirical formula can be used for dose calculation which relies on the estimated 
creatinine clearance and a defined target AUC [97]. However, the platinum plasma 
concentration or AUC is usually not measured to control for an adequate dosing so 
that the feedback control of a TDM is missing. 5-FU is applied via continuous infusion. 
Because of the short elimination half-life of 10 to 20 minutes, the AUC can be 
calculated with a simple formula, often referred to as “rectangle” – equation due to the 
shape of the concentration-time curve of 5-FU. Based on predefined algorithms a 
percentage dose increase or decrease can be chosen with respect to the calculated 
AUC value [98]. Despite some promising results, a TDM for 5-FU is usually not 
performed in clinical practice.  
Modern targeted therapies are usually applied in fixed dose regimens with adaptions 
mostly based on the occurrence of certain adverse events. However, TKIs show large 
inter-individual variation in PK/PD parameters [59,96]. In addition, oral administration 
introduces several complications such as additional drug-drug or drug-food 
interactions, e.g. observed for pazopanib and sorafenib with increased drug exposure 
when taken after a meal. Oral therapies are also potentially prone to poor adherence, 
which is known from other medical fields, and can also be observed in targeted cancer 
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therapies [96,99]. Recent reviews summarized potential reasons for non-adherence in 
oral cancer therapies: among others the incidence of adverse events as well as 
duration of therapy were mentioned as crucial [100,101]. Both factors may be reduced 
with optimized and individualized treatments. 
 
1.5 Outcome analysis 
1.5.1 Survival analysis 
Main purpose of every cancer treatment is to maximize the survival of the patient while 
maintaining a certain degree of quality of life. In general, survival analysis in oncology 
differentiates between two types of clinical endpoint: overall survival (OS) and 
progression-free survival (PFS). OS comprises the period from treatment start until the 
patient’s death regardless of the cause. In contrast, PFS includes the time until disease 
progression [4]. PFS is often used as main endpoint, especially in pivotal phase III 
studies, as it allows shorter observation times and is usually a good predictor for OS 
[99]. Furthermore, with the emergence of sequential therapies in almost all fields of 
oncology, the value a drug cannot be assessed by the OS when second and third-line 
therapies may vary among patients [102]. 
One classical and common non-parametric method is the Kaplan-Meier analysis, 
which was already developed in 1958 by two biostatisticians Edward Kaplan and Paul 
Meier. The Kaplan-Meier analysis solves a problem which is frequent in survival data: 
patients dropping out of the study or undefined reasons before the endpoint or the end 
of the study is achieved, so called right-censored data [103]. The patients affected are 
not removed from the analysis but included in the calculation of the results. Another 
important method was introduced by David Cox in 1972. While two or more groups can 
be compared with the Kaplan-Meier method using the log-rank test, it is not possible 
to test continuous or time-dependent influence factors. This was enabled by the Cox 
regression model allowing the calculation of the probability per time unit that an event 
occurs in a patient using the so-called hazard function [103]. Model-based time-to-
event (TTE) analysis can be considered as the evolution of the Cox regression model. 
By linking PK/PD models with an outcome model it is possible to quantify the effects 
of a therapeutic intervention and to estimate their variability [104]. Ideally, such a model 
can be used to simulate clinical set-ups of interest or do discriminate between 
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responders or non-responders (see Section 3.11. for a more detailed description of the 
methodology). 
 
1.5.2 Toxicity analysis 
Management of toxic effects caused by anticancer treatments has always been one 
key intervention to the success of a therapy. In the worst case, adverse events can 
lead to therapy failure and, depending on severity, cause permanent damage or death. 
However, the strength of an adverse event is not easily determined, especially when 
no objective parameter, e.g. laboratory values, can be measured or the patients 
themselves have to rate it based on scales or questionnaires. In most cases this 
automatically leads to a bias either introduced by the physician or the patient. In 
oncology, toxicity is evaluated by the so called Common Terminology Criteria for 
Adverse Events (CTCAE) [105]. This scale orders toxicity into five categories ranging 
from grade 1 (mild) to grade 5 (death). A more detailed description of all grades is 
presented in Table 1.2. 
 
 
While grading allows a better comparability across patients it is also associated with a 
loss of information. This is of particular importance, when the grade of an adverse 
event is included in the dose adaption algorithm as it has been tested for 5-FU [98]. 
Similar to model-based survival analysis, models for adverse events can help to 
quantify the relationship between drug exposition and toxic response, and to identify 
influential factors across populations. Although this is possible by analogous TTE 
approaches, where an event is defined as the occurrence of an adverse event, semi-
mechanistic models are more common. A good example is the model for 
Tab 1.2:  Toxicity grades according to CTCAE v 4.03 [105] 
Grade Description 
1 Mild; asymptomatic or mild symptoms 
2 Moderate; minimal, local or noninvasive intervention indicated 
3 Severe or medically significant but not immediately life-threatening 
4 Life threatening consequences  
5 Death related to adverse events 
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chemotherapy-induced myelosuppression allowing a prediction of the extent of 
myelosuppression independent of the drug used [106]. As the authors stated this 
model could be used for either drug development or to determine the effect of different 
dosage strategies (Figure 1.9). 
 
 
While this approach is highly informative, it is not applicable for all types of toxicity as 
either the required data is not available or, as stated above, no objectively quantifiable 
parameter exists. Hence, alternative methods are being approached. The most 
promising is the use of Markov models which is already established in other fields of 
science. Markov models can make use of categorical data by estimating the probability 
of developing an adverse event of a certain CTCAE grade based on the current state 
(see Section 3.11.4. for a more detailed description of the methodology). One of the 
first pharmacometric applications of Markov models was performed by Karlsson et al., 
who modeled the probability of different sleep states during temazepam therapy [107]. 
In a more recent investigation Markov models have been successfully integrated in a 
modeling framework for lung cancer patients treated with erlotinib [108]. 
Fig. 1.9.: Semi-mechanistic model for chemotherapy-induced myelosuppression 
by Friberg et al. (modified from [106]). Compartments represent the 
different states of neutrophils: Drug effect and a feedback effect regulate 
cell proliferation. 
PROL = proliferating cells, CIRC = circulating cells, TRANS = 
intermediate progenitor cells, ktr, kprol, kcirc  = rate constants between 
different states.  
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2 AIMS AND OBJECTIVES 
Pharmacometric approaches have the potential to individualize and guide anticancer 
therapies. However, the multi-tyrosine kinase inhibitors (TKI) pazopanib and suntinib, 
which are common first-line therapies in patients with metastasized renal cell 
carcinoma (mRCC), are still applied in fixed-dose regimens. Thus, the inter-individual 
variability of drug exposure may be responsible for differences in response or toxicity. 
The development of more rational dosing strategies based on pharmacokinetic and 
pharmacodynamic (PK/PD) models is therefore a promising strategy to optimize 
mRCC treatment. 
Aim of this work was to develop pharmacometric models for sunitinib and pazopanib 
and to integrate them into a greater modeling framework for mRCC patients (Figure 
2.1). Pharmacokinetics of both TKIs were linked to a pharmacodynamic response such 
as plasma concentration of sVEGFR-2, sVEGFR-3 or blood pressure. In a final step 
the established models were linked to models for clinical outcome, in particular 
progression-free survival and toxicity, to explore the potential relationships. 
Data for sunitinib-treated mCRC patients as well as healthy volunteers was already 
available from a previous study. Therefore, a first step was to generate similar data for 
mRCC patients. This was done within the EuroTARGET project, which aimed to 
identify predictive biomarkers in mRCC using a diverse range of state-of-the-art 
methods. 
In case of sunitinib, a pharmacokinetic model for the parent drug and its active 
metabolite SU12662, which was based on data from healthy volunteers by Lindauer et 
al. [109], served as basis for model development. This model was compared to another 
published semi-mechanistic model by Yu et al. [110]. For pazopanib, no internally 
developed model was available; hence a literature research was conducted to identify 
suitable pharmacokinetic models. The pharmacodynamic models for sVEGFR-2, 
sVEGFR-3 and blood pressure developed for healthy volunteers by Lindauer et al. 
were adapted to cancer patients and linked to the respective pharmacokinetic models. 
The developed models for both substances were then used to estimate individual 
pharmacokinetic and pharmacodynamic parameters. Based on these findings outcome 
models were established to explore the relationship between pharmacokinetics, 
biomarker response and the endpoints progression-free survival and toxicity. In 
26  Aims and objectives 
 
   
particular, a time-to-event (TTE) model was developed to describe the patients’ 
progression-free survival during first line-therapy with sunitinib or pazopanib, whereas 
toxicity was integrated into the modeling framework with a Markovian approach and, 
in case of blood pressure, with a semi-mechanistic model.  
 
 
Fig. 2.1: Scheme of a PK/PD modeling framework for sunitinib and pazopanib. 
Conc. = Concentration, PFS = Progression-free survival; sVEGFR = 
soluble vascular endothelial growth factor receptor 
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3 MATERIAL AND METHODS 
3.1 Materials 
Relevant material used for the underlying analytical methods as well as the technical 
equipment and software packages used for modeling and simulation activities is 
summarized in Tables 3.1. to 3.4. 
 
3.1.1 Chemical substances and reagents 
Tab. 3.1: ELISA Kits and related reagents 
Name Company 
Human VEGF R2/KDR Quantikine® ELISA Kit 
Catalog Number : SVR200 
R&D Systems, Minneapolis, 
USA 
Contains: 
− VEGF R2 Microplate 
− VEGF R2 Conjugate 
− VEGF R2 Standard 
− Assay Diluent RD1W 
− Cell Lysis Buffer 2 
− Calibrator Diluent RD6-31 
− Wash Buffer Concentrate 
− Color Reagent A (Hydrogen peroxide) 
− Color Reagent B (Tetramethylbenzidine) 
− Stop solution (N sulfuric acid) 
− Plate sealers 
 
Human sVEGF R3/Flt-4 DuoSet® ELISA 
Catalog Number: DY349 
R&D Systems, Minneapolis, 
USA 
Contains: 
− Capture Antibody 
− Detection Antibody 
− Standard sVEGF R3 (Flt-4) 
− Streptavidin-HRP 
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Tab. 3.1 continuation  
DuoSet® Ancillary Reagent Kit 2 
Catalog Number: DY008 
R&D Systems, Minneapolis, 
USA 
Contains: 
− ELISA Plate-Coating Buffer 
− Reagent Diluent Concentrate 2 
− Stop Solution 
− Color Reagent A (Hydrogen peroxide) 
− Color Reagent B (Tetramethylbenzidine) 
− Wash Buffer Concentrate 
− Clear Microplates 
− ELISA Plate Sealers 
 
CrossDown® Buffer Appli Chem, Darmstadt 
Fetal Calf Serum (FCD) Sigma-Aldrich, St. Louis, USA 
PURELAB® Plus Water ELGA Berkefeld GmbH 
Sodium Chloride (NaCl) - 
Potassium Chloride (KCl) - 
Biphasic Hydrated Sodium Phosphate 
(Na2HPO4) 
- 
Potassium Dihydrogen Phosphate (KH2PO4) - 
 
3.1.2 Solutions and Buffer 
Tab. 3.2: Overview on solutions and buffers used and their composition 
Constituent  
Phosphate buffered saline (PBS buffer) 
 137 mM NaCl 
 2.7 mM KCl 
 8.1 mM Na2HPO4 
 1.5 mM KH2PO4 
 PURELAB® Plus Water 
 pH 7.2 – 7.4  
 sterile-filtered with a 0.2 µm filter 
 
8.0 g 
0.2 g 
1.15 g 
0.204 g 
Ad 1000 mL 
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Tab. 3.2 continuation  
Reagent Diluent (1:10) 
 Reagent Diluent Concentrate 2 
 PURELAB® Plus Water 
 
1 P 
9 P 
  
Substrate Solution (1:1) 
 Color Reagent A 
 Color Reagent B 
 
1 P 
1 P 
Wash Buffer Dilution (1:25) 
 Wash Buffer Concentrate 
 PURELAB® Plus Water 
 
20 mL 
Ad 500 mL 
Capture Antibody Dilution - 
Detection Antibody Solution - 
Streptavidin-HRP - 
 
3.1.3 Consumables 
Tab. 3.3:  Consumables for one-time usage 
Name Company 
Sarstedt K-Monovetten® Sarstedt AG & Co, Nümbrecht 
Micro tubes 1.5 mL (lightprotected) Sarstedt AG & Co, Nümbrecht 
Pipettes and glass vessels - 
Pipette tips Greiner Labortechnik, 
Frickenhausen 
 
3.1.4 Technical Equipment 
Tab. 3.4:  Technical equipment used for drug and biomarker analysis 
Name Company 
Single-channel pipette E4 XLS 
(10 – 100 µL, 100 – 1000 µL) 
Mettler Toledo GmbH, Gießen 
Multi-channel pipette (12 channels) 
Transferpette® 
(10 – 100 µL, 30 – 300 µL) 
Brand GmbH & Co KG, 
Wertheim 
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Tab. 3.4 continuation  
accu-jet® pro pipette controller Brand GmbH & Co KG, 
Wertheim 
Vortex-Mixer ZXE3 Velp Scientifica srl, Usmate 
(MP), Italien 
Edmund Bühler® TH 15l Incubator Edmund Bühler GmbH Lab Tec, 
Hechingen 
Unimax® 1010 shaker Heidolph Instruments GmbH & 
Co KG, Schwabach 
Multiscan® EX Multiwellreader 
Quartz-Wolfram halogen lamp (450 nm, 570 nm) 
Thermo Electron Corporation, 
Vantaa, Finland 
 
3.1.5 Software 
Tab. 3.5:  Software used for modeling and associated tasks 
Name Company/Authors 
NONMEM® 7.3 Icon Development Solutions, Ellicott City, 
MD, USA 
Pearl-speaks-NONMEM® (PsN)  
v4.4.8 and beyond 
Mats Karlsson, Andrew Hooker, Rikard 
Nordgren, Kajsa Harling (2013-2015) 
Pirana® v2.9.1 and beyond Pirana Software & Consulting BV 2014 
R 
v3.2.3 and beyond  
R Foundation for Statistical Computing, 
Vienna, Austria 
Including the packages: 
 Xpose  
 Lattice 
 drc 
 reshape2 
 survival 
 coin 
 ggplot2 
 clinfun 
 
Niclas Jonsson, Mats Karlsson (2014) 
Deepayan Sarkar (2016) 
Christia Ritz, Jens C. Streibig (2016) 
Hadley Wickham (2016)  
Terry M. Therneau (2016) 
Torsten Hothorn (2008) 
Hadley Wickham (2009) 
Venkatraman E. Seshan (2016) 
Microsoft Excel® 2007 Microsoft Corporation, Redmond, USA 
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NONMEM® [88] was used for the pharmacokinetic and pharmacodynamic data 
analysis. Pearl-speaks-NONMEM® (PsN) served as an additional toolbox for 
computationally intensive statistical methods including bootstraps, visual predictive 
checks (VPC) and case deletion diagnostics (CDD) for model qualification as well as 
stepwise covariate analysis [111]. Pirana® is a user interface developed for NONMEM® 
and was used to simplify model and data management [112].  
Graphical analysis was primarily conducted using the statistical programming 
language R including various supplementary packages [113]. Xpose is a package 
specifically developed to process output from NONMEM and to generate plots for non-
linear mixed effects models, e.g. Goodness-of-fit (GOF) plots and VPCs [114]. Lattice 
and ggplot2 are packages for advanced graphics in R [115,116]. For dataset 
generation and management, the R package reshape2 as well as Microsoft Excel® 
were used dependent on the specific task [117,118]. The package drc was used for 
generating standard curves for the biomarker analytics and calculating the respective 
results [119] Survival analyses were conducted using the survival package together 
with the coin and clinfun packages for the permutation tests [120–122]. 
 
3.1.6 Hardware 
All modeling tasks were performed on an Intel i7® 4970 processor with 4 physical and 
4 theoretical threads (Hyperthreading) on a Windows 64-Bit platform. 
 
3.2 The EuroTARGET project 
3.2.1 Objectives 
EuroTARGET denotes for “European collaborative project on Targeted therapy in 
Renal cell cancer: Genetic and Tumor-related biomarkers for response and toxicity”. 
The general aim was to identify and characterize host- and tumor-related predictive 
biomarkers for response to targeted therapy in patients with metastasized renal cell 
carcinoma (mRCC). For this purpose several state-of-the-art approaches were 
combined to generate as much information as possible on host- and tumor-specific 
factors which could potentially be predictive for therapy outcome.  
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Hence, the main aim can be further divided into several objectives, where each work 
package contributed results with different approaches and methodology. A complete 
description of the work packages can be found in Section 3.2.2, Figure 3.1 and Table 
3.6. 
The following list comprises all project objectives ordered according to the study 
protocol without assigning them to specific work packages or project partners: 
− Create a standardized European clinical databank and bio-repository (germline 
DNA of all patients and serum and frozen tumor tissue of a subgroup) of a large 
series of patients with mRCC treated with different targeted agents. 
− Identify genetic markers for treatment response and toxicity by performing high-
resolution germline whole-genome profiling in patients treated with sunitinib or 
sorafenib 
− Identify exon and microRNA expression markers for treatment response and 
toxicity by gene expression profiling of tumors from patients with and without 
good response 
− Identify kinase activity profiles related to TKI response 
− Identify promoter hypermethylations markers in TKI response 
− Identify resulting protein profiles corresponding to genomic, epigenetic and 
expression alterations related to TKI response 
− Replicate all identified markers in independent patient series 
− Study the functional relevance of replicated markers/networks in vitro by knock-
out and knock-in transfection experiments 
− Identify differentially expressed proteins before and after knock-down/ 
upregulation of genes of interest 
− Identify plasma drug and metabolite levels as phenotype of results 
− Explore the possibility of individualizing dosage regimens by integrating 
biomarker concentration – time profiles into PK/PD models for sunitinib (and 
pazopanib) 
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− Conduct integrated bioinformatical analyses of the results obtained by all 
different approaches in order to maximize the probability to find new markers 
and to understand the interrelatedness between them 
− Construct new risk stratification criteria to be used for personalized mRCC 
patient management 
− Disseminate the new knowledge to medical oncologists, urologists and the 
scientific community 
 
3.2.2 Project design and duration 
The EuroTARGET project was designed as a European-wide non-interventional 
prospective cohort study with an overall duration of 5 years [123]. 
Based on their expertise, project partners were assigned to 12 different work packages 
with one partner taking supervision on all tasks of the respective package. An overview 
on all work packages, their main subjects and the responsible project partner can be 
found in Table 3.6. Focus of the underlying work were the results of work packages 2 
and 7 in a subcohort of the EuroTARGET study population which was additionally 
 
Fig. 3.1:  General concept of the EuroTARGET project. 
34  Material and methods 
 
   
monitored over a defined period during the first-line therapy with sunitinib or pazopanib 
(Section 3.3). Therefore, methods used in other work packages are not explained here 
in detail as it would be beyond the scope of this thesis. 
Design and methods of work packages 2 and 7 are addressed in the following 
paragraphs beginning with 3.3. 
 
WP = Work package  
Tab. 3.6:  Overview of EuroTARGET work packages 
WP Description Lead participant 
1 Retrospective and prospective 
collection of clinical data, genomic 
DNA and tumor tissue 
University of Cambridge 
2 Genetic profiling of mRCC patients Leiden University Medical Center 
3 Transcription profiling of tumor 
material from mRCC patients 
Radboud University Medical 
Center, Nijmegen 
4 Kinase activity profiling of mRCC PamGene, s-Hertogenbosch 
5 DNA methylation biomarkers of 
mRCC 
Bellvitge Biomedical Research 
Institute, Barcelona 
6 Functional studies University Hospital 
Homburg/Saar 
7 PK/PD studies (EuT-PK/PD 
substudy) 
University of Bonn 
8 Data management deCODE Genetics, Reykjavik 
9 Integrated data analysis Netherlands Cancer Institute, 
Amsterdam 
10 Dissemination and Training Central European Society for 
Anticancer Drug Research, 
Vienna 
11 Ethics Institut national de santé et de la 
recherché médicale, Paris 
12 Project Management Radboud University medical 
Center, Nijmegen 
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3.2.3 Patients 
Patients were applicable for the EuroTARGET project if they were 18 and above years 
old, newly diagnosed with metastatic renal cell carcinoma and did not receive a 
treatment for their metastatic disease. Furthermore, patients had to be able to 
understand the patient information and to give informed consent. Recruitment was 
conducted in Germany, Austria, Switzerland, The Netherlands, United Kingdom, 
Iceland and Romania. Although the study was planned as prospective study, 
retrospective inclusion of patients was also possible under the requirement that at least 
one blood sample was available for germline analysis.  
It was planned to include a total of 1100 patients. There was no intention to test a 
formal hypothesis. Hence, a sample size calculation was not conducted.  
 
3.2.4 Medication 
All possible targeted first-line therapies according to the recent guidelines for 
metastasized renal cell carcinoma were allowed. Since this study had a purely 
observational purpose, no dose or treatment recommendations were given. 
 
3.2.5 Sampling procedure 
Each patient was asked to donate 8-10 mL whole blood either collected in Lithium-
Heparin or EDTA tubes for germline analysis. Blood samples were then stored at  
-20°C or, preferably, -80°C until analysis. 
Tumor tissue was collected from each patient, if available. Fresh frozen tumor material 
stored at -80°C was preferable; however, paraffin blocks were also a valid option. All 
tumor samples were reviewed by a designated reference pathologist and then sent to 
the respective project partners for further analyses. 
 
3.2.6 Endpoints 
Progression-free survival (PFS) was chosen as primary endpoint with progression 
ideally defined with respect to the Response Evaluation Criteria In Solid Tumors 
(RECIST) [124]. Usually, the RECIST assessment is not part of the clinical routine; 
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hence, progression documented based on the treating physicians’ expert opinion was 
also viable when no RECIST information was available. 
Treatment toxicity was determined as secondary endpoint. Documentation was 
handled using the Common Terminology Criteria for Adverse events (CTCAE,v 4.03) 
[105]. Only adverse events with grade 3 or higher had to be captured in the electronic 
case report form (eCRF). However, low-grade toxicity could be documented indirectly, 
when it was the reason for a dose reduction of the drug. 
 
3.3 The EuroTARGET-PK/PD (EuT-PKPD) sub-study  
3.3.1 Objectives 
The EuT-PKPD study was designed as a sub-study of the EuroTARGET project and 
comprised the work packages 2 and 7. Main objective was to develop pharmacokinetic 
and pharmacodynamic models by linking sunitinib and pazopanib plasma 
concentrations with biomarker response, here, sVEGFR-2/3 plasma concentrations 
and blood pressure. The final PK/PD models were then used to analyze correlations 
between individual pharmacokinetic disposition, pharmacodynamic response and 
clinical outcome, in particular progression-free survival and therapy-related toxicity.  
In addition, several genotypes were preselected from the literature which have shown 
potential predictive performance or influence on pharmacokinetic, especially sunitinib, 
and pharmacodynamic parameters as well as outcome (Appendix A).  
 
3.3.2 Study design 
The study was conducted as a multi-centric, prospective, open-label, non-randomized 
single-arm phase IV trial. Unlike the main EuroTARGET project, it was not possible to 
keep this work package completely observational due to the legal requirements 
regarding the use of blood samples for pharmacokinetic analyses in Germany. 
Therefore, this work package was handled as a clinical phase IV study embedded in 
the overarching EuroTARGET project. As a consequence, all inclusion criteria for the 
observational EuroTARGET project also applied to sub-study patients in addition to 
the stricter criteria necessary for a phase IV study. To avoid recruitment errors 
“Participation in the EuroTARGET project” was added as an additional requirement for 
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inclusion in the phase IV sub-study. This ensured that only one study population was 
generated and that patients additionally participating in the sub-study were 
documented in the same eCRF as all other patients in the EuroTARGET project. 
However, additional paper CRFs were needed to document sampling times for 
pharmacokinetic samples, blood pressure measurements and adverse events below 
grade 3. 
In total, 9 centers actively recruited patients for this sub-study. Seven were located in 
Germany and two in The Netherlands.  
Study duration was limited to 18 weeks of treatment which corresponds to 3 regular 
sunitinib cycles. In this time frame all sub-study procedures had to be conducted. 
However, patients who completed the phase IV study remained in the non-
interventional part of the EuroTARGET project and were observed for a minimum of 6 
additional months or until disease progression. Official censoring date for all patients 
was the 1th of July 2015. 
 
3.3.3 Patients 
Patients were eligible for this study with an age equal or above 18 years, diagnosed 
metastasized renal cell carcinoma and a planned first-line therapy with either sunitinib 
or pazopanib. Furthermore, the participation in the EuroTARGET project was a 
requirement for the inclusion (Section 3.3.2). Each patient who met the inclusion 
criteria was asked to sign two informed consent forms, one for the EuroTARGET 
project and another one for the EuT-PK/PD sub-study. Both were consistent with the 
newest version of the declaration of Helsinki [125].  
In total, 44 patients were included, with 27 patients receiving sunitinib and 17 
pazopanib. One sunitinib patient was excluded from all analyses due to the lack of 
plasma samples beyond a baseline measurement. Additionally, three patients (two 
sunitinib patients and one pazopanib patient) were excluded from the outcome 
analyses, since the TKI treatment during the study period was not first- but second-
line. However, the pharmacokinetic data from these patients was still used for PK/PD 
model development.  
Patients’ demographics (median and range) per study center and independent of the 
study drug are listed in Table 3.7.  
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3.3.4 Medication 
Patients were treated in accordance to the newest guidelines for the treatment of 
mRCC, the respective summary of product characteristics (SmPC) of sunitinib or 
pazopanib and the treating physician’s discretion [46,47]. No dosing recommendations 
Tab. 3.7:  Patients demographics stratified by study center and total (median and 
range) 
ID1 Age 
[years] 
Gender 
[m/f] 
Weight 
[kg] 
Height 
[cm] 
BMI 
[kg/m2] 
Drug 
[S/P] 
1 
54 
(51 - 74) 
4/0 
84.5 
(83.0 - 87.5) 
184 
(155 – 186) 
25.2 
(24.9 – 34.5) 
4/0 
2 
69.5 
(57 – 75) 
5/1 
80.0 
(75.5 – 83.5) 
179 
(162 – 181) 
25.7 
(23.0 – 30.5) 
6/0 
4 
64 
(47 – 77) 
4/2 
75.5 
(64.5 – 98.0) 
172 
(160 – 183) 
26.9 
(22.3 – 29.3) 
0/6 
7 
67.5 
(55 – 77) 
2/2 
96.0 
NA 
159 
(158 – 172) 
32.4 
NA 
2/2 
8 
67 
(65 – 74) 
3/1 
81.5 
(71.0 – 98.0) 
178 
(165 – 186) 
26.7 
(24.0 – 28-3) 
3/1 
9 
62 
(43 – 80) 
6/1 
85.5 
(71.0 – 106.0) 
180.5 
(175 – 185) 
26.3 
(23.2 – 31.7) 
5/2 
10 
65 
(60 – 70) 
2/0 
70.5 
(65 – 76) 
174.5 
(167 – 182) 
23.1 
(22.9 – 23.3) 
2/0 
14 
75 
(67 – 87) 
1/2 
71.0 
(64.0 – 72.0) 
168 
NA 
25.5 
NA 
0/3 
15 
70.5 
(48 – 82) 
6/2 
77.0 
(76.0 – 91.0) 
170 
(170 – 185) 
26.3 
(22.5 – 31.5) 
5/3 
T 
65 
(43 - 87) 
33/11 
80.0 
(64.0 – 106.0) 
175 
(155 – 186) 
26 
(22 – 35) 
27/17 
1Number assigned to each center according to the study protocol. Note that not all 
EuroTARGET centers participated in the sub-study 
m = Male, = Female; S = Sunitinib, P = Pazopanib; NA = Not applicable, T = Total 
BMI = Body mass index 
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were made in the study protocol and the decision which drug to use was entirely up to 
the treating physician. 
Sunitinib was usually applied in cycles of 6 weeks with a daily dose of 50 mg in patients 
with mRCC. One therapy cycle included 4 weeks on treatment and a therapy 
intermission of two weeks. Besides, alternative schemes like 37.5 mg daily in a 2 
weeks on/1 week off cycle were also applicable dependent on the treating physician’s 
discretion or other considerations [46]. Standard treatment with pazopanib consisted 
of 400 to 800 mg daily without interruptions [47]. 
 
3.3.5 Sampling procedure 
During the study period up to 12 plasma samples were collected from each patient. All 
samples had to be taken during routine check-ups. As these were timed differently in 
the between study centers, there was no fixed sampling schedule. Except for a 
mandatory baseline measurement before treatment start, each center was free to 
develop a schedule according to their specific clinical routine. An example of a possible 
sampling scheme for sunitinib is shown in Figure 3.2.  
 
Since pazopanib is not applied in treatment cycles, a scheme dividing the plasma 
samples within the first 18 weeks of treatment was applicable. 
Once taken, samples were further processed in the respective study center. All 
samples were centrifuged at 1000 g and 4°C for 15 minutes within 30 minutes after 
Fig. 3.2: Example of a sampling schedule for a sunitinib patient receiving a 
standard 4 on/2 weeks off sunitinib cycle. Arrows indicate sampling time-
points. 
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collection. Plasma was then split into 6 aliquots per sample and stored in light-
protected micro tubes at -80°C until analysis. 
 
3.3.6 Endpoints 
Endpoints were chosen in accordance with the main EuroTARGET study (Section 
3.2.6). Outcome was analyzed as progression-free survival, which was defined as the 
time from treatment start to documented disease progression.  
Progression was defined as follows: 
− Progressive disease specified by RECIST [124] 
− Therapy stop/change due to progression 
− New lesion occurred during first-line therapy (date of diagnosis as progression) 
− Death due to the malignancy 
Events were counted as censored data, when the treatment was stopped or changed 
due to a documented toxicity or without any reason, the patient was lost to follow up, 
or no progression occurred until the official censoring date.  
 
3.4 The C-II-005 study 
In order to improve the precision of parameter estimates the final EuroTARGET cohort 
of patients receiving sunitinib was pooled with patients from the C-II-005 study for 
model development. Demographics of this cohort can be found in Table 3.8. 
The C-II-005 study was performed to investigate the beneficial effect of sunitinib as 
add-on to a FOLFIRI therapy schedule including folinate, fluorouracil, and irinotecan, 
in patients with metastasized colorectal cancer (mCRC) and liver metastases. Primary 
endpoint was the reduction of tumor vessel permeability and blood flow determined by 
dynamic-contrast-enhanced magnetic resonance imaging as well as dynamic-
contrast-enhanced ultrasound imaging (DCE-MRI and DCE-USI). Time-to-progression 
(TTP) was defined as a secondary endpoint. Twenty eight patients were included into 
the clinical trial receiving a daily dose of 37.5 mg sunitinib on a 4 weeks on/2 weeks 
off treatment schedule in addition to (FOLFIRI) as first-line therapy. Seven patients 
were excluded from the analysis because of missing drug administration (n = 5), 
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missing data (n = 1), or uncertainty in the documentation of sunitinib intake (n = 1). In 
case of toxicity, sunitinib therapy was interrupted or continued after dose reduction to 
25 mg per day until the symptoms disappeared. Sunitinib was administered around 
breakfast between 7 and 10 am and FOLFIRI was infused biweekly always after 
sunitinib intake [126,127]. 
A detailed PK/PD analysis of the C-II-005 study was conducted by Kanefendt [126]. 
Data from this study was used to improve the PK/PD modeling process and to and to 
increase the chance of correctly identifying genetic covariates for model parameters 
which are independent of tumor entity.  
 
 
3.5 Drug and biomarker analysis 
Plasma concentrations of sunitinib, SU12662 and pazopanib were analyzed at the 
Institute for Biomedical and Pharmaceutical Research (IBMP) in Heroldsberg by 
Christoph Stelzer and Dr. Martina Kinzig under supervision of Prof. Dr. Fritz Sörgel. All 
substances were analyzed by LC-MS/MS using a Tripel-Quadrupol Mass spectrometer 
for detection (Applied Biosystems/MDS Sciex API 5000TM LC-MS/MS, Framingham, 
USA). 
 
3.5.1 Sunitinib and N-Desethylsunitinib (SU12662)  
Sunitinib and SU12662 plasma concentrations were analyzed using a method 
validated according to the recent guidelines of the European Medicines Agency (EMA) 
and the FDA [128,129]. Samples were strictly protected from light during the 
measurement procedure. D5-sunitinib served as internal standard for quantification. 
Lower limit of quantification was determined with 0.06 ng/mL for both, parent drug and 
Tab.3.8:  Demographics for the cohort of mCRC patients (median and range) [126] 
Parameter Unit Median Range 
Age years 61 33 – 85 
Sex m/f 12/9 - 
Weight kg 73 57 – 106 
Height cm 172 149 – 184 
BMI kg/m2 26.0 13.3 – 39.3 
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metabolite. Absolute recovery was reported with 86.0% for sunitinib and 84.8% for 
SU12662. Likewise analytical recovery was equally high for both substances, with 
99.8–109.1% for sunitinib and 99.9–106.2% for SU12662. Linearity was guaranteed 
over a concentration range of 0.06 – 100 ng/mL with r2 > 0.999. Additionally, both 
analytes proved to have a high between-day precision (1.6–6.1% sunitinib, 1.1–5.3% 
SU12662) [130]. 
 
3.5.2 Pazopanib 
The method used for determination of pazopanib concentrations in plasma were based 
on a LC/MS method published by Sparidans et al. [131].  
Analogously to sunitinib, pazopanib plasma concentrations were analyzed using a 
method validated according to recent guidelines of the European Medicines Agency 
(EMA) and the FDA [128,129]. Samples were strictly protected from light during the 
measurement procedure. [13C,2H3]-Pazopanib served as internal standard for 
quantification. Lower limit of quantification was determined with 0.109 µg/mL. Absolute 
recovery was reported with 92%. Likewise analytical recovery was equally high with 
94.8 to 101.8%. Linearity was guaranteed over a concentration range of 0.109 – 107 
µg/mL with r2 > 0.999. Additionally, pazopanib proved to have a high between-day 
precision (2.2 – 10.4%). 
 
3.5.3 sVEGFR-2 
For quantification of sVEGFR-2 in plasma a commercially available immune assays by 
R&D Systems were used [132]. Reproducibility was guaranteed by abiding to internally 
developed standard operating procedures (SOP) (Appendix B.IV). Each run was 
documented with the respective form (Appendix C). Relevant information regarding the 
assay precision, linearity and sensitivity can be found in Table 3.9.  
Quality control (QC) samples in three different concentrations were generated from a 
different batch of the standard solution. All samples as well as the standards were 
measured in duplicate while quality control samples analyzed only once. 
The VEGFR-2 concentrations were calculated with a four parametric logistic curve fit 
using the drc package in R. Baseline values were defined as concentrations measured 
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before the first drug intake. The mean of the measured biomarker response at each 
time-point was used for generating concentration-time profiles stratified by the study 
drug. In order to detect possible confounders, individual concentration-time profiles 
were plotted and investigated. 
 
 
3.5.4 sVEGFR-3 
sVEGFR-3 concentrations were determined with a previously developed and validated 
method by Kanefendt et al. using an Elisa DuoSet® [133,134]. Reproducibility was 
guaranteed by abiding to internally developed SOPs (Appendix B.IV). Each run was 
documented with the respective form (Appendix C). Quality control samples in three 
different concentrations were generated from a different batch of the standard solution. 
All samples as well as the standard were measured in duplicate whereas quality control 
samples were quantified only once. The validation criteria can be found in Table 3.10.  
The concentrations were calculated with a four parametric logistic curve fit using the 
drc package in R®. The mean of the measured biomarker response at each time-point 
was used for generating concentration-time profiles stratified by the study drug. 
Baseline values were defined as concentrations measured before the first drug intake. 
In order to detect possible confounders, individual concentration-time profiles were 
plotted and investigated. 
  
Tab. 3.9:  Validation criteria for the determination of sVEGFR-2 in plasma [127] 
Parameter  
Lower limit of quantification1 4.6 pg/mL  
Between-day precision (CV %)1 5.7 - 7.0% 
Within-day precision (CV %)1 2.9 - 4.2% 
1Determined by R&D Systems 
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3.6 Statistical analysis 
Statistical analysis of the soluble biomarkers sVEGFR-2 and sVEGFR-3 as well as 
blood pressure was performed using R. As two drugs were investigated all analyses 
were performed for both drugs combined and for each treatment subgroup in order to 
rule out major differences. 
 
3.6.1 Outlier analysis 
To identify potential outliers, boxplots of the absolute sVEGFR-2 and -3 concentrations 
were generated. Since the sampling time-points were not unified across patients, all 
measurements were stratified by week of treatment with a maximum observation time 
of 18 weeks. If necessary, sunitinib and pazopanib were administered in different 
doses; therefore, absolute biomarker concentration values were dose normalized 
before plotting. This guaranteed that no values were mistakenly identified as outliers. 
Baseline values (treatment week 0) were excluded from the dose normalization and 
compared separately [135]. Outliers were determined using a model-based approach 
by calculating the conditional weighted residuals (CWRES, Section 3.8.3.). A value 
greater or equal 6 or lower or equal -6 was considered as an outlier. If applicable, the 
respective observation was excluded from the analysis and the influence on parameter 
estimates was investigated. 
 
3.6.2 Assessment of normality 
Parametric statistical tests require the data to be normality distributed. Although 
physiological parameters are usually non-normally distributed, it is still necessary to 
verify this assumption in order to avoid errors by using the wrong test statistics [135]. 
Tab. 3.10: Validation criteria for the determination of sVEGFR-3 in plasma 
(modified from [126,134]) 
Parameter  
Lower limit of quantification1 513.9 pg/mL 
Between-day precision (CV %) 18.3% 
Within-day precision (CV %) 4.9% 
1Not determined. Based on calibration curve 
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In case of violations of the normality assumption, non-parametric methods are highly 
recommended for testing e.g. correlations.  
Normality was tested via graphical examination by generating histograms and quantile-
quantile plots stratified by protein and by treatment. In addition, the Shapiro-Wilk test 
was performed with the same stratification pattern. For this test the following 
calculation was performed [135]: 
With W as the statistic of interest, n as independent and identically distributed 
observations from a normal distribution with unspecified mean and variance. ai 
represents constants that are functions of n. The null hypothesis states that the data is 
normally distributed, whereas the alternative hypothesis implies that the distribution is 
not normal. With a significance level of p < 0.05 the null hypothesis can be rejected.  
 
3.6.3 Correlation analysis 
Since both, sVEGFR-2 as well as sVEGFR-3, are involved in tumor angiogenesis and 
down-regulated under TKI therapy, the correlation between the plasma concentrations 
of both proteins was quantified. Correlation was assessed graphically by linear 
regression and the determination of the correlation coefficient r. In addition the 
Spearman’s rank correlation coefficient (rs) was calculated [135]: 
Sxy denotes for covariance between x and y and Sx/y for the variance of x and y, 
respectively. 
 
3.6.4 Comparison of mean biomarker levels across treatment groups 
To detect differences in drug response the mean levels of sVEGFR-2 and sVEGFR-3 
per treatment week were compared between the respective groups of patients either 
treated with sunitinib or pazopanib. For this purpose the Mann-Whitney-Wilcoxon test 
was used, which is applicable for comparing a non-normally distributed continuous 
variable in two groups [135].  
 = [∑ []]	
 ∑ ( − ̅)	
  (Eq. 3.1) 
 =  (Eq. 3.2) 
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3.7 Genetic analysis 
The selection of single nucleotide polymorphisms (SNPs) was based on previously 
reported studies (p < 0.05) of SNPs associated with the treatment outcome of sunitinib 
(or pazopanib) with regard to toxicity and efficacy. Herein, the focus was on SNPs that 
are likely to have an effect on VEGF or VEGF receptors, blood pressure, and SNP 
associations from confirmatory studies in large cohorts. Selected SNPs or combination 
of SNPs were included as covariates if they improved the respective model 
significantly. A list of the selected SNPs can be found in Appendix A. 
SNP analysis was performed at the University of Leiden in the group of Prof. Henk-Jan 
Guchelaar by Dr. Meta Diekstra. Germline DNA was isolated from whole blood 
samples using the Chemagic® Blood kit (PerkinElmer). Genotyping was performed on 
the selected SNPs, using Taqman probes (Applied Biosystems, Nieuwerkerk aan den 
Ijssel, the Netherlands) on the LightCycler480® Real-Time PCR Instrument (Roche 
Applied Science, Almere, The Netherlands). Quality control procedures included SNP 
genotyping plots for each assay. To test for inconsistencies, 5% of all samples were 
measured as duplicates. Samples with a call rate below 80% were excluded from the 
analysis. All SNPs were tested for the Hardy-Weinberg equilibrium [136]. 
 
3.8 Pharmacokinetic/pharmacodynamic data analysis 
3.8.1 Non-Linear Mixed Effects modeling 
Non-Linear Mixed Effects (NLME) modeling is the gold standard in population analysis. 
As initially stated (Section 1.4.2), this method allows the analysis of datasets with only 
sparse individual sampling. In addition to typical estimates of the respective PK/PD 
parameters it is possible to quantify the variability within the population and, if sufficient 
data is available, to explain this variability by inclusion of covariate effects. 
The term NLME is derived from the different effects which are investigated with a 
population models. Mixed effects comprise the so called fixed effects, which refer to 
the population parameters without inclusion of variability, but also includes covariate 
effects. On the other hand, random effects comprise all forms of estimated variability 
in the model. In this study, the software NONMEM® was used for population PK/PD 
analysis [88]. NONMEM® is written in FORTRAN 90/95, which is still evident in the 
modified syntax that is used to define models. The software consists of several core 
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modules with different tasks within the overall package. An overview of the structure of 
NONMEM® is shown in Figure 3.3.  
NM-TRAN is a module which translates the user-supplied data and control files into 
readable data for NONMEM®. A compiler is necessary for adequate translation of the 
code into a format which can be executed by the computer. NONMEM® itself does not 
directly provide models, but relies on user written subroutines for parameter 
estimations via the command PRED. However, NONMEM® also includes the so-called 
PREDPP module which is short for PRED for Population Pharmacokinetics. This 
module simplifies the model building process to a certain degree as it already includes 
subroutines helpful for population analysis as well as subroutines which provide 
already analytical solutions for simple one, two or three compartment models. In the 
simplest case, only PK or PD model parameters and a residual error model have to be 
specified. Though, it is also possible to define more sophisticated models with 
differential equations in PREDPP using the $DES option [88]. 
 
 
  
 
Fig. 3.3: Scheme of the general structure of NONMEM® and important steps 
(modified from [88]). 
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Fixed effects are referred to as THETA (θ) in the NONMEM® while random effects are 
further differentiated into inter-individual (IIV) (ETA, η), intra-occasion (IOV) (KAPPA, 
κ) and residual variability (EPSILON, ε). Variability is assumed to be normally 
distributed across all random effects with a mean 0 and a variance of ω2, κ2 or σ2, 
respectively (Section 3.8.2). 
Methodologically, NONMEM® uses a maximum likelihood approach with an objective 
function (OBJ) based on extended least squares to obtain parameter estimates which 
provide the best fit to the underlying data. In the simplest case a population 
pharmacokinetic model can be described as follows: 
Where θ denotes for the model parameter vector x for the dependent variable, ε for the 
residual variability. Assuming that the total residual variance of Y is a function of the 
structural model f(θ;x) it can be simplified: 
With g being the variance function with respect to f(θ;x) and  the variance of the 
random variable ε. 
Based on this, the OBJ can be written as: 
 =   [ − (|!)]"() + $% ["()]&
	


 (Eq. 3.5) 
Where n is the number of patients in the investigated population and Yi, xi and θ refer 
to the vectors of dependent and independent variables as well as model parameters. 
Even though NONMEM® uses a maximum likelihood approach for parameter 
estimation, the OBJ is calculated as two times the negative log-likelihood; hence, the 
OBJ is minimized during parameter estimation [84,86,88]. However, due to the 
inclusion of random effects, especially inter-individual variability, the calculation of the 
likelihood is no longer trivial as no analytical solution exists. Therefore, NONMEM® 
uses an approximation of the true model by linearization. The most basic variant of this 
approach implemented in NONMEM® is the first-order (FO) method which relies on a 
first-order Taylor series. Mathematically, a Taylor series is a polynomial function which 
is used to approximate a function at a point x given the original function and its 
derivatives at the initial point. The order of a Taylor series is given by the number and 
degree of derivations that are added up to the original function. By definition, a first-
 = (!|) + ε (Eq. 3.3) 
"() = ['((!|))] (Eq. 3.4) 
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order Taylor series includes the first derivation of the base function [86]. As NONMEM® 
performs the linearization at η=0 using only population mean values, an additional 
step, called POSTHOC, is required after the estimation in order to obtain individual 
parameter estimates. While the FO is approved for simple modeling problems, it could 
be shown that it is less reliable in more sophisticated models as it may introduce bias. 
A well-established method is the first-order conditional estimation (FOCE), which is 
essentially an improved FO algorithm. FOCE uses the same first-order expansion as 
the FO method with the difference that conditional individual estimates are used 
instead of setting η equal to 0. Furthermore, FOCE allows to address the potential 
η,ε-interaction which is relevant when certain residual error models are used that 
incorporate the residual variance as a function of the model prediction (Section 3.8.2) 
[84,86,88]. Another common method is the Laplacian approach: similar to FOCE, 
Laplacian is also a conditional estimation method, however, a second-order Taylor 
expansion is used in this case. Laplacian has proved to be reliable and particularly 
useful for time-to-event and other categorical data as it does not need to calculate a 
likelihood and is directly minimized [88,137]. 
 
3.8.2 Model development 
A population model usually consists of three submodels: a structural model or base 
model, a stochastic model and a covariate model [84,86]. Development of a population 
model starts with the choice of an appropriate structural model. This comprises the 
compartmental model with fixed effect parameters to describe the relevant 
pharmacokinetic processes such as absorption, distribution and elimination. Graphical 
inspection of the data was performed for an initial assumption on the required number 
of distribution compartments and the kinetics of the absorption and elimination 
process. Goodness-of-fit (GOF) plots and changes in the objective function value 
(OFV) were compared in all tested models. Furthermore, visual predictive checks 
(VPCs) were generated for candidate models; this process is explained in detail in 
Section 3.8.3.  
Once a proper structural model was selected, random effects were tested on each 
parameter. As stated above, variability was differentiated in three levels, which require 
different approaches for a correct implementation into the model: Inter-individual (IIV), 
inter-occasion (IOV) and residual variability.  
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Inter-individual variability  
Inter-individual variability (IIV), describes differences between individuals in a 
population of interest. While other models are possible, the standard approach is to 
model IIV with a log-normal distribution (Equation 3.6) as this constraints the 
pharmacokinetic parameters to be greater than zero. This is of particular importance 
for physiological parameters such as clearance and volumes [84,85,137]. 
! = !* ∙  ,-. (Eq. 3.6) 
θi denotes for the individual parameter estimate, θµ represents the population mean 
and ηi the deviation from this mean for patient i. The underlying assumption is that ηi 
has a mean of zero and a variance of ω2. When assuming that all parameters are 
uncorrelated, the variance-covariance matrix can be expressed as a diagonal matrix. 
However, NONMEM® allows the implementation of block matrices to address and 
estimate correlations between model parameters.  
IIV is usually stated as coefficient of variation (CV). This can be calculated using the 
following equation [86]: 
/"(%) =  ,12 − 1 ∙ 100% (Eq. 3.7) 
IIV was tested on all relevant pharmacokinetic and pharmacodynamic parameters 
during model development. If necessary, correlations between parameters were 
handled by introduction of off-diagonal elements in the variance-covariance matrices. 
 
Inter-occasion variability 
Inter-occasion variability (IOV) describes the variation of pharmacokinetic parameters 
within one individual. Various reasons for time dependency of a parameter exist and 
they can be a consequence of intrinsic, e.g. pathophysiological, or extrinsic changes 
and influence factors. For example, if the clearance of a drug is dependent on renal 
function a progressive renal impairment will have a significant impact on this 
parameter. 
In oncology it is common to interpret therapy cycles as different occasions, since they 
span over a long time period with or without treatment intermission. The importance of 
modeling IOV was pointed out by Karlsson et al. in 1993. The implementation of IOV 
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can prevent the false data acceptance of covariates and reduce bias of parameter 
estimates [138]. 
IOV, denoted with κ, is modeled on the same level of random effects as IIV: 
! =  !* ∙ ,(-.567) (Eq. 3.8) 
Hence, the additional parameter κj denotes for the deviation from the population mean 
with respect to occasion j. The impact of IOV was tested on relevant parameters, if 
applicable. An occasion was either defined as treatment cycle of sunitinib, which 
corresponds to 6 weeks of pazopanib treatment, or as treatment week. 
 
Residual variability 
Residual variability comprises all variability which cannot be explained by IIV, IOV or 
covariate effects. This includes for example assay variability, errors in dosing histories 
but also model misspecification. To account for this, a proper residual error model has 
to be chosen.  
The most common residual error models include an additive (Equation 3.3), a 
proportional (Equation 3.9) and a combined error model (Equation 3.10): 
 = (!|) ∙ (1 + 8) (Eq. 3.9) 
 = (!|) ∙ (1 + 8) + 8 (Eq. 3.10) 
The additive model assumes an error of the same absolute magnitude across the 
range of plasma concentrations. In contrast, the proportional error applies a fixed 
coefficient of variation which results in smaller absolute errors for low values and vice 
versa. The combined error model is most useful when there is a wide range of plasma 
concentration measurements, since the additive error usually applies to smaller 
concentrations and the proportional error to values of higher magnitude [86,137]. The 
usual assumption is that the residual error is equal across all patients. However, this 
is not always the case, especially when data from different studies is pooled in one 
dataset as different sampling and analytical approaches may result in varying residual 
errors across studies. This can be resolved by estimating center or study specific 
residual errors.  
Even though all samples analyzed in this study were processed in the same 
laboratories, residual errors in all models were tested for systematic differences among 
patient groups.  
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Covariate model 
Covariates are described by fixed effects to explain parts of the inter-individual 
variability of a pharmacokinetic parameter. Usually, covariate analysis is performed in 
a step-wise manner [86,137]. Preselected covariates, based on clinical relevance and 
graphical analysis, are implemented into the model in a forward search process. 
Covariates which led to a significant decrease of the objective function value (p < 0.05) 
are kept for the next step. The final forward model is then re-evaluated by backwards 
elimination of each covariate with a stricter significance level (p < 0.01). If a covariate 
effect was still significant in this step, it was kept in the model. 
However, if the investigated population is too small it is difficult to detect a covariate 
effect. To take this into account, potential covariates were identified in the literature 
and then tested manually in addition to the step-wise approach in this study. The 
advantage is that the quantity of the possible effect is already known, and the 
underlying study could be used as verification for previous findings. Clinical and 
biological relevance of newly identified covariates was carefully assessed. 
A full list of all covariates tested in the respective models can be found in Appendix A. 
 
3.8.3 Model qualification 
Model qualification covers methods which allow determining the overall fit of the model, 
the validity of estimated parameters and if the model is suitable for extrapolation, for 
example simulation of different dosing regimens which were not part of the original 
dataset. Due to the lag of validation data set and a small sample size, which did not 
allow data splitting, only internal qualification methods were used [84,139]. 
 
Likelihood ratio test   
The objective function value (OFV) provided by NONMEM® (Section 3.8.1) was used 
primarily for model comparison of nested models depending on the degrees of 
freedom, or more exactly, the number of parameters that changed between models. 
The objective function used by NONMEM® is defined by minus twice the log-likelihood 
with respect to the model parameters. The difference of this value between two nested 
models (dOFV) is chi-square distributed. In this case the term “nested” refers to models 
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which can be converted into each other by addition or removal of one or several 
parameters. As a result, the statistical significance of a parameter or several 
parameters can be assessed by comparing the dOFV with the respective statistic from 
the chi-square distribution [88]. For one degree of freedom, which translates to one 
additional parameter in the model, the OFV has to decrease by at least 3.84 to confirm 
a significant improvement of the model fit with a p-value less than 0.05. Depending on 
the chosen significance criteria and the number of parameters included or removed 
from a model different threshold values were apply. 
 
Goodness-of-fit plots  
Goodness-of-fit (GOF) plots can be used to graphically assess the model fit and help 
to identify model misspecifications. To avoid misinterpretation and ensure easy 
comparability these plots were standardized depending on the model drug [84,139].  
General GOF plots include population predictions vs. observations and individual 
predictions vs. observations. Both types of plots were used to assess the goodness-
of-fit with regard to the estimates of population parameters, without taking inter-
individual variability into account, and individual parameter estimates. X- and Y-axis 
were fixed to have the same length with a line of identity dividing the plot exactly by 
half. Furthermore, a locally weighted scatterplot smoothing (LOESS) was added for a 
better identification of potentially ill-conditioned patterns in the plot [139]. 
Depending on the purpose, different types of residuals are needed and have to be 
computed beforehand to generate plots for model evaluation. Weighted residuals are 
calculated by NONMEM® based on the older FO method, whether this method was 
used for parameter estimation or not. In the worst case this can lead to false decisions 
during the modeling process. Hence, the individual weighted (IWRES) and the 
conditional weighted residuals (CWRES) were used in the underlying analyses [140]. 
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Individual weighted residuals  
Individual weighted residuals (IWRES) were calculated by using the difference 
between the observed dependent variable (DV) and individual model predictions 
(IPRED) divided by the square root of the variance   as weighting factor. The 
variance is defined by the residual error model (Section 3.8.2) 
9:; = <" − 9=:;<√  (Eq. 3.11) 
 
Conditional weighted residuals  
As FOCE with η,ε-interaction (Section 3.8.1) is the estimation method of choice, 
standard residuals are no longer a reliable diagnostic tool, due to their reliance on the 
older FO method. However, Hooker et al. introduced conditional weighted residuals 
(CWRES) in 2007 which are now a standard diagnostic criterion [140]. Therefore, 
CWRES were automatically calculated for every run. 
/:; = ? − @ABC(!, )@ABC (?)  (Eq. 3.12) 
By using Equation 3.12 the (estimation by using FOCE) empirical Bayes estimates 
(EBE) are taken into account for residual computation whereas the usual WRES are 
calculated at η = 0. 
One major assumption is that residuals are normally distributed with a mean of 0 and 
variance σ2 (Section 3.8.1). Graphically, this can be assessed using quantile-quantile 
plots as well as histograms of CWRES. The former uses the residual quantiles and 
plots them against the quantiles of the normal distribution. Whereas information 
between both types of plots is comparable, quantile-quantile plots are more sensitive 
to violations of the underlying assumptions and can therefore be used in addition to 
classical histogram plots. 
To identify model misspecifications, especially of the structural and residual model, 
plots of CWRES vs. PRED and CWRES vs. TIME and/or TIME AFTER DOSE (TAD) 
were used. Furthermore, plots of |IWRES| vs PRED and vs. TIME were used to 
evaluate the residual error model regarding the independence of residuals, (individual) 
predictions and the independent variable, respectively [139]. All plots were generated 
after every model run using the R packages lattice and xpose (Section 3.1.5). 
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η- and ε-Shrinkage  
Individual estimates of population pharmacokinetic model parameters are highly 
dependent on the quality of the underlying data. While the strength of NLME modeling 
is the analysis of sparse data, too sparse data or varying data quality among patients 
can lead to uninformative parameter estimates. In an extreme case the individual would 
be identical to the population estimates. A misleadingly lower estimate of the variance 
would be the result.  
This phenomenon is called η-shrinkage and can be calculated with the following 
equation 
E − ℎG%H', = 1 − <(E;;)I  (Eq. 3.13) 
Where <(E;;) denotes for the standard deviation from the population mean and I 
is the standard deviation of the population. 
Similarly, the lack of sufficient data for the proposed model can lead to a systematic 
decrease of IWRES (see above) which is also called “overfitting” or ε-shrinkage. 
Analogous to the η-shrinkage, ε-shrinkage can be calculated as follows: 
8 − ℎG%H', = 1 − <(9:;) (Eq. 3.14) 
There is no defined cut-off value for η- or ε-Shrinkage, but a commonly used threshold 
is that either value should not exceed 30% [141]. Shrinkage was calculated for every 
relevant model parameter, if applicable. 
 
Bootstrap  
Nonparametric bootstraps were used to obtain standard errors (SE) and confidence 
intervals (CI) for model parameters. By randomly sampling from the original data set 
with replacement, n new data sets were generated and used for re-estimation of the 
model parameters. Each data set consisted of the same number of patients; however, 
the composition of each set varied as patients could be drawn multiple times or not at 
all. Based on the number of replicates, the bootstrap results were used to calculate the 
variance, and hence standard errors, and confidence intervals of the model parameters 
without knowing the true distribution of the data [86]. 
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The bootstrap variance VarB is calculated using the estimated parameter vector f(xi*) 
and the number of replicates n. 
"J =  ∑ K(
∗) − ∑ (∗)	
% M
	
 % − 1  (Eq. 3.15) 
By taking the square root of the variance an estimate of the standard error was 
calculated. By default CIs were obtained using the percentile method, assuming that 
the parameter estimates were asymptotically normally distributed around their means. 
All bootstrap estimates were ranked according to their value, confidence interval 
boundaries were then calculated by N(α/2) and N(1-α/2), respectively [86]. 
In this study, 1000 replicates per bootstrap were generated, which is in accordance 
with the common practice and population pharmacokinetic guidelines [84]. The 95th 
and 5th percentile were then used for calculation of the respective CIs. In case of 
asymmetrical bootstrap distributions the accelerated bias-corrected (BCa) method 
could be used [84,111]. Here, two additional parameters are calculated: b to correct 
for asymmetry and a to correct for skewness. The equation for calculating bias-
corrected confidence intervals is then given by: 
N ∙  O P ± RS/ + P1 − (RS/ +  P)& (Eq. 3.16) 
Where N denotes for the bootstrap sample size, φ for the standard normal distribution 
and Z for the Z-distribution. The process of resampling and re-estimation of datasets 
and model parameters was automated by using PsN [111]. 
 
Visual predictive check  
Visual predictive checks (VPCs) are a simulation based diagnostic tool for nonlinear 
mixed effect models. Here, the model of interest is used to simulate data based on the 
final estimates including variability, hence sampling from the OMEGA and SIGMA 
matrices corresponding to inter-individual and residual variability [89]. The simulated 
predictions are then graphically compared to the observed data. By binning of the 
independent variable (usually “Time”) it is assured that all observed data points are 
grouped within other values of comparable magnitude and in a similar observation 
time. It is common practice to use bins equal to the number of observations per patient. 
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However, it is also possible to automatically assign observations into bins in cases 
where a manual subdivision is not feasible [142,143]. 
Prediction-corrected VPCs (pcVPC) are a further advanced version of the original 
approach proposed by Bergstrand et al. [144]. This method is of particular importance 
when data with differences in independent variables, e.g. doses or covariate effects, is 
analyzed as it corrects for these. This is done by normalization of the observed and 
simulated dependent variable with respect to the median prediction of each bin: 
UVW = XW + (W − XW) ∙ =:;<Y	 − XW=:;<W − XW  (Eq. 3.17) 
Where pcYij denotes for the prediction-corrected observation of the ith individual at the 
jth time-point and LB is the lower bound at the respective time-point j of individual i. 
PREDbin is the mean population prediction, while PREDij corresponds to the population 
prediction of individual i at time j. 
pcVPCs were generated based on 1000 simulated datasets with regard to the original 
data structure. Bin arrays were constructed based on the weeks on treatment and 
sampling schedules. Graphical presentation of the VPC results included the simulated 
and observed mean as well as the 90% prediction interval with the respective 95% 
confidence bands. Due to the heterogeneity of the sampling schedules across the 
study centers and due to the fact that, in case of sunitinib, two different patient cohorts 
were analyzed simultaneously only the first cycle is shown in the plots. For pazopanib 
the first 6 weeks on treatment were chosen to ensure comparability. VPCs of the full 
observation time for each drug can be found in Appendix D. Furthermore, VPCs for 
sunitinib PK and PK/PD models were stratified by tumor entity to detect potential 
differences between both studies. VPCs used for evaluating the survival model show 
the observed Kaplan-Meier estimates with a 90% prediction interval and were stratified 
by covariates if necessary. In the same way the results of the toxicity models are 
presented. Here, the observed fraction of patients, who developed a certain adverse 
event over time with a 90% prediction interval is shown. 
 
Case deletion diagnostics  
Case deletion diagnostics (CDD) were used to identify individuals with influential 
characteristics within the dataset. In addition, CDD allowed the calculation of bias for 
every model parameter. In principle CDD resembles the so called jackknife approach 
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where n new datasets are generated by removing one individual at a time. Model 
parameters are then re-estimated for each set. In this case n equates to the number of 
individuals in the original data set [86,145]. The jackknife estimate of a model 
parameter !Z is defined by 
!Z[\B] =  1%  !Z([\B])
	


 (Eq. 3.18) 
With !Z([\B]) as the parameter estimate at the ith jackknife sample [146]. 
Based on this value it is possible to calculate the jackknife bias, which is the average 
deviation of the replicated parameter estimates from the original estimate [84,145]: 
[\B] = (% − 1) ∙ (!Z[\B] −  !Z) (Eq. 3.19) 
Influential subjects can be accessed graphically by plotting the calculated covariance 
ratios versus the Cook’s distance. Cook’s distance is a metric which quantifies the 
change of parameter estimates when a specific subject is removed from the dataset, 
whereas an increase of the covariance ratio is an indicator for a change in parameter 
variability [86]. Furthermore, it is possible to assess the relative changes of each model 
parameter separately to identify subjects with a high influence on the estimate. 
Resampling and re-estimation of datasets and model parameters was automated by 
using PsN [111]. 
 
3.8.4 Bayes estimation  
Bayesian estimation is a common mathematical approach in Therapeutic Drug 
Monitoring (TDM) to gather information on individual pharmacokinetic parameters 
based on an a priori probability which comprises the known distribution of the 
pharmacokinetic parameters in the model and a posteriori probability including the 
plasma concentration(s) of the respective patient. Basis for this method is the Bayes 
theorem with describes the conditional probability of an event A provided B [92]: 
=(^|) =  =(|^) ∙ =(^)=()  (Eq. 3.20) 
With P(B|A) being the probability of B provided A and P(A) and P(B) the probabilities 
for A and B, respectively. Applied to pharmacokinetics, the same problem can be 
stated as the probability of a model parameter vector A (e.g. clearance, volume of 
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distribution) provided plasma concentration B. The advantage of this method is that 
even in situations where only very limited data is available, reliable parameter 
estimates can be obtained.  
For application in NONMEM® all model parameters were fixed to their respective value 
from the literature (a priori probability) and used for prediction of the individual 
pharmacokinetic parameters based on the sparse samples available (a posterori 
probability). The estimated individual plasma concentrations of each patient were used 
to calculate the relative prediction error (RPE, Equation 3.21) which served as a tool 
to identify potential outliers in the data set. A RPE of 50% was set as threshold for 
excluding a value from the analysis. 
 
3.8.5 Handling of missing data  
Missing data was handled according to predefined rules. For continuous covariates the 
population mean was used as imputed value whereas for categorical covariates the 
most common expression in the respective population was chosen for imputation. In 
case of missing time of drug intake or missing sampling time two options were 
available. If at least one dosing or sampling time was documented, this was also used 
for all cases were this information was missing. Only in the case of a complete lack of 
data on drug intake the clock time was set to 8.00 a.m. assuming that an administration 
in the morning was the most likely scenario. In the same way, clock time was set to 
12.00 p.m. for all cases with no information on sampling time, assuming that a routine 
check-up was most likely scheduled during mid-day. However, since these are rather 
uncertain assumptions, the influence of dosing time was assessed in a sensitivity 
analysis (Section 3.8.6). 
 
3.8.6 Sensitivity analysis 
Fixed model parameters 
Due to the nature of sparse data, not all parameters of a highly sophisticated semi-
mechanistic model can be or should be estimated. In case of physiological processes, 
e.g. liver blood flow, it is a common approach to fix related model parameters to values 
obtained from the literature. However, this demands a high confidence in the reported 
value as all other model parameters could potentially be influenced by this value, 
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introducing a bias in the worst case. To test the influence of the fixed model parameters 
in the underlying study, a sensitivity analysis was performed [147]. The parameters of 
concern were therefore varied between -50 and +50% of the final value used in the 
analysis. Variation of all non-fixed model parameters was quantified using the relative 
prediction  error (RPE) which is defined as 
:=; (%) = !	_` − !Ya_!	_`  (Eq. 3.21) 
Where θnew denotes for the parameter estimate obtained after varying the concerned 
fixed model parameter and θbase for the original estimate, respectively. 
 
Time of drug intake 
Since the time of drug intake was only documented poorly and the clock-time had to 
be imputed (Section 3.8.5) in several cases, a sensitivity analysis quantifying the 
influence of dosing time was performed. Therefore, time of drug intake was randomly 
varied for each occasion between +3 and -3 hours. This procedure was repeated 50 
times. Based on the parameter estimates of each model the RPE was calculated. 
 
3.8.7 Data below the quantification limit 
Data below the limit of quantification (BQL) can be informative and have a significant 
effect on parameter estimates of a PK/PD if not handled correctly. Several methods on 
how to approach BQL data in modeling can be found in the literature. Two of the most 
common methods are referred to as M1 and M3 [148,149].  
M1 denotes for the removal of all BQL values from the dataset, thus ignoring this data 
completely. While this approach is widely used and reliable if the amount of BQL data 
is low, there is a certain probability of introducing a bias into the parameter estimates. 
A more sophisticated approach is the M3 method. Here, BQL values are included into 
the model fitting process and the likelihood that these values are effectively below the 
quantification limit is estimated [148]. Ideally this should avoid misinterpretation of BQL 
values and reduce bias which can be introduced by omitting these data points 
[148,149]. According to recent comparison between all available methods the M3 
approach is currently the method of choice for handling BQL data [150]. 
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However, as the relative number of BQL data in the underlying study was below 2% 
the M1 method was decided to be sufficient.  
 
3.9 Pharmacokinetic models 
3.9.1 Sunitinib and N-Desethylsunitinib (SU12662) 
Two published semi-mechanistic models for sunitinib and its active metabolite 
SU12662 were considered as basis for describing the study data.  
The model proposed by Lindauer et al. [109], used a transit-compartment approach to 
describe the delayed absorption of sunitinib and takes into account the fraction of the 
parent drug which is metabolized to SU12662 pre-systemically, before entering 
systemic circulation. Distribution of sunitinib is described by a two-compartment model, 
whereas for SU12662 only one compartment was sufficient. The fraction metabolized 
to SU12662 (FM) was fixed to 0.21, however the ratio of pre-systemic (pre) to systemic 
(sys) metabolite formation (RPS) could be estimated with the given parameterization 
of the model: 
bc = bc,de_ + (1 − bc,de_) ∙ bc, (Eq. 3.22) 
:= =  bc,de_bc,  (Eq. 3.23) 
Basis for this model was a data set of 12 healthy volunteers (6 male and 6 female) who 
received 50 mg sunitinib for 3 or 5 consecutive days [109]. This model was successfully 
applied by Kanefendt et al. to describe sunitinib and SU12662 pharmacokinetics in 21 
patients with colorectal cancer originating from the C-II-005 study (Section 3.4) [126]. 
The second model that was tested was developed by Yu et al. [110] based on data 
from 70 cancer patients with doses ranging from 25 to 50 mg daily. Here, pre-systemic 
metabolization of sunitinib to its active metabolite was described by a hypothetical 
enzyme compartment. This was assumed to be in equilibrium with the central 
compartment, connected by the hepatic blood flow (QH) which was fixed to 80 L/h 
scaled by weight relative to a standard weight of 70 kg.  
The hypothetical compartment was parameterized as follows, with CH being the 
calculated concentration: 
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/f = Ha ∙ ^g + hf ∙
^i,j	k	Y"i,j	k	Yhf + /Xj	k	Y  (Eq. 3.24) 
ka denotes for the absorption rate constant while AD and Ac,sunitinib represent the 
amounts in the dosing or central compartment, respectively. CLsunitinib and Vc,sunitinib 
denote for the clearance and volume of distribution of the central compartment of 
sunitinib, respectively [110]. 
Distribution was, in contrast to the model by Lindauer et al. described by a one- 
compartment model for sunitinib and a two-compartment model for SU12662. For 
comparison with the reported estimates all relevant parameters were also scaled by 
patients’ weight relative to a standard weight of 70 kg in this study.  
 
3.9.2 Pazopanib 
Two population pharmacokinetic models for pazopanib were published so far. Imbs et 
al. used a simple one-compartment model with a dosing lag-time to account for delays 
in absorption processes [151]. The model was based on data from 25 patients who 
received pazopanib in combination with bevacizumab. Yu et al. used a semi-
mechanistic approach to cope with the rather complex absorption process of 
pazopanib (Section 1.1.4) [152]. Pharmakokinetics were described using a two-
compartment model with two first-order absorption rate constants. One fraction of the 
dose was absorbed instantaneously whereas the rest followed with a defined lag-time. 
In addition, the relative dose-related fraction absorbed (rFDose) was accounted with an 
Emax model: 
bgl_ = ;ma ∙ (<no, − 200);<qr + (<no, − 200) (Eq. 3.25) 
Here, Emax describes the maximum effect of the dose on the bioavailable fraction. ED50 
represents the dose level with half of the maximal bioavailable fraction at a dose of 200 
mg. Furthermore, Yu et al. observed that pazopanib bioavailability decreases over time 
with significant differences between expected plasma concentrations after a single 
dose and at steady-state.  
To acknowledge this, an exponential time-decrease was applied to bioavailable 
fraction: 
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bsm_ = 1 − ;t + ;t ∙ ,uv∙sm_ (Eq. 3.26) 
Where Ed denotes for the maximum effect of time.The relative fraction absorbed rF 
was assumed to be 1 if no influencing factors were present. The effects of time and 
dose on rF could be described by the following equation. 
b = 1 ∙ bgl_ ∙ bsm_ (Eq. 3.27) 
Due to sparse sampling and missing information on drug intake and measurement 
times for pazopanib it was difficult to obtain reliable population parameter estimates 
with the chosen model. Hence, a Bayesian approach as described in Section 3.8.4 
was used to estimate individual pharmacokinetic parameters for each patient. 
Whereas both models were tested for applicability on the underlying data set, the semi-
mechanistic approach by Yu et al. was used for the final analysis due to the superiority 
of the model regarding already included information on pazopanib pharmacokinetics. 
 
3.10 Pharmacokinetic/pharmacodynamic models 
The final pharmacokinetic models for sunitinib, its active metabolite and pazopanib 
were linked in individual pharmacokinetic/pharmacodynamic (PK/PD) models for each 
biomarker to quantify the relationship between drug plasma concentrations and 
biomarker response. Individual pharmacokinetic parameters of each patient were used 
to calculate plasma concentration-time profiles of the respective drug as influence 
factor for changes in sVEGFR-2 and sVEGFR-3 plasma concentrations as well as 
blood pressure over time. 
 
3.10.1 sVEGFR-2 
The pharmacodynamic model for sVEGFR-2 was originally developed by Lindauer et 
al. in healthy volunteers and linked with the respective pharmacokinetic model for 
sunitinib and SU12662 (Section 3.9.1) [109]. Applicability for cancer patients was 
already demonstrated by Kanefendt et al. in the analysis of mCRC patients alone [126]. 
In this study, this model was tested for its applicability in both tumor entities in patients 
treated with sunitinib and pazopanib, respectively. 
In the following the links between PK and PD models are separately described for the 
study drugs sunitinib and pazopanib. 
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Sunitinib 
VEGFR-2 plasma levels during sunitinib therapy were described using an indirect 
response model: 
wo";xb:2wy = H	 ∙ K 1(1 + z{C|@} ∙ 9N~)M − Hljk ∙ o";xb:2 (Eq. 3.28) 
kin is a zero-order production rate, which was assumed to be equal to the product of 
individual sVEGFR-2 baseline value (BLsVEGFR-2) and the first-order elimination rate 
kout. Mathematically, the baseline can then be calculated by the quotient of kin and kout. 
α denotes for the intrinsic activity of sunitinib on sVEGFR-2 production. The inhibitory 
function INH comprises a hyperbolic function which describes the fractional tyrosine 
kinase inhibition of sunitinib and SU12662 based on the total unbound active 
concentration (ACU). This approach assumes an identical potency of both molecules, 
which has been reported by Faivre et al. [153]. The fixed value of the dissociation 
constant (KD) was originally derived from Mendel et al. [58], whereas protein binding 
values for both substances were fixed to 0.95 and 0.90 for sunitinib and its active 
metabolite, respectively [46,59]: 
9N~ = ^/g + ^/ (Eq. 3.29) 
 
Pazopanib 
As the pharmacodynamics can be regarded comparable between both TKIs, the same 
base indirect response model was initially used for pazopanib. However, the drug-
specific component, INH, had to be defined for pazopanib as the original PK/PD model 
was developed solely for sunitinib. In case of pazopanib, the active concentration is 
equal to the total concentration with a protein-bound fraction reported between >0.99 
and >0.999 [47,59,151]. Several fixed values in this range were tested in the model. 
However, due to the model structure the actual effect was negligible. The value chosen 
in the final model was 0.999, which is more in accordance with the overall data from 
the literature.  
Furthermore, different transducer signals were tested for pazopanib. These included, 
in addition to the inverse linear relationship used in the PK/PD models for sunitinib 
(Equation 3.28), a linear (with γ fixed to 1), a power (Equation 3.30) and a hyperbolic 
relationship (Equation 3.31). Fractional tyrosine kinase inhibition (INH) was calculated 
Material and methods  65 
   
using the active, unbound concentration of pazopanib and the in vitro dissociation 
constant (KD) reported in the SmPC of Votrient® (Equation 3.29) [47]. It was also 
explored if the active concentration of pazopanib is better suited to describe the effect 
(EFF) on sVEGFR-2 plasma concentration in the respective models.  
The following equations were tested in addition to Equation 3.28 during model 
development: 
;bb = 1 +  z ∙ 9N~/^/j (Eq. 3.30) 
;bb =  1 + z ∙ 9N~/^/j(9N~qr +  9N~/^/j) (Eq. 3.31) 
Besides that, an Emax-model was also tested for comparison as potential relationship 
between PK and PD. As increasing sVEGFR-2 levels were observed in some patients 
while still on treatment according to the documented dosing schemes, the 
implementation of resistance models was investigated by testing feedback models. 
 
Feedback-mechanism 
A potential feedback mechanism induced by pazopanib was tested and integrated 
based on the neutropenia model by Friberg et al. [106]. Here, a rebound effect (REB) 
is calculated based on the individual baseline value of sVEGFR-2 relative to the current 
sVEGFR-2 concentration at time t. An additional exponent γ was included to account 
for the steepness of the effect: 
:; =  (o,$G%,{C|@}o";xb:2(y) ) (Eq. 3.32) 
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3.10.2 sVEGFR-3 
The pharmacodynamic model for sVEGFR-3 was originally developed by Kanefendt et 
al. in patients with mCRC treated with sunitinib based on the sVEGFR-2 model 
reported by Lindauer et al. [109,126]. Here, this model was tested for its applicability 
in both tumor entities in patients treated with sunitinib and pazopanib, respectively.  
In the following the links between PK and PD models are separately described for the 
study dugs sunitinib and pazopanib. 
 
Sunitinib 
As stated above the analogous indirect response model with an inverse linear 
relationship was already shown to be applicable for sunitinib-treated mCRC patients. 
Hence, the same approach detailed in Section 3.10.1 was used for model development 
analyzing data from both cohorts.  
 
Pazopanib 
Comparable to sVEGFR-2 no PK/PD relation for pazopanib was known from the 
literature. Again, the model developed for linking sunitinib pharmacokinetics with 
sVEGFR-2 plasma concentrations served as basis for model development. Hence, as 
detailed in section 3.10.1, three different transducer signal models as well as Emax and 
feedback relationships were tested for linking pazopanib pharmacokinetics with 
sVEGFR-3 response. The dissociation constant (KD) necessary for calculation of an 
INH (Equation 3.29) value was taken from in the official EPAR/SmPC of Votrient® [47] 
 
3.10.3 Blood Pressure 
The model for systolic and diastolic blood pressure used in this study was also 
developed based on data from 12 healthy volunteers by Lindauer et al. [109]. The 
impact of sunitinib on patients’ blood pressure was described by two separate signals: 
an immediate and a time-delayed effect. The immediate effect was set equivalent to 
the fractional inhibition by sunitinib (INH, Equation 3.29).  
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The time-delayed effect was described by using the following equation: 
w<9N/wy = 1 ∙ (9N~ − <9N/) (Eq. 3.33) 
Where τ denotes for the time needed until the effect occurs and DINC for the time-
delayed effect. 
Diastolic and systolic blood pressure (BPsys/dia) were then described by the sum of both 
signals linked by a proportionality factor R which quantified the proportional 
contribution of the slower signal to the overall effect:  
=/ta = X/ta  ∙ 1 +  z/ta ∙ (9N~ + : ∙ <9N/) (Eq. 3.34) 
Where, BSLsys/dia denotes for the baseline systolic or diastolic blood pressure. 
Analogous to the other pharmacodynamics models used z/ta  denotes for the 
intrinsic activity of sunitinib and its metabolite. 
The individual blood pressure baseline (BSLmsys/dia) was assumed to be variable over 
the course of a day. Therefore, a model reflecting the circadian rhythm of blood 
pressure was implemented. This model was parameterized with two cosine terms 
whereas AMP1 and AMP2 represented the amplitudes and PS1 and PS2 the phase 
shifts: 
X/ta =  X/ta ∙  


1 +

^=1 ∙ cos
9; ∙ 224 − =1+
^=2 ∙ cos 9; ∙ 224 − =2




 (Eq. 3.35) 
As this model is highly parameterized and only sparse blood pressure measurements 
were available for each patient, several values of this model had to be fixed to the 
respective estimates reported by Lindauer et al. [109]. 
 
3.11 Survival analysis 
In general, methods for analyzing survival data can be categorized in parametric and 
non-parametric approaches. Both were applied in this thesis. Non-parametric survival 
analysis does not rely on a fixed amount of model parameters and makes no 
assumptions on the underlying distribution. The main advantage of this type of analysis 
is that it is easy to use and interpret as it provides a fast summary of the data. On the 
other hand, the implementation of potential predictors is limited [103,154]. In contrast, 
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parametric methods assume a defined distribution of the underlying data and allow the 
implementation of potential influential variables. The most common distributions used 
in models are shown in Section 3.11.3 (Equation 3.45 – 3.47).  
Key feature of all types of survival analyses is that the various types of censored data 
are taken into consideration [103,155]: 
− Right-censored: Data is described as right-censored when patients drop out of 
a study for undefined reasons before the endpoint or the end of the study is 
achieved. Right-censoring can be further classified into three subtypes: 
o Type I: Censoring of patients at time of study end due to not achieving 
the expected endpoint (e.g. not developing a progressive disease). 
o Type II: Censoring of patients due to premature termination of a study 
when the expected number of events already occurred. 
o Randomly censored: Censoring of patients leaving the study prematurely 
due to unknown reasons (Lost to follow-up) 
− Interval censored: Censoring of patients within a certain time interval, as the 
exact date is not known.  
− Left censored: Censoring of patients when an event already happened in an 
undefined time in the past. 
Whereas right-censored data, including the various subtypes, is quite common in 
survival analysis, left-censored data is usually not to be expected. 
The mathematical basis for survival analysis is given by the survivor and the hazard 
function. The survivor function is defined as [103]: 
(y) = =( ≥ y) =  1 − b(y) (Eq. 3.36) 
Where F(t) is 
b(y) =   ()wkr  (Eq. 3.37) 
F(t) is the cumulative distribution function of a random variable T which describes the 
distribution of survival at time t and is determined by the integral of its probability 
density function f(u). Based on this the survival function S(t) expresses the probability 
that an event has not occurred by time t with P(T≥t). Applied to progression-free 
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survival as endpoint T describes the time until progression and S(t) the probability of 
not developing a progressive disease after time t [103,156].  
The hazard function h(t) describes the instantaneous risk of an event at time t. 
Mathematically, h(t) is defined by  
ℎ(y) =  lim∆k →r =[(y ≤  < y + ∆y)| ≥ y]∆y  (Eq. 3.38) 
Where Δt is an additional time frame of survival beyond time t [103,155,156]. The 
hazard rate can be calculated from the relationship between the survivor function and 
probability density function f(t), which is the derivative of F(t): 
(y) =  (y) ∙ ℎ(y) (Eq. 3.39) 
Progression-free survival under first-line therapy with sunitinib and pazopanib, as 
described in section 3.3.6, was evaluated as endpoint in all survival analyses. 
Progression was denoted with 1 and censored data with 0. The non-parametric Kaplan-
Meier analysis is described in section 3.11.1. Parametric methods used in this work 
comprise the Cox regression analysis as well as a model-based time-to-event (TTE) 
approach using NONMEM® described in section 3.11.2 and 3.11.3., respectively. 
 
3.11.1 Kaplan-Meier analysis 
The Kaplan-Meier analysis is one of the most common non-parametric methods used 
in survival analysis. Probability of survival (or the probability of not suffering from a 
progression) can be calculated by multiplying the quotient of patients still alive, which 
results from the difference between the number of patients at risk ni and the number of 
patients with an actual event di at time ti, and divided by the patients at risk at time ti 
for each observed time-point: 
¥(y) =  ¦ % − w% 
§


 (Eq. 3.40) 
Where ¥(y) denotes for the estimate of the survivor function at time ti with k as vector 
of observed time-points [103,155].  
For graphical analysis the cumulative probability of survival (or no progression) was 
plotted against the observation time. Censored data was denoted with a vertical line at 
the respective point in time. Potential influential factors on progression were tested in 
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univariate analyses. While covariates with only two characteristic values, like gender 
or prior nephrectomy, could be used without modification, continuous covariates had 
to be categorized. Here, categorization was limited to two groups per variable using 
the median as indicator. Single nucleotide polymorphisms, which were already 
categorized, were dichotomized. A list of all tested covariates is shown in Appendix A. 
For assessing potential effects the log-rank test was applied and the p value was 
calculated. In addition, it was necessary to prove these results with a permutation test, 
due to the small sample size as otherwise p values could be false significant. Kaplan-
Meier analysis was performed using the survival package of R whereas the coin 
package was used for permutation tests (Table 3.5) [120,157]. 
 
3.11.2 Cox regression 
The Cox regression model is a semi-parametric model for survival data based on the 
proportional hazard model. The general expression is given by 
ℎ(y) =  ℎr(y) ∙ ,¨ (Eq. 3.41) 
In this case ψ is the linear combination of covariates Xi and their corresponding hazard 
β: 
© =  ª ∙ « +  ª ∙ « … + ª	 ∙ «	 (Eq. 3.42) 
h0(t) can be described as the baseline hazard without any influential factor 
acknowledged. The baseline hazard h0(t) is an unknown entity as the only requirement 
is that h0(t) > 0 ; however by using a maximum likelihood approach the model 
parameters can be estimated [103]. In principle the Cox regression is used to compare 
groups of patients or the influence of covariates based on the hazard ratio (HR) which 
is in general the quotient of hazard functions of two groups with the main assumption 
that the hazard is constant over time [158]: 
~: =  ℎ\(y)ℎJ(y) (Eq. 3.43) 
For parameter estimation the log-likelihood function of the proportional hazard model 
is maximized. This function is specified by [103]: 
Xn'X(ª) = ∑ <ª« − ∑ ,­®¯∈}(k.) 	
   (Eq. 3.44) 
with Di being the event indicator which is zero in case of a right censored event and 
one in case of a documented progression. Xi is a vector of covariates for the ith 
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individual with a progression event and the term on the right hand side sums up all 
patients at risk at time ti. The standard method used in the survival package in R is the 
efron algorithm which is a modified version of the likelihood approach explained above. 
However, this method was primarily designed for dealing with tied observations [159]. 
With regard to the low sample size in the underlying cohort every event could be 
assigned to a specific subject. Hence, the use of efron compared to the standard 
approach did not result in different parameter estimates. 
Covariates were tested in a stepwise manner, analogously to the covariate analyses 
for the PK/PD models. The significance criterion for forward inclusion was set to p > 
0.05 and for backward exclusion to p < 0.01. P values were calculated using the Wald- 
and the Likelihood ratio test. Appropriateness of included covariates was assessed by 
calculation of 95% confidence intervals for the estimated β, if possible. Here, the null 
hypothesis (no effect of the respective covariate) could be rejected, if zero was not 
included in the interval. Furthermore, the final models were used for simulation of 
survival curves and compared. A list of all tested covariates is shown in Appendix A. 
Cox regression was performed using the survival package of R [120]. 
 
3.11.3 Model-based time-to-event analysis  
A model-based time-to-event (TTE) approach allows, in contrast to the classical 
survival analysis methods, the direct connection of a PK/PD model with an outcome 
model. In principle, this corresponds to the proportional hazard model used in the Cox 
regression analysis. The hazard β is then estimated similarly to a rate constant in a 
pharmacokinetic model and shares the same unit of time-1. 
Different distributions were tested in this study. The most common distribution used in 
TTE analysis is the exponential distribution with the assumption of a constant hazard 
(β = 0) (Equation 3.45). Due to the relatively short observation times, a constant hazard 
model is usually the appropriate choice for oncology studies. However, additionally two 
time-dependent models were investigated for their applicability. The Gompertz model 
assumes an exponential increase of the baseline hazard over time (Equation 3.46) 
while the Weibull distribution (Equation 3.47) shows a stronger increase of the hazard 
in the beginning becoming almost linear at later time-points [104]. 
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ℎ(y) =  ±r ∙  ,­ (Eq. 3.45) ℎ(y) =  ±r ∙  ,­∙k (Eq. 3.46) ℎ(y) =  ±r ∙  ,­∙²³ (k) (Eq. 3.47) 
A graphical presentation of all three functions is shown in Figure 3.4. Covariates tested 
included the categorical factors which were also investigated in the classical 
approaches as well as time-dependent covariates. These comprised the plasma 
concentrations and AUC values of sunitinib, SU12662 and pazopanib as well as the 
biomarkers sVEGFR-2/3 and blood pressure. For this purpose the developed PK/PD 
models were linked with the TTE model in a PK/PD/outcome model. Thus, the 
respective exposure parameters could be calculated for every point in time based on 
the individual pharmacokinetic or pharmacodynamic parameter estimates. A covariate 
was kept in the model when its inclusion led to a significant decrease of the objective 
function value (-3.84 with one degree of freedom, p = 0.05). Model appropriateness 
was evaluated, similar to the PK/PD models, with visual predictive checks by simulating 
1000 replicates using the final model parameters and comparing the results to the 
observed survival data using PsN (Section 3.1.5) [111]. Model-based TTE was 
conducted using NONMEM® [88]. 
 
 
  
 
Fig. 3.4: Graphical presentation of the investigated distributions in the model-
based time-to-event analysis. 
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3.12 Markov models for toxicity analysis 
With the exception of hypertension, which was quantified as blood pressure in mmHg 
over the course of the study in all patients, severity of therapy-related toxicity was 
documented using the latest version of the CTCAE v4.03 [105] (Section 1.5.2,  
Tab. 1.2).  
To describe this data appropriately, Markov models were developed to capture the 
presence of certain adverse events and their respective grade over the course of the 
study duration. As only limited data was available for the pazopanib cohort, 
development of these models was solely conducted for sunitinib patients and adverse 
events with a high incidence. The two most common adverse events  
observed in renal cell cancer patients treated with sunitinib patients were 
myelosuppression as well as fatigue. Myelosuppression comprised all blood-related 
adverse events such as anemia, neutropenia, thrombocytopenia and pancytopenia. If 
two blood-related adverse events occurred simultaneously in one patient, the one with 
the highest documented CTCAE grade was included in the analysis. In total, 9 of 24 
sunitinib patients developed a myelosuppression of any grade during the first-line 
therapy and 9 a fatigue of any grade. 
A general statistical approach for analysis of ordered categorical data is the 
proportional odds model [160]. This method allows the modeling of the probability of a 
certain event based on multiple influence factors [154]. For a binominal case, e.g. no 
toxicity or a severity grade of 1, the model can be written as  
$n'Gy(U) = log  U1 − U =  z ∙ ª« (Eq. 3.48) 
Here, logit(p) is the logarithm of the odd p suffering from grade 1 toxicity. β describes 
the strength of influence of variable X on p and α can be interpreted as baseline risk 
[160,161]. If multiple factors should be acknowledged in the model this can be 
expressed by a linear relationship, similar to the equivalent parameter in the 
proportional hazard model. Main assumption of this approach is that coefficient β is 
identical for every step within the categorized data. In case of drug related toxicity, this 
means that the increase in risk of sustaining a certain grade quantified by β is equal 
for every grade [162]. 
However, one drawback of this method is that all observations are treated as 
independent, which can be quite problematic with regard to the reliability of the 
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estimated probabilities [160]. To cope with this issue a first-order continuous-time 
Markov process was implemented to describe the probabilities of transitions between 
the different toxicity grades in this study. Contrary to the proportional odds model, the 
probability of transition between states is dependent solely on the current observation, 
which is referred to as the Markov property. All other states in the past are ignored and 
have no influence on the transitions [84]. The general definition of the Markov property 
is given by [163]: 
=(«	5 = µ|« = G, … , «	u = G	u, «	 = G) (Eq. 3.49) 
X is a random variable with a discrete number of possible states, in this case the 
potential CTCAE grades. Assuming that n defines the current time then the equation 
states that the next transition is independent of past events given the actual event. 
However, in this thesis a continuous-time Markov model was used, hence the Markov 
property changes as follows: 
=(«k5e = µ|«e = G) (Eq. 3.50) 
Where t is defined as time at which state i is prevalent and r is the time period the state 
i lasts. Analogous to the discrete case (Equation 3.49) the Markov property is defined 
as memoryless as the possible transition in another state j or the remaining time in the 
current state i is independent of the time already spent in i [163]. 
Analogously to a pharmacokinetic model, a continuous-time Markov process can be 
modeled using a compartmental approach. Each compartment represents a possible 
state with the amounts in a compartment as probabilities which sum up to one in total. 
Transitions between compartments are modeled with rate constants interpreted as 
probabilities for changing the state based on the current state, e.g. k01 for transition 
between no adverse event and CTCAE grade 1 [163,164]. Rate constants describing 
the change to a higher grade can be referred to as “worsening rates”, while “recovery 
rates” characterize the opposite direction. Mathematically, these processes are 
described with ordinary differential equations.  
The number of possible transitions is dependent on the observed data. Usually, it can 
be expected that a toxicity increases gradually over time, so that when severity reaches 
grade 3 the patient has already undergone grade 1 and 2. However, in this study it was 
more often the case that the first grade documented of any toxicity was grade 2 or 
higher. With regard to the CTCAE grading, it is possible that toxicity was nearly 
asymptomatic in the beginning or worsened so fast that no differentiation was possible. 
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Therefore a model which only allowed transitions from the current to the next higher or 
lower state served as basis for analysis. A similar approach was already successfully 
applied to lung cancer patients receiving erlotinib continuously on a daily basis [108]. 
Several reductions of the primary model were tested by assuming that rate constants 
between states are possibly indistinguishable. For comparison a model which allowed 
transitions between all compartments, e.g. switching from the highest grade back to 
the lowest was also considered. The influence of drug exposure (or biomarker 
response) on the worsening and recovery rate constants for blood-related toxicity of 
any grade was tested by using  
− total drug concentration over time 
− active, unbound drug concentration over time 
− cumulative, active, unbound drug AUC over time 
− sVEGFR-2/3 plasma concentration over time  
− sVEGFR-2/3 plasma concentration relative to estimated baseline over time  
In case of missing time frames, e.g. the start of an adverse event was documented, 
but the time-point of recovery was not specified, the duration was set to the end of drug 
intake of the respective cycle. Regardless of the on- or off-phase of sunitinib, the 
minimum duration of an adverse event was assumed to be one week. Model 
performance was evaluated using visual predictive checks for categorical data. The 
model was qualified using the methods as described in Section 3.8.3. Parameter 
estimation was performed using NONMEM® [88].  
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4 RESULTS 
4.1 Biomarker and drug analysis  
4.1.1 sVEGFR-2 
Quality control 
Quality control (QC) samples were analyzed during each assay run to confirm the 
specifications given on precision and accuracy given by the manufacturer. Since 
plasma samples were not available from another cohort of patients, QC samples were 
generated from a different batch of the sVEGFR-2 Kit. Except for one measurement, 
the concentrations of all quality control samples were within the reference range. An 
overview of the QC results for sVEGFR-2 is shown in Table 4.1. 
 
Tab. 4.1: Mean and relative standard deviation (CV, %) of quality control (QC) 
samples for the sVEGFR-2 analysis 
Reference range Mean [pg/mL] CV [%] 
216 - 370 315.5 14.8 
1171 - 1920 1297.9 10.5 
2340 - 3413 2541.0 8.1 
 
Concentration-time profiles (mRCC patients) 
Baseline values were available of 39 patients (88.6%), 25 (92.6%) treated with sunitinib 
and 14 (82.4%) with pazopanib. Missing baseline values were either a result of missing 
samples or the lack of enough material for analysis.  
Mean and median baseline value of the overall population were 9368.4 pg/mL and 
9117.5 pg/mL with a range of 5561.7 – 14211.6 pg/mL, respectively. When building 
subgroups for each drug treatment an arithmetic mean and median of 8982.3 pg/mL 
and 8890.4 pg/mL (range: 5561.7 – 14211.6 pg/mL) were observed for sunitinib 
patients. For pazopanib patients these values denoted with 9937.2 and 9743.6 (range: 
7676.7 – 12679.1 pg/mL), respectively. Figure 4.1 and Figure 4.2 show the mean 
concentration of sVEGFR-2 over the course of the study in patients treated with 
sunitinib and pazopanib, respectively.  
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As expected, sVEGFR-2 concentrations increased to rise again once the off-phase of 
the first cycle started after 4 weeks of continuous dosing in sunitinib patients. 
Pazopanib was given on a daily basis without interruptions; hence the sVEGFR-2 
plasma concentrations did not recover and stayed on a comparable level during the 
whole treatment. Since not all patients were treated over the whole period of 18 weeks 
the most reliable results for biomarker response could be obtained for the first six 
weeks. 
The lowest mean concentration during the first cycle was reached in the fourth 
treatment week for sunitinib with an absolute value of 5069.2 pg/mL which denotes 
with 0.54 relative to baseline. After the same period of time the mean sVEGFR-2 
plasma concentration under pazopanib treatment denoted with 6179.2 pg/mL. 
Whereas the absolute response was slightly lower after 4 weeks of treatment the 
relative response to pazopanib was comparable with 0.56.  
 
Fig. 4.1: Mean relative sVEGFR-2 concentration over time for the first 18 weeks 
after treatment start with sunitinib (not dose normalized). The dashed line 
indicates the mean sVEGFR-2 baseline value of sunitinib patients. Light-
grey boxes indicate the time on treatment. 
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Assessment of normality 
Normality of the sVEGFR-2 plasma concentrations was assessed graphically with QQ-
Plots (Figure 4.3) and using the Shapiro-Wilk test.  
For sunitinib and pazopanib patients combined, the test indicated non-normally 
distributed data with a highly significant p value of 0.00004. This was confirmed when 
building subgroups per treatment resulting in a p value of 0.0008 for sunitinib and 0.004 
for pazopanib.  
The combined data was then log-transformed and tested again. However, this had no 
effect on the overall results with a p-value of 0.001 still indicating non-normally 
distributed data. As a consequence of these findings, solely non-parametric methods 
were used for further analyses (Correlation analysis, 4.1.3). 
 
Fig. 4.2: Mean relative sVEGFR-2 concentration over time for the 18 weeks after 
treatment start pazopanib (not dose normalized). The dashed line 
indicates the mean sVEGFR-2 baseline value of pazopanib patients. The 
light-grey box indicate the time on treatment. 
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Comparison of mean response between sunitinib and pazopanib 
The Mann-Whitney-U test was used to compare the mean responses during the first 4 
treatment weeks, which corresponds to one on-phase of a sunitinib cycle. sVEGFR-2 
response was stronger with sunitinib, independent of dosage. Relative to the mean 
baseline value of each treatment group, sVEGFR-2 plasma levels are decreased by 
43.9% in sunitinib and 37.8% in pazopanib patients in week 4. A comparison of mean 
sVEGFR-2 response to the respective treatment is shown in Table 4.2. 
 
Comparison mRCC and mCRC patients (Sunitinib) 
For mCRC patients, a median baseline value of 9362 pg/mL (range: 7869 – 9941 
pg/mL) was observed, which is slightly higher compared to mRCC patients with a 
median of 8890.4 pg/mL (range: 5561.7 – 14211.6 pg/mL). However, the difference 
was not significantly different. Similar to the mRCC cohort the maximum reduction of 
sVEGFR-2 plasma concentration was achieved after 4 weeks of treatment. 
  
 
Fig. 4.3: Quantile-Quantile plot of absolute sVEGFR-2 concentrations versus the 
quantiles of normal. 
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4.1.2 sVEGFR-3 
Quality control 
Quality control samples were analyzed during each assay run to confirm precision and 
accuracy given by the manufacturer. Since plasma samples were not available from 
another cohort of patient, QC samples were generated from a different batch of the 
sVEGFR-3 Kit. Mean values and relative standard deviations are shown in Table 4.3.  
 
Tab. 4.3:  Mean and relative standard deviation (CV, %) of quality controls for 
sVEGFR-3 
Reference concentration [pg/mL] Mean [pg/mL] CV [%] 
10000.0 9997.2 3.1 
6000.0 5937.5 4.8 
2045.5 2142.7 7.2 
 
  
Tab. 4.2:  Comparison of mean sVEGFR-2 response between sunitinib and 
pazopanib for the first 4 weeks of treatment independent of dose (mRCC 
patients) 
Treatment 
week 
Mean sVEGFR-2 
concentration [pg/mL] 
Mean sVEGFR-2 
concentration [pg/mL] 
p value 
 Sunitinib Pazopanib  
1 8003.6 9116.0 0.26 
2 7282.4 7876.2 0.31 
3 6197.8 7033.5 0.34 
4 5069.2 6179.1 0.24 
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Concentration-time profiles (mRCC patients) 
Baseline values were available from 39 patients (88.6%), 24 (88.9%) treated with 
sunitinib and 15 (88.2%) with pazopanib. Missing baseline values were either a result 
of missing samples or the lack of enough material for analysis.  
Mean and median baseline values of the overall population were 65365.6 pg/mL and 
63132.7 pg/mL with a range of 35854.5 – 103886 pg/mL, respectively. When analyzing 
subgroups for each drug treatment a mean and median of 65433.8 and 64442.1 
(range: 35754.5 – 103886) pg/mL can be observed for sunitinib. For pazopanib 
patients, these values were comparable with 65256.4 and 60247.3 (range: 37159.0 – 
95998.2) pg/mL. Figure 4.4 and Figure 4.5 show the mean concentration of  
sVEGFR-3 over the course of the study in patients treated with sunitinib and 
pazopanib, respectively.  
 
Fig. 4.4: Mean relative sVEGFR-3 concentration over time for the first 18 weeks 
after treatment start with sunitinib (not dose normalized). The dashed line 
indicates the mean sVEGFR-3 baseline value of sunitinib patients. Light-
grey boxes indicate the time on treatment. 
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Assessment of normality 
Analogously to the sVEGFR-2 analysis, normality of the sVEGFR-3 plasma 
concentrations was assessed graphically with QQ-Plots (Figure 4.6) and using the 
Shapiro-Wilk test.  
For sunitinib and pazopanib patients combined, the test indicated non-normally 
distributed data with a highly significant p value < 0.0001. This was confirmed when 
analyzing subgroups per treatment resulting in a p value < 0.0001 for sunitinib and  
< 0.01 for pazopanib.  
The combined data was then log-transformed and tested again. However, this had no 
effect on the overall results with a p value < 0.0002 still indicating non-normally 
distributed data. As a consequence of these findings further analyses used solely non-
parametric methods (Correlation analysis, Section 4.1.3)  
 
Fig. 4.5: Mean relative sVEGFR-3 concentration over time for the first 18 weeks 
after treatment start pazopanib (not dose normalized). The dashed line 
indicates the mean sVEGFR-3 baseline value of pazopanib patients. 
Light-grey boxes indicate the time on treatment. 
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Comparison of mean response between sunitinib and pazopanib 
Whereas the absolute concentrations differed at least at week 4 quite substantially, the 
difference was not statistically significant (Table 4.4). When comparing the mean 
sVEGFR-3 decrease relative to baseline this becomes more evident. At treatment 
week 4 pazopanib led to a 41% lower sVEGFR-3 plasma concentration compared to 
baseline, whereas the effect of sunitinib was slightly stronger with 48%. 
 
Comparison mRCC and mCRC patients (only sunitinib) 
For mCRC patients a median baseline value of 17501 (range: 14617 – 30632) pg/mL 
was observed, which was significantly lower compared to mRCC patients with a 
median of 63133 (range of 35854.5 – 103886) pg/mL. Similarly to the mRCC cohort 
the maximum reduction of sVEGFR-3 plasma concentration was achieved after 4 
weeks of treatment. 
  
 
Fig. 4.6: Quantile-Quantile plot of absolute sVEGFR-3 concentrations versus the 
quantiles of normal. 
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Tab. 4.4:  Comparison of mean sVEGFR-3 response between sunitinib and 
pazopanib for the first 4 weeks of treatment 
Treatment 
week 
Mean sVEGFR-3 
concentration [pg/mL] 
Mean sVEGFR-3 
concentration [pg/mL] 
p value 
 Sunitinib Pazopanib  
1 65511.6 62826.9 0.45 
2 54453.4 54405.0 0.78 
3 39239.16 45604.0 0.43 
4 31730.01 41679.6 0.38 
 
4.1.3  Correlation analysis of sVEGFR-2 and sVEGFR-3 plasma concentrations 
Correlation between sVEGFR-2 and sVEGFR-3 response to sunitinib and pazopanib 
was assessed by graphical inspection (Figure 4.7) and calculation of the Spearman’s 
correlation coefficient (Table 4.5). The use of Spearman’s correlation coefficient was 
necessary due to the non-normal nature of the underlying data. Correlation coefficients 
for the combined cohort as well as separated by drugs were in a similar range, 
indicating that both proteins were comparable in their informative value.  
 
  
Fig. 4.7: Scatterplots of sVEGFR-2 and sVEGFR-3 plasma concentrations.  
(A = under sunitinib treatment, B =  under pazopanib treatment) 
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Tab. 4.5: Correlation analysis sVEGFR-2 and sVEGFR-3 
Treatment Spearman’s correlation coefficient 
Sunitinib/Pazopanib 0.616 
Sunitinib only 0.593 
Pazopanib only 0.658 
 
4.1.4  Blood pressure 
Blood pressure measurements were conducted based on the same schedule for 
determined for plasma sampling. At least one measured value was available for 42 of 
44 patients, including 26 sunitinib and 16 pazopanib patients. Diagnosed hypertension 
was documented for 31 patients (21 sunitinib, 10 pazopanib) while at least 28 patients 
(18 sunitinib, 10 pazopanib) did already receive an antihypertensive treatment before 
or right after starting the targeted therapy.  
In total, 300 measurements were available for analysis. The mean response during 
therapy separated for sunitinib and pazopanib is shown in Figure 4.8. 
Baseline measurements were available for 41 of 44 patients (93.2%) with 25 
accounting for sunitinib (92.6%) and 16 for pazopanib (94.1%). Mean and median 
systolic blood pressure at treatment start was 138.2 mmHg and 136.0 mmHg with a 
range between 99.0 and 179.0 mmHg. After dividing the cohort in subgroups per study 
drug a mean and median of 140.0 mmHg and 137.0 mmHg (range: 99.0 –  
179.0 mmHg) was observed for sunitinib patients and 135.4 mmHg and 133.0 mmHg  
(range: 106.0 – 168.0 mmHg) for pazopanib, respectively. 
Diastolic blood pressure baseline values ranged between 66.0 and 105.0 mmHg for all 
patients with a mean of 82.0 mmHg and a median of 83.0 mmHg. With regard to the 
different treatment groups a mean and median of 83.6 mmHg and 86.0 mmHg  
(range: 66.0 – 105.0 mmHg) resulted for sunitinib and 79.4 mmHg and 78.0 mmHg 
(range: 66.0 – 102.0 mmHg) for pazopanib, respectively. 
  
Results  87 
  
 
 
Fig. 4.8.A: Mean relative systolic (upper panel) and diastolic (lower panel) blood 
pressure over time for the first 18 weeks after treatment start with 
sunitinib. The dashed line indicates the mean blood pressure baseline 
value of sunitinib patients. Light-grey boxes indicate the time on 
treatment. 
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Fig. 4.8.B: Mean relative systolic (upper panel) and diastolic blood (lower panel) 
pressure over time for the first 18 weeks after treatment start with 
pazopanib. The dashed line indicates the mean blood pressure 
baseline value of pazopanib patients. Light-grey boxes indicate the 
time on treatment. 
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Comparison of mean response between sunitinib and pazopanib 
Mean response of systolic and diastolic blood pressure show the expected fluctuation 
under sunitinib therapy with increasing values during on-phases and a decrease even 
below the initial baseline value in off-phases. Since pazopanib is administered on a 
daily basis without interruptions a stable increase of systolic and diastolic blood 
pressure was observed with a maximum after 4 weeks of treatment.The Mann-
Whitney-U test was used to compare the mean responses during the first 4 treatment 
weeks, which corresponds to one on-phase of a sunitinib cycle. Mean values per week 
and per drug and their corresponding p values are shown in Table 4.6 A for systolic 
and in Table 4.6 B for diastolic blood pressure. There was no statistically significant 
difference between the mean blood pressure response in sunitinib and pazopanib after 
the first 4 treatment weeks. 
 
Tab. 4.6 A:  Comparison of mean systolic blood pressure response between 
sunitinib and pazopanib for the first 4 weeks of treatment 
Treatment 
week 
Mean systolic blood 
pressure [mmHg] 
Mean systolic blood 
pressure [mmHg] 
p value 
 Sunitinib Pazopanib  
1 134.9 138.2 0.48 
2 140.8 147.5 0.47 
3 157.5 150.6 0.59 
4 138.2 155.0 0.06 
 
Tab. 4.6 B:  Comparison of mean diastolic blood pressure response between 
sunitinib and pazopanib for the first 4 weeks of treatment 
Treatment 
week 
Mean diastolic blood 
pressure [mmHg] 
Mean diastolic blood 
pressure [mmHg] 
p value 
 Sunitinib Pazopanib  
1 83.4 86.5 0.51 
2 85.1 88.2 0.36 
3 91.6 87.4 0.44 
4 84.4 90.3 0.25 
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4.1.5 Sunitinib and N-Desethylsunitinib (SU12662) 
374 samples from 26 mRCC patients were available for analysis (excluding baseline 
measurements for biomarker analysis before treatment start). 8 samples (2.1%) were 
below the limit of quantification for sunitinib or SU12662, respectively. Referring to the 
M1 method (Section 3.8.7), these values were excluded from the dataset. For details 
on the measurements in the included mCRC patients please refer to Kanefendt et al. 
[126]. 
 
Link between pharmacokinetics and pharmacodynamic response 
The relationship between sunitinib pharmacokinetics and biomarker response in 
mRCC patients was assessed by graphical inspection of the mean response of the 
respective biomarker and the INH calculated from the mean measured active 
concentration of sunitinib and SU12662 (Equation 3.29). This PK/PD relationship was 
previously proposed by Lindauer et al. in healthy volunteers [109]. 
As the Figures 4.9 A-D indicate, the effects of active, unbound sunitinib and SU12662 
concentration were time-delayed and full response was reached later in the treatment 
cycle. During the off-phase of two weeks the concentrations of sVEGFR-2 and 
sVEGFR-3 as well as blood pressure recovered. 
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.  
Fig. 4.9:  Mean relative sVEGFR-2 concentration (A), mean relative sVEGFR-3 
concentration (B), mean relative systolic blood pressure (C) and mean 
relative diastolic blood pressure (D) vs. inhibitory function (INH) for the 
first 6 weeks of sunitinib treatment. 
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4.1.6  Pazopanib 
98 samples from 17 mRCC patients were available for analysis (excluding baseline 
measurements for biomarker analysis before treatment start). 3 samples (3.1%) were 
below the limit of quantification for pazopanib (0.1086 µg/mL). Referring to the M1 
method, these values were excluded from the dataset (Section 3.8.7). 
 
Link between pharmacokinetics and pharmacodynamic response 
The relationship between pazopanib pharmacokinetics and the pharmacodynamic 
response was assessed by graphical inspection. Here, the plasma concentration of 
pazopanib and the calculated INH for pazopanib were plotted against the respective 
pharmacodynamic parameter. As the final PK/PD models used the total plasma 
concentration of pazopanib to describe the pharmacodynamic effects on blood 
pressure, sVEGFR-2 and sVEGFR-3, (see Section 4.3) only this relationship is 
presented in Figure 4.10 A-D. 
Similarly to sunitinib, a time delay between the plasma concentrations of pazopanib 
and the maximum decrease or increase of the respective pharmacodynamic effect was 
observed. The usual therapy scheme does not include an off-phase without drug 
administration comparable to sunitinib, but is given continuously instead. Therefore, a 
hysteresis curve could not observed in the underlying data.  
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Fig. 4.10: Mean relative sVEGFR-2 concentration (A), mean relative sVEGFR-3 
concentration (B), mean relative systolic blood pressure (C) and mean 
relative diastolic blood pressure (D) vs. the mean pazopanib plasma 
concentration for the first 6 weeks of pazopanib treatment. 
94  Results 
   
4.2 Pharmacokinetic Models 
4.2.1 Sunitinib and N-Desethylsunitinib (SU12662) 
Model development based on Lindauer et al. [109] 
Absorption was described via a transit compartment model. The respective parameters 
could not be estimated with enough precision with the underlying data and were 
therefore fixed to the values reported by Lindauer et al. [109]. The estimated population 
parameters of the remaining model parameters of the base model were different to 
what was previously reported in other analyses [109,126].  
To account for missing dosing information in some cases, a parameter to estimate the 
variability on time of drug intake was considered. Introduction of this parameter led to 
an OFV decrease by 776.8 (p < 0.0001) and highly improved the overall model fit. 
However, the estimation of an inter-individual variability (IIV) on this parameter did not 
improve the model fit further. This was especially obvious when comparing the 
individual concentration vs time plots before and after the inclusion, which did not show 
any improvement. The same was observed when fixing the IIV to an arbitrary high 
value.  Similar to the previous analysis of the mCRC patient data alone by Kanefendt 
et al. [126], the introduction of an additional peripheral compartment for SU12662 led 
to a significant improvement of the model (-30.2, p < 0.0001). However, the population 
parameter for the peripheral volume of the parent drug could not be estimated with 
enough precision and was therefore fixed to the reference value reported by Lindauer 
et al. [109] Separate proportional residual errors were best describing the remaining 
residual variability of the model. 
IIV estimated on clearance, central volume of sunitinib (V1Sunitinib), central volume of 
SU12662 (V1SU12662) and the fraction metabolized to SU12662 (FM) improved the 
model further. The removal of those parameters from the model led to significant 
worsening of the objective function value (CLSunitinib: +55.1 p < 0.0001, V1Sunitinib: +20.3 
p < 0.0001, V1SU12662: +25.3 p < 0.0001, FM: +106.7 p < 0.0001). Estimation of a 
covariance between the IIV of CLSunitinib and the IIV of V1Sunitinib decreased the objective 
function value (OFV) by 20.9 and was therefore kept in the model. 
η- and ε-Shrinkage was below 20% for all estimated parameters, hence a model 
misspecification regarding the statistical model could be excluded. 
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Inter-occasion variability (IOV), based on therapy cycles of sunitinib, was tested on IIV 
of CLSunitinib and V1Sunitinib, but did not lead to a statistically significant model 
improvement, indicating that the pharmacokinetics to not vary over time.  
Based on analysis of the CWRES, six observations were removed from the dataset, 
exceeding values over or under 4.5 and -4.5, respectively. Even though not all of these 
values did exceed the threshold of ± 6 for outliers defined in Section 3.6.1, their 
influence on the model parameters was investigated. The percentage change of the 
model parameters after exclusion is shown in Table 4.7. 
 
Tab. 4.7.:  Percentage changes of population parameters after exclusion of 
potential outliers 
Parameter Unit Percentage change after outlier exclusion 
CLSunitinib [L/h] -1.18 
V1Sunitinib [L] -1.75 
V2Sunitinib [L] Parameter fixed 
QP [L/h] +2.74 
CLSU12662 [L/h] -0.50 
V1SU12662 [L] +2.43 
V2SU12662 [L] -6.41 
QM [L/h] -19.78 
Lag-time [h] +4.47 
ηCLSunitinib  +0.64 
ηV1Sunitinib  -0.53 
ηV1SU12662  -41.10 
ηFM  +1.54 
 
Final parameter estimates of this model can be found in Table 4.8 B. 
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Model development based on Yu et al. [110] 
Similarly to the reference model, liver blood flow (QH) was fixed to 80 L/h and the 
fraction metabolized to SU12662 to 0.21. A second compartment for sunitinib improved 
the model fit significantly (dOFV -128.5, p < 0.0001). However, the volume for the 
respective compartment could not be estimated with sufficient precision and was 
therefore fixed to a value previously reported by Houk et al. (Table 4.8 A) [165]. Fixing 
this parameter increased the OFV by 11.6. However, compared to the base model, the 
effect was still highly significant (dOFV 118.9, p < 0.0001). Similar to the reference 
model, clearance and volume parameters were scaled to a reference body weight of 
70 kg to allow a better comparison with the literature values. In case of missing weight 
data the value was set to the respective population mean, stratified by gender. A 
proportional error model described the residual variability for both molecules best. 
IIV was estimated for sunitinib clearance, central volume of sunitinib and SU12662 as 
well as the fraction metabolized to SU12662. Removal of these parameters from the 
model led to significant worsening of the model fit (CL +90.6 p < 0.0001, V1Sunitinib 
+42.0, p < 0.0001; V1 (SU12662) +18.5, p < 0.0001; FM: +134.7, p < 0.0001). While 
the removal of the IIV on the absorption rate constant ka increased the OFV by 27.3, 
the η-shrinkage on this parameter was reported with > 40% and was therefore 
considered as non-reliable estimate of the variability. η- and ε-Shrinkage was below 
20% for all other estimated parameters, hence a model-misspecification regarding the 
statistical model could be excluded.  
IOV, based on therapy cycles of sunitinib, was tested on the IIV of CL and IIV of 
V1Sunitinib, but did not lead to a statistically significant model improvement, indicating 
that the pharmacokinetics did not vary over the course of the therapy.  
 
Model selection 
The PK model based on the one published by Yu et al. was considered superior and 
was therefore used for further analysis. This decision was based on the comparison of 
goodness-of-fit plots, visual predictive checks, and the reliability of the parameter 
estimates (Figure 4.11 and Appendix D.I). An overview on the final parameter 
estimates including bootstrap residuals and 90% confidence intervals for both models 
can be found in Table 4.8 A-B. 
Results  97 
  
While the VPCs for both models indicate an adequate description of the data over the 
course of the therapy, the GOF plots showed that the model based on Lindauer et al. 
was not able to adequately describe maximum plasma concentrations of sunitinib and 
its metabolite, which is illustrated by a sharper cut-off of the population predictions. In 
addition, when plotting the individual and population predictions of both models against 
each other, it becomes more evident, that some higher plasma concentrations are not 
adequately described when using the model by Lindauer et al. (Appendix D.I). 
In addition the individual predictions, population predictions and CWRES of both 
models were plotted against each other to identify deviations between predictions. For 
this purpose identical data sets, thus without the exclusion of the observations 
mentioned above for the transit compartment based model, were used. These plots 
indicated that the use of the model based on healthy volunteers led to a mistakenly 
identification of potential outliers. The respective observations could be described by 
the other model and were therefore not removed during the modeling process.  
Furthermore, the need for a correction parameter to account for missing or unreliable 
information on dosing time, introduced additional uncertainty when the model based 
on Lindauer et al. was used. This approach was particularly problematic, as it was not 
possible to estimate variability on the correction factor without destabilizing the model. 
Hence, one fixed-effect parameter was applied to all patients which leads to a high 
uncertainty.  
A schematic overview of the final structural model can be found in Figure 4.12. 
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Fig 4.11: Visual predictive check of sunitinib (A) and SU12662 (B) concentrations 
for the first 6 weeks of treatment. The black solid lines indicate the mean 
model prediction and the 90% prediction interval. Dotted lines show the 
measured mean and interval, respectively. Dark and light grey areas 
represent the respective confidence bands.  
 
  
Results  99 
  
Tab 4.8 A:  Final parameter estimates for sunitinib and SU12662 based on the 
model by Yu et al. [110] 
Parameter Unit Estimate (RSE, %) 
Mean 
(Bootstrap) 
90% CI 
Sunitinib     
ka [1/h] 0.133 (34.6) 0.149 0.097 – 0.251 
CLSunitinib [L/h] 33.9 (6.0) 33.9 30.8 – 37.5 
V1Sunitinib [L] 1820.0 (6.6) 1812.1 1607.8 – 1812.2 
V2Sunitinib [L] 588* - - 
QP [L/h] 0.371 (18.9) 0.373 0.263 – 0.494 
QH [L/h] 80* - - 
σP  -0.367 (14.1) -0.361 -0.450 – (-0.283) 
SU12262     
CLSU12262 [L/h] 16.5 (5.4) 16.5 15.0 – 17.9 
V1SU12262 [L] 730 (14.1) 713.6 545.9 – 872.9 
V2SU12262 [L] 592 (13.2) 604.9 481.0 – 737.4 
QM [L/h] 2.75 (24.6) 2.90 1.96 – 4.27 
FM - 0.21 * - - 
σM - -0.281 (10.8) -0.276 -0.326 – (-0.229) 
IIV     
ηCLSunitinib % 30.3 (29.0) 29.0 22.2 – 35.2 
ρ(CLSunitinib, 
V1Sunitinib) 
. -0.061 (48.3) -0.069 -0.127 – (-0.019) 
ρ(CLSunitinib, 
FM) 
% -0.0425 (40.8) -0.0392 -0.0671 – (-0.0130) 
ηV1Sunitinib % 25.3 (30.3) 23.0 18.0 – 29.7 
ρ(V1Sunitinib, 
V1SU12662) 
- 0.0481 (51.8) 0.0534 0.0091 - 0.0996 
ηV1SU12262 % 42.9 (54.8) 46.5 30.3 – 65.9 
ηFM % 34.6 (20.5) 33.5 27.5 – 38.7 
*Parameter fixed 
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Tab 4.8 B: Final parameter estimates for sunitinib and SU12662 based on the 
model by Lindauer et al. [109] 
Parameter Unit Estimate (RSE, %) 
Mean 
(Bootstrap) 
90% CI 
Sunitinib     
ka [1/h] 0.54* -  
CLSunitinib [L/h] 41.8 (6) 41.0 36.9 – 45.5 
V1Sunitinib [L] 3350 (7) 3330 2952 - 3772 
V2Sunitinib [L] 221* - - 
QP [L/h] 0.674 (29) 0.677 0.368 – 1.037 
NN - 1.46*  - 
RFP - 1.91*  - 
MTT [h] 1.48*  - 
Lag-time [h] -3.97 -3.87 -4.83 - -2.79 
σP mRCC - -0.328 (20) -0.318 -0.430  - (-0.221) 
σP mCRC - -0.365 (15) -0.355 -0.446 – (-0.249) 
SU12262     
CLSU12262 [L/h] 19.8 (5) 19.62 17.84 – 21.66 
V1SU12262 [L] 2110 (8) 2080 1793 - 2376 
V2SU12262 [L] 540 (13) 575 445 – 731 
QM [L/h] 1.46 (26) 1.56 0.98 – 2.43 
FM - 0.21* -  
σM mRCC - 0.322 (11) 0.320 0.260 – 0.382 
σM mCRC  0.273 (9) 0.268 0.224 – 0.308 
IIV     
ηCLSunitinib % 41.4 (15) 38.3 28.7 – 47.6 
ρ(CLSunitinib, 
V1Sunitinib) 
- 0.153 0.144 0.074 – 0.225 
ηV1Sunitinib % 45.3 (16) 43.2 27.2 – 47.5 
ηV1SU12262 % 32.2 (20) 32.3 21.1 – 44.7 
ηFM % 46.8 (11) 43.7 35.8 – 51.6 
RFP = ratio of presystemic to systemic metabolite formation; MTT = mean transit 
time; NN = Number of transit compartments; *Parameter fixed 
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Fig. 4.12: 
 
Schematic overview of the structure of the pharmacokinetic model for 
sunitinib and its active metabolite (modified from Yu et al. [110]). 
 
Covariate Analysis 
The systematic covariate search did not reveal any significant effects on one of the 
model parameters. Of particular interest was the effect of the ABCB1 SNP on 
clearance, which was previously reported by Diekstra et al. [166]. However, this effect 
could not be reproduced with the underlying data. An overview on all covariates tested 
can be found in Appendix A. 
 
Influence of fixed parameters in the final model 
Variation of the fixed parameters of QH, V2Sunitinib and FM resulted in differences 
between the estimated population means of the final model and the respective 
modified models. When fixing the value for QH between -50 and +50% the highest 
effect could be observed for the central volumes of sunitinib and SU12662 with a RPE 
varying between -23.6 - 11.5% and -19.5 – 42.5%, respectively. However, mean RPE 
was below 12% for all parameters and the estimated means were all within the 90 % 
confidence interval of the final model. 
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The variation of V2Sunitinib only affected the estimate of the intercompartmental 
clearance (QP) between the central and the peripheral compartment of with a RPE 
varying between -10.8 and 13.5%. Again, mean RPE was fairly low for all parameters 
with a maximum of 0.43% for QP. Estimated means were all within the 90% confidence 
interval of the final model. 
Varying the fraction metabolized to SU12662 led to expected results. Due to the close 
relationship to all parameters related to the active metabolite, in detail the metabolite 
clearance, the central and peripheral volume and the intercompartmental clearance, 
changing the metabolized fraction resulted in comparable variations in these 
parameters. 
 
Influence of dosing time in the final model 
Due to the inconsistent documentation of dosing time in the mRCC dataset and the 
fixed dosing time-point for the mCRC patients, the influence of the time of drug intake 
was investigated in a sensitivity analysis. Absorption rate constant (ka), in particular, 
was affected by dosing time with a RPE of -36.9%. However, mean (0.084 h-1) and 
median (0.065 h-1) were still within the 90% confidence interval of the final parameter 
estimate. Furthermore, the peripheral volume of distribution and the 
intercompartmental clearance related to SU12622 showed a rather large variation with 
a RPE of -21.7 and 26.5%, respectively. Again, mean and median of both parameters 
were still within the 90% confidence interval of the final parameter estimates of the 
reference model. 
Similarly affected was the residual error estimated for sunitinib, which was increased 
by 25.2% on average. Inter-individual variability on the central compartment of 
SU12662 varied also by a rather large margin with an estimated RPE of 29.8%. Yet, 
all 50 simulated data resulted in comparable parameter estimates with the main 
influence on the absorption process, which was expected due to variability and quality 
in data available for drug intake. Since all parameters estimates were always within 
the bootstrap confidence interval of the main model, the influence of dosing time was 
considered negligible. Fixing the time of drug intake using a consequent rule, as 
described in 3.8.5, resulted in reliable parameter estimates, given the fact that the 
quality of documentation was variable in the underlying study. Results of the sensitivity 
analysis are shown in Table 4.9. 
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Tab. 4.9:  Results of the sensitivity analysis with respect to dosing time 
Parameter Unit Estimate CI (90%) Mean Median RPE, % 
ka 1/h 0.133 0.010 – 0.250 0.084 0.065 -36.9 
V1Sunitinib L 1820 1607.8 – 1812.2 1778.6 1780 -2.3 
CLSunitinib L/h 33.9 30.8 – 37.5 35.3 35.4 4.2 
CLSU12662 L/h 16.5 15.0 – 17.9 16.97 16.9 2.8 
V1SU12662 L 730 545.9 – 872.9 571.36 571 -21.7 
QM L/h 2.75 1.96 – 4.27 3.48 3.4 26.5 
V2 SU12662 L 592 481.0 – 737.4 615.33 633.5 3.9 
QP L/h 0.371 0.263 – 0.494 0.353 0.3555 -4.9 
σP - -0.367 -0.45 - -0.283 -0.459 -0.457 25.2 
σM - -0.281 -0.326 - -0.229 -0.297 -0.295 5.5 
ηV1Sunitinib % 25.3 24.5 - 30.0 29.50 29 16.6 
η V1SU12262 % 42.9 42.42 - 66.3 55.68 47.9 29.8 
ηCLSunitinib % 30.3 29 - 35.9 28.34 29.2 -6.5 
ηFM % 34.6 33.5 - 39.0 34.52 35.2 -0.2 
 
4.2.2 Pazopanib 
Since only limited pharmacokinetic data on patients treated with pazopanib was 
available. A Bayesian approach was chosen to obtain individual pharmacokinetic 
parameters for each individual patient. Basis for this analysis was the model published 
by Yu et al. [152]. No structural changes were made to this model and all population 
parameters and their respective variability were fixed to the reported values, with the 
exception of IOV, as this parameter was very specific to the published analysis (Table 
4.10). A schematic overview of the final model used can be found in Figure 4.13. 
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Fig. 4.13: 
 
Schematic overview of the structure of the pharmacokinetic model for 
pazopanib (modified from Yu et al. [152]). 
 
In this model IIV was only considered for pazopanib clearance (CLPazopanib) the fast 
absorption rate constant (ka(fast)), peripheral volume of distribution (V2Pazopanib) and 
bioavailable fraction (F). Hence, only these parameters varied across the patients in 
this study. Descriptive statistics for each model parameter are shown in Table 4.11. 
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Tab 4.10:  Parameter estimates for pazopanib pharmacokinetics reported by  
Yu et al. [152] 
Parameter Unit Estimate RSE (%) IIV (%) IOV (%) 
ka(fast) h-1 0.40 31 140 - 
ka(slow) h-1 0.12 28 - - 
Ffast % 36.1 34 - - 
Fslow % 63.9 34 - - 
Lag-time h 0.98 6 - - 
CLPazopanib L/h 0.27 23 30.9 - 
V1Pazopanib L 2.43 34 - - 
QP L/h 0.99 29 - - 
V2Pazopanib L 25.1 27 98.2 - 
Rel. F at dose 200 mg - 1* - 35.6 75.5 
Max effect of dose level 
on F 
- 1* - - - 
Half max dose level mg 480 23 - - 
Decrease of F over time % 50.1 27 - - 
Decay constant day-1 0.15 43 - - 
 
Tab. 4.11: Descriptive statistics of individual parameter estimates for pazopanib 
based on the model by Yu et al. [152] 
Statistic CLPazopanib [L/h] VPazopanib [L] ka(fast) [h-1] Rel. F at dose 
200 mg 
Mean 0.24 29.61 0.81 0.36 
Median 0.23 23.50 0.52 0.34 
Range 0.18 – 0.35 3.73 – 95.32 0.08 – 4.25 0.24 – 0.57 
SD 0.05 23.74 0.99 0.10 
Relative  
SD (%) 
19.15 80.18 121.66 27.08 
SD = Standard deviation 
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4.3 PK/PD models 
4.3.1 sVEGFR-2 
Sunitinib 
The model originally developed for healthy volunteers and for sVEGFR-2 could 
successfully be adapted to patients with mRCC and mCRC. The concentration-time 
profile of the soluble receptor was best described using an inverse-linear link between 
PK and PD (Section 3.10.1). An Emax model was tested for comparison but did not 
result in a statistically significant improvement of the model fit. 
 
Tab. 4.12: Final parameter estimates of the sunitinib PK/PD model for sVEGFR-2 
Parameter Unit 
Estimate 
(RSE, %) 
Mean 
(Bootstrap) 
Median 
(Bootstrap) 
90% CI 
(Bootstrap) 
Structural model 
Baseline pg/mL 9030 (2.9) 9038 9030 8602 – 9477 
α - 2.31 (8.8) 2.31 2.31 1.98 – 2.64 
kout 1/h 0.0043 (7.6) 0.0043 0.0043 0.0038 – 0.0049 
KD µg/mL 4* - - - 
Statistical model 
σ - 0.124 (6.8) 0.122 0.122 0.108 – 0-136 
η (Baseline) % 19.9 (21.4) 19.4 19.2 16.0 – 22.8 
Covariate model 
Tumor type 
on α 
- -0.328 (24.6) -0.322 -0.329 -0.440 – -0-186 
FLT-1 on α - -0.565 (25.4) -0.557 -0.562 -0.787 – -0-319 
ABCR2 on 
α 
- -0.311 (37.9) -0.307 -0.306 -0.497 – -0-117 
FLT-1 = VEGFR-3 rs6877011; ABCR2 = ABCB1 rs2032582 
 
In contrast to the reference model by Lindauer et al., the residual error was best 
described by a proportional error model. A combined additive and proportional error 
model did not result in a significant improvement of the model fit (dOFV = -2.64). 
Neither did the subdivision of the residual error by tumor type (mRCC vs mCRC). Using 
solely an additive residual error even worsened the overall model performance (dOFV 
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= +11.59). While the inclusion of IOV per cycle on the estimated baseline and α did 
result in a significant decrease of the OFV (-11.59 and -15.85, respectively), the 
estimated parameter was not reliable due to a high RSE and a shrinkage above 40% 
in both cases. Furthermore, the estimated IOV on sVEGFR-2 baseline was relatively 
low with 9% and therefore most likely not relevant. 
Including an IIV on sVEGFR-2 baseline, intrinsic activity α and degradation constant 
kout lead to a highly significant decrease of the OFV by -261.4 (p < 0.0001). However, 
after stepwise elimination of each IIV from the full statistical model only η (α) and η 
(Baseline) were kept. The removal of η (kout) showed no significant worsening of the 
model fit (dOFV = +3.52) and was therefore not included in the final model. However, 
after the full covariate model was established, the IIV on α approached zero and was 
removed without any effect on the model fit and the OFV, respectively. 
Final parameter estimates and the respective bootstrap mean, median and 90% 
confidence interval can be found in Table 4.12. For comparison the estimates for each 
parameter from the original analysis in healthy volunteers is also shown. 
 
Covariate analysis 
Systematic covariate search revealed three statistically significant covariates which 
were kept in the final model: 
− Higher intrinsic activity of sunitinib/SU12662 for patients with mRCC  
Compared to mRCC patients, mCRC patients showed a 32.8% lower intrinsic 
activity of sunitinib on sVEGFR-2 levels (2.31 vs 1.55). Exclusion of this 
covariate in the final backward elimination step increased the OFV by 8.78 (p = 
0.003) 
− Decreased intrinsic activity of sunitinib/SU12662 for patients with VEGFR-3 
rs6877011 (1=CG/GG;0=CC): 
Patients with a CG/GG allele showed a 56.5% decreased intrinsic activity α 
compared to the wildtype (2.31 vs 1.00 in case of mRCC patients and 1.55 vs 
0.65 for mCRC patients). Exclusion of this covariate in the final backward 
elimination step increased the OFV by 12.35 (p = 0.0004). 
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− Decreased intrinsic activity of sunitinib/SU12662 for patients with ABCB1 
rs2032582 (1=GT/TT; 0=GG)  
Patients with a GT/TT allele had a 31.1% decreased intrinsic activity of 
sunitinib (2.31 vs 1.59 in case of mRCC patients and 1.55 vs 1.07 for mCRC 
patients) on sVEGFR-2 levels compared to wildtype GG carriers. Exclusion of 
this covariate in the final backward elimination step increased the OFV by 6.7 
(p = 0.01). 
In the full covariate model shrinkage on α increased above the threshold value of  
30 % (Section 3.8.3). Removing this parameter from the model increased the OFV by 
2.42. 
  
The pcVPC indicates that the model is able to sufficiently describe the underlying data. 
No model misspecification or systematic errors could be identified in the GOF plots. 
However the population predictions (PRED) vs. dependent variable (DV) plot shows a 
cut-off at high concentrations, indicating that these cannot be described well by the 
population model. This is most likely explained by the individual sVEGFR-2 baseline 
 
Fig 4.14: Visual predictive check of sVEGFR-2 for the first 6 weeks of sunitinib 
treatment. The black solid lines indicate the mean model prediction and 
the 90% prediction interval. Dotted lines show the measured mean and 
interval, respectively. Dark and light grey areas represent the respective 
confidence bands. The dark-grey rectangle represents the time on 
treatment. 
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values, since the PRED do not include inter-individual variations, applying the same 
baseline value for all patients. (Appendix D.II). The covariate effects are listed in Table 
4.12, where FLT-1 denotes for VEGFR-3 rs6877011 and ABCR2 for ABCB1 
rs2032582. 
 
Pazopanib 
sVEGFR-2 plasma concentrations during pazopanib treatment were also best 
described with an inverse-linear relationship of the active pazopanib concentration and 
the turnover rate constant kin. The Emax and the power function provided comparable 
results regarding the overall fit. However, the turnover model using an inverse linear 
relationship was preferred as a similar relationship between sunitinib pharmacokinetics 
and sVEGFR-2 was already successfully established (see above). Using the fractional 
tyrosine kinase inhibition INH (Equation 3.29) instead of the active concentration 
worsened the model fit significantly (dOFV = +5.2). Furthermore, goodness-of-fit plots 
indicated that low plasma concentrations of sVEGFR-2 could not be predicted 
sufficiently enough using INH. Active concentration of pazopanib assumed a protein 
binding of 99.9% [45]. Parameter estimates, except for the magnitude of α, were not 
influenced by this value. 
Applying an IIV on sVEGFR-2 baseline, α and kout decreased the OFV significantly by 
96.52. Systematically removing each parameter again from the model worsened the 
model fit in all cases. OFV increased by 23.9 when fixing IIV on sVEGFR-2 baseline 
concentration to 0 and by 30.5 and 18.2 for IIV on α and kout respectively. 
Although the exclusion of IIV on kout worsened the model fit significantly, this parameter 
introduced a high bias of the model parameters. A case deletion diagnostic (CDD) 
analysis revealed a bias of 281.7% for η (α), 75.5% for α and 82.5% for η (Baseline). 
Removing the parameter from the model reduced the bias (η (α): 9.8%, α: 22.1%,  
η (Baseline): 41.2%) and stabilized the model. Estimation of correlations between 
model parameters had no significant impact on the model performance. 
Table 4.13 shows an overview of the final parameter estimates including bootstrap 
confidence intervals. The respective pcVPC is shown in Figure 4.15. 
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Tab. 4.13: Final parameter estimates of the pazopanib PK/PD model for  
sVEGFR-2 
Parameter Unit 
Estimate 
(RSE, %) 
Mean 
(Bootstrap) 
Median 
(Bootstrap) 
90% CI 
(Bootstrap) 
Structural model 
Baseline pg/mL 9820 (3.4) 9825 9825 9271 – 10390 
α - 22.1 (21.4) 22.5 21.5 15.7 – 30.9 
kout 1/h 0.0038 (27.9) 0.0040 0.0040 0.0022 – 0.0059 
Statistical model 
Residual 
Error 
pg/mL 846 (21.6) 794 818 593 – 981 
η (Baseline) % 12.7 (38.0) 12.4 12.2 8.0 – 15.9 
η (α) % 46 (48.2) 46.0 44.9 26.7 – 62.8 
 
  
 
Fig. 4.15: Visual predictive check of sVEGFR-2 for the first 6 weeks of pazopanib 
treatment. The black solid lines indicate the mean model prediction and 
the 90% prediction interval. Dotted lines show the measured mean and 
interval, respectively. Dark and light grey areas represent the respective 
confidence bands. The dark-grey rectangle represents the time on 
treatment. 
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4.3.2 sVEGFR-3 
Sunitinib 
The model originally developed for healthy volunteers and for sVEGFR-2 could 
successfully be adapted to patients with mRCC and mCRC. Again, the concentration 
time profile of the soluble receptor was best describe using an inverse-linear link 
between PK and PD. Introduction of IIV on all model parameters except KD, which was 
fixed to a literature value, led to a highly significant decrease of the OFV  
(dOFV: -743.56). Yet, the estimated variability on kout showed a shrinkage higher than 
the threshold value of 30% and was therefore removed. This did not lead to a 
significant worsening of the model (dOFV: 0.79). Inter-occasion variability was tested 
on both, the intrinsic activity α and the baseline values, but did not result in a significant 
model improvement (dOFV:-1.96 and -3.31, respectively). Estimation of a covariance 
between α and the sVEGFR-3 baseline value further improved the model, decreasing 
the OFV significantly by -8.03. 
 
Covariate analysis 
In the covariate analysis one influential factor was identified. The inclusion of “tumor 
entity” on the estimated baseline value of sVEGFR-3 highly improved the model fit, 
shown by an increase of 53.68 in the OFV after removal of this parameter. The 
population mean for mRCC patients was estimated to be 63500 pg/mL, whereas for 
mCRC patients a lower value of 22733 pg/mL was predicted. 
Goodness-of-fit plots of the final model can be found in Appendix D.III. Whereas the 
IPRED vs DV plot, where inter-individual variability is taken into account, suggests a 
good model performance, the PRED vs DV graphics reveal that the maximum 
concentrations of sVEGFR-3 cannot be adequately be described using the population 
model, showing a cut-off at a certain concentration. The same was observed for 
sVEGFR-2 and can also be explained by the estimated baseline concentration at time 
zero, which is a set to an identical value for all patients. However, the pcVPC shown 
in Figure 4.16 indicates that the model is able to describe the data sufficiently well. 
An overview on the final model parameters and their respective 90% bootstrap 
confidence interval and standard error is shown in Table 4.14. 
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Tab. 4.14:  Final parameter estimates of the sunitinib PK/PD model for sVEGFR-3 
Parameter Unit 
Estimate 
(RSE, %) 
Mean 
(Bootstrap) 
Median 
(Bootstrap) 
90% CI 
(Bootstrap) 
Structural model 
Baseline pg/mL 63500 (5.9) 63750 63853 57305 – 69800 
α - 1.74 (9.8) 1.76 1.75 1.49 – 2.05 
kout 1/h 0.0053 (7.2) 0.0054 0.0054 0.0047 – 0.0060 
KD µg/mL 4* - - - 
Statistical model 
Residual Error - 0.15 (6.9) 0.15 0.15 0.13 – 0.17 
η (Baseline) % 42.6 (24.4) 40.1 39.8 31.8 – 48.1 
η (α) % 54.3 (43.5) 51.3 50.3 30.9 -68.8 
ρ (Baseline, α)  - 0.123 (39.6) 0.123 0.122 0.045 – 0.209 
Covariate model 
Tumor type on 
baseline 
- -0.642 (6.5) -0.640  -0.703 – (-0.569) 
*Parameter fixed 
 
Fig 4.16: Visual predictive check of sVEGFR-2 for the first 6 weeks of sunitinib 
treatment. The black solid lines indicate the mean model prediction and 
the 90% prediction interval. Dotted lines show the measured mean and 
interval, respectively. Dark and light grey areas represent the respective 
confidence bands. The dark-grey rectangle represents the time on 
treatment. 
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Pazopanib 
Several models showed potential to be best describing PK/PD relationship between 
pazopanib and sVEGFR-3.  
Using the fractional inhibition (INH, Equation 3.29) as influence factor in an inverse-
linear model resulted in poor estimation of low observed concentration. When using 
only the active concentration the model fit highly improved (dOFV: – 20.98). Using a 
direct linear approach decreased the OFV further. However, when adding IIV on all 
relevant parameters both models performed equally well. VPCs indicated that the 
inverse-linear relationship was favorable in this case. Due to the parameterization of 
the model, the choice of the fraction of protein binding had no significant influence on 
parameter estimates except for the magnitude of α. A pcVPC of the final model is 
shown in Figure 4.17.  
 
  
 
Fig 4.17: Visual predictive check of sVEGFR-3 for the first 6 weeks of pazopanib 
treatment. The black solid lines indicate the mean model prediction and 
the 90% prediction interval. Dotted lines show the measured mean and 
interval, respectively. Dark and light grey areas represent the respective 
confidence bands. The dark-grey rectangle represents the time on 
treatment. 
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Introduction of IIV on model parameters improved the fit significantly (dOFV: -106.2). 
However, comparable to the model for sVEGFR-2 in pazopanib patients, IIV on kout 
resulted in a high bias for almost all parameters (α: 80.4%, kout: 568.0%, η (α): 175.4%). 
Removal of η (kout) resolved this issue sufficiently (α: 27.5%, kout: 7.1%, η (α): 121.7%) 
with a moderate increase of the OFV only. 
Table 4.15 shows an overview of the final parameter estimates including bootstrap 
confidence intervals. 
 
Tab 4.15:  Final parameter estimates of the pazopanib PK/PD model for  
sVEGFR-3 
Parameter Unit 
Estimate 
(RSE, %) 
Mean 
(Bootstrap) 
Median 
(Bootstrap) 
90% CI 
(Bootstrap) 
Structural model 
Baseline pg/mL 64300 (5.2) 64300 64178 58672 - 70047 
α - 17.5 (16.5) 18.3 18.0 13.9 – 23.5 
kout 1/h 0.0047 (23) 0.0048 0.0047 0.0032 – 0.0069 
Statistical model 
Residual error % 14.2 (13.0) 13.6 13.8 11.0 – 16.0 
η (Baseline) % 23.6 (39.4) 23.1 22.7 15.0 – 30.2 
η (α) % 61.9 (49.0) 56.1 56.0 24.1 – 75.0 
 
4.3.3 Blood pressure 
Sunitinib 
Similar to the PD models for sVEGFR-2 and -3, the blood pressure model used was 
originally developed using data from healthy volunteers. In this study it could be 
successfully adapted to patients with mRCC. In the base model all parameters 
describing the circadian variation of systolic and diastolic blood pressure were fixed to 
their respective reference values from healthy volunteers. Estimation of these 
parameters was not possible due to the sparse sampling and documentation gaps (e.g. 
missing day-time). Residual error was best described using separate proportional 
models for systolic and diastolic blood pressure. 
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Introduction of an IIV on the estimated baseline values for systolic and diastolic blood 
pressure, as well as for the respective intrinsic activities (α) improved the model fit 
significantly shown by a combined OFV decrease of -214.18. By removing the IIV from 
baseline systolic and diastolic blood pressure the OFV increased by 30.3 and 42.8 (p 
< 0.0001), respectively. A statistically significant worsening of the model fit was also 
observed when removing the estimated IIV from both intrinsic activity parameters. The 
OFV increased by 8.2 (p < 0.01) and 6.0 (p < 0.025). However, both parameters 
showed a high shrinkage value (> 30%). Estimation of a covariance between systolic 
and diastolic IIV decreased the OFV by -14.86. Though, the estimated correlation was 
nearly 100%. Therefore, the statistical model was restructured with both fixed-effect 
parameters for intrinsic activity sharing one η parameter connected via a 
proportionality factor [86]. Here, an additional parameter is estimated, which accounted 
for the correlation between the variability on both intrinsic activities α. Whereas the 
OFV did not change significantly, shrinkage on both parameters decreased below the 
threshold value, leading to more reliable estimates. Removing the IIV on both activity 
parameters from the model showed a significant worsening of the model fit  
(dOFV = 27.2). Final parameter estimates including RSE, bootstrap mean and median 
values as well as the 90% confidence interval are shown in Table 4.16 
 
Covariate analysis 
Since blood pressure data was only available for 25 mRCC patients, only selected 
covariates were tested manually using the same criteria for significance (p < 0.05 for 
forward inclusion and p < 0.01 for backward elimination). Covariates tested included 
diagnosed hypertension at time of treatment start and the intake of antihypertensive 
medication during the targeted therapy. Here, especially the fixed parameters for 
circadian variation were of interest. A significant effect was found for the covariate 
“antihypertensive medication” (BPTRT) on the second amplitude parameter (AMP2), 
which was decreased by 202% (90% CI: 80-315). This resulted in a more even course 
of systolic and diastolic blood pressure throughout the day.  
The visual predictive checks for systolic and diastolic blood pressure are shown in 
Figure 4.18. Whereas the time course of blood pressure could be well described during 
the first 6 weeks of sunitinib treatment, predictions were less reliable at later time-
points, as the VPC of the full time period indicates (Appendix D.X). This can also be 
116  Results 
   
observed in the GOF plots shown (Appendix D.IV). The PRED vs DV plot clearly 
indicates that the model cannot cope with unexpectedly high blood pressure values.  
Furthermore, residuals were evenly distributed and did not show any model 
misspecification. 
 
Tab 4.16:  Final parameter estimates of the sunitinib PK/PD model for systolic and 
diastolic blood pressure 
Parameter Unit Estimate 
(RSE, %) 
Mean 
(Bootstrap) 
Median 
(Bootstrap) 
90% CI 
(Bootstrap) 
Structural model 
BSLsyst mmHg 138.0 (2.2) 137.8 137.8 132.7 – 142.6 
BSLdiast. mmHg 82.8 (1.9) 82.8 82.8 80.2 – 85.43 
αsyst - 0.064 (30.9) 0.064 0.063 0.034 – 0.098 
αdiast  0.048 (38.5) 0.048 0.047 0.020 -0.080 
τ h 121* - - - 
PS1 - 0* - - - 
PS2 - 1.4* - - - 
AMP1 - 0.025* - - - 
AMP2 - -0.016* - - - 
σsyst - 0.094 (10.2) 0.093 0.093 0.077 – 0.110 
σdiast - 0.079 (6.3) 0.079 0.079 0.07 – 0.087 
Prop. factor - 1.21 (27) 1.25 1.23 0.85 – 1.69 
Statistical model 
η (BSLsyst) % 9.3 (46.7) 9.1 8.9 5.2 – 12.2 
η (BSLdiast) % 7.4 (28.7) 7.2 7.2 5.1 – 8.8 
η (αsyst) % 105.8 (105.1) 89.0 82.7 42.6 – 123.2 
η (αdiast) % 105.8 (105.1) 89.0 82.7 42.6 – 123.2 
Covariate model 
BPTRT on 
AMP2 
- -2.02 (36.3) -1.99 -1.99 -3.15 - -0.80 
BSL = Baseline; PS = Phase shift; AMP = Amplitude; BPTRT = Treated hypertension; 
Prop. factor = Proportionality factor ; *Parameter fixed 
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Simulations 
Based on these findings simulations were performed to illustrate the effect of 
antihypertensive treatment during sunitinib therapy. Figure 4.19 shows the simulated 
systolic and diastolic blood pressure after one intake of 50 mg sunitinib with and without 
antihypertensive medication. Here, the course of blood pressure is flatter, with delayed 
extreme values due to the co-medication. It has to be noted that here only the direct 
effect of sunitinib on blood pressure is shown, and the delayed one is missing due to 
the simulated intake of only one dose. 
  
 
Fig 4.17: Visual predictive check for systolic (A) and diastolic (B) blood pressure 
during the first six weeks on sunitinib treatment. Black solid lines indicate 
the mean model prediction and the 90% prediction interval. Dotted lines 
show the measured mean and interval, respectively. Dark and light grey 
areas represent the respective confidence bands.  The dark-grey rectangle 
represents the time on treatment. 
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Pazopanib 
Based on the PK/PD model developed for sunitinib, several potential relationships for 
linking pazopanib pharmacokinetics with systolic and diastolic blood pressure were 
tested. Parameters describing the circadian rhythm of blood pressure could not be 
estimated and were fixed to the values reported by Lindauer et al. [109] Best results 
were obtained using active, unbound pazopanib concentration as predictor. Intrinsic 
activity α was quantitatively comparable for systolic and diastolic blood pressure; 
 
 
Fig. 4.18: Simulated systolic/diastolic blood pressure for one day after a single 
dose of 50 mg sunitinib with (A) and without (B) antihypertensive 
treatment. 
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hence, estimation of one αfor both physiological parameters did not result in a 
statistically significant worsening of the model fit (dOFV = +0.16).  
Significant improvements were achieved by estimating IIV on both baseline 
parameters (dOFV = -96.6), while the estimates for IIV on α approached zero signaling 
a non-significant effect. Final parameter estimates including RSE, bootstrap mean and 
median values as well as the 90% confidence interval are shown in Table 4.17 
 
Tab 4.17: Final parameter estimates of the pazopanib PK/PD model for blood 
pressure 
Parameter Unit Estimate 
(RSE, %) 
Mean 
(Bootstrap) 
Median 
(Bootstrap) 
90% CI 
(Bootstrap) 
Structural model 
BSLsyst mmHg 130.0 130.6 130.7 122.2 – 138.2 
BSLdiast mmHg 80.2 80.5 80.3 76.6 – 84.8 
αsyst/diast - 0.91 0.87 0.87 0.39 – 1.32 
τ h 121* - - - 
PS1 - 0* - - - 
PS2 - 1.4* - - - 
AMP1 - 0.025* - - - 
AMP2 - -0.016* - - - 
σsys/dia - 0.091 0.093 0.094 0.079 – 0.107 
Statistical model 
η (BSLsyst) % 6.8 6.3 6.3 3.6 – 8.2 
η (BSLdiast) % 7.8 7.6 7.6 2.4 – 11.0 
Covariate model 
BPDIAG 
on BSLsyst 
- 0.091 0.091 0.094 0.019 – 0.172 
BSL = Baseline; PS = Phase shift; AMP = Amplitude; BPDIAG = Diagnosed 
hypertension; *Parameter fixed 
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Covariate analysis 
Due to the small samples size only the influence of diagnosed hypertension as well as 
active antihypertensive therapy was tested as potential covariate effects. 
Here, patients diagnosed with hypertension had a 9.1% increased mean systolic blood 
pressure baseline throughout the day. Inclusion of this effect into the model decreased 
the OFV significantly by 4.2 (p < 0.05). Furthermore, diagnosed blood pressure had an 
effect on amplitude 1 (AMP1, dOFV = -5.5, p < 0.05). However, inclusion of both effects 
simultaneously showed no significant improvement over the univariate approach. 
Furthermore, the effect on AMP1 was clinically not plausible. Therefore the final model 
featured only the increased systolic baseline blood pressure in patients with diagnosed 
hypertension. The effect of antihypertensive treatment on AMP2 found in the sunitinib 
cohort could not be observed here.  
A pcVPC of the final model is shown in Fig 4.20. The blood pressure values during the 
first six weeks can be predicted reasonably well, while later time-points showed wider 
prediction intervals due to the sparse data (Appendix D.XII). 
 
  
Fig. 4.20: Visual predictive check for systolic (A) and diastolic (B) blood pressure 
during the first six weeks on pazopanib treatment. Black solid lines 
indicate the mean model prediction and the 90% prediction interval. 
Dotted lines show the measured mean and interval, respectively. Dark 
and light grey areas represent the respective confidence bands. The 
dark-grey rectangle represents the time on treatment. 
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4.4 Survival analysis 
4.4.1 Kaplan-Meier analysis and Cox regression 
Details on the registered events and which patients were included in the analysis can 
be found in Appendix E. 
 
Kaplan-Meier analysis (Sunitinib) 
Median PFS for sunitinib patients was calculated with 6.9 months (CI 95%: 4.1 – 12.7 
months, n = 24). For the Kaplan-Meier analysis all continuous covariates were 
dichotomized to allow comparison between two groups, respectively. Patients were 
subdivided by the population median of the sVEGFR-2 and sVEGFR-3 baseline value. 
For sVEGFR-2 this resulted in 11 patients with a higher baseline level than the median 
of 8814.68 pg/mL and 13 patients below this threshold. Median baseline of sVEGFR-
3 for patients investigated was calculated with 63132.66 pg/mL (10 patients above and 
14 patients below). Dichotomized baseline levels of both circulating proteins showed a 
significant favorable effect for patients with a sVEGFR-2 or sVEGFR-3 baseline below 
the population median on PFS (sVEGFR-2, p = 0.005; sVEGFR-3, p = 0.02). Total 
AUC and total steady-state concentration above the population median showed a weak 
but favorable effect for patients with values below the population median (p = 0.048). 
However, permutation tests with n = 100000 confirmed only the effects found for 
sVEGFR-2 and 3 baseline values above the population median (p = 0.008 and 0.03). 
Median survival for patients with sVEGFR-2 baseline levels above the population 
median were estimated with 4.73 months vs 12.65 months. A similar result could be 
observed for sVEGFR-3 with a median survival of 4.11 months vs. 9.07 months. The 
Kaplan-Meier plot for patients treated with sunitinib is shown in Figure 4.21. 
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Cox regression (Sunitinib) 
The results from the Kaplan-Meier analysis could be confirmed in a Cox regression 
analysis. In the univariate analysis the hazard ratio (HR) for a sVEGFR-2 baseline 
above the population median was estimated with 5.60 (p = 0.006, CI 90%: 1.82-17.24). 
For sVEGFR-3 the HR amounted for 3.74 (p = 0.031, CI 90%: 1.36-10.27). 
Furthermore the absolute sVEGFR-2 baseline value in µg/L also showed a significant 
effect in this analysis with a hazard ratio of 1.00028 (p = 0.044, CI 90 %:1.00006-
1.00049). However, the only significant covariates after multivariate analysis were the 
dichotomized baseline values of both soluble proteins (Table 4.18). 
Predicted survival curves using either sVEGFR-2 or sVEGFR-3 baseline as predictor 
are comparable and no difference between both covariates can be observed (Figure 
4.22) 
 
  
 
Fig. 4.21: Kaplan-Meier plot for patients treated with sunitinib including 95%  
confidence interval. The dotted vertical line indicates the median 
survival. 
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Tab. 4.18:  Results of the multivariate Cox regression for sunitinib 
Covariate Hazard ratio p value 
All significant covariates included 
sVEGFR-2 baseline above pop. median 4.64 0.061 
sVEGFR-3 baseline above pop. median 6.27 0.018 
Absolute sVEGFR-2 baseline 1.0003 0.990 
Age 0.926 0.061 
Reduced covariate model 
sVEGFR-2 baseline above pop. median 4.68 0.017 
sVEGFR-3 baseline above pop. median 6.28 0.014 
Age 0.93 0.053 
Final covariate model 
sVEGFR-2 baseline above pop. median 7.50 0.006 
sVEGFR-3 baseline above pop. median 5.36 0.015 
 
 
 
  
Fig. 4.22: Predicted survival curves by the Cox regression model using (A) the 
sVEGFR-2 baseline (dichotomized) and (B) the sVEGFR-3 baseline 
(dichotomized). 
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Kaplan-Meier analysis (Pazopanib) 
Median survival for pazopanib patients was calculated with 12.1 months (80% CI: 5.3 
– 12.5 month). Similar to patients treated with sunitinib the dichotomized covariates 
based on the sVEGFR-2 and sVEGFR-3 baseline values were evaluated. Threshold 
values for sVEGFR-2 and sVEGFR-3 in this cohort were set to 9938.4 pg/mL and 
62412.3 pg/mL, respectively. Patients with a high sVEGFR-2 baseline value had a 
median survival of 2.3 months compared to 12.4 months in the other group. However, 
the effect was not statistically significant (p = 0.051). The other tested covariates 
(radiotherapy, nephrectomy/metastasectomy, sVEGFR-3 baseline) did not have a 
statistically significant effect on PFS in pazopanib patients. The Kaplan-Meier plot for 
patients treated with pazopanib is shown in Figure 4.23. 
 
 
  
 
Fig. 4.23: Kaplan-Meier plot for patients treated with pazopanib including 95% 
confidence interval. The dotted vertical line indicates the median 
survival. 
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Cox regression (Pazopanib) 
Cox regression analysis in the pazopanib cohort did not reveal any significant 
predictors for PFS. However, the strongest effect was observed for baseline sVEGFR-
2 (dichotomized) with a HR of 5.1 (p = 0.06), which is comparable in effect strength to 
sunitinib for the same covariate. In contrast, the effect strength of the dichotomized 
sVEGFR-3 baseline levels was comparatively low in this cohort with a HR of 1.19  
(p = 0.85). Absolute sVEGFR-2 and sVEGFR-3 baseline concentrations as continuous 
covariates were even less informative (HR: 1.0003, p = 0.92 and 1.000007, p = 0.81). 
As stated above, other covariates tested were not significant either. A full list of all 
covariates tested can be found in Appendix A. 
 
Kaplan-Meier analysis (Sunitinib and pazopanib combined) 
A Kaplan-Meier analysis was also performed for all patients (n = 40) regardless of 
treatment group. Median survival in both groups combined was 6.9 months (CI 95%: 
5.3 – 12.5). The respective Kaplan-Meier plot is shown in Figure 4.24.A. However, both 
treatments did not differ statistically significant from each other (p = 0.73) (Figure 24 
B). A sVEGFR-2 baseline value above the median of the investigated population of 
9049 pg/mL (n = 40) was again associated with a longer PFS (p = 0.003). Here, 17 
patients were above and 23 below this threshold. Median survival was calculated with 
5.4 vs. 12.5 months. The same effect was observed for sVEGFR-3: dividing the 
population in two groups below and above the median of 63133 pg/mL showed a 
favorable prognosis for patients with lower baseline concentrations (p = 0.041). The 
other tested covariates did not reveal any additional effects. 
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Fig. 4.23.A: Kaplan-Meier plot of both treatment groups (no stratification) including 
95% confidence interval. The dotted vertical line indicates the median 
survival. 
 
Fig. 4.23.B: Kaplan-Meier plot including all patients (stratified by treatment). 
The dotted vertical lines indicate the median survival for each 
subgroup. 
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Cox regression (Sunitinib and pazopanib combined) 
Comparable to the Cox regression analysis performed for sunitinib patients 
exclusively, sVEGFR-2 baseline values as well as the dichotomized covariate showed 
statistically significant effects with hazard ratios estimated with 1.00028 (p = 0.026, 
95% CI: 1.00008 – 1.00048)  and 3.86 (p = 0.006, 95% CI: 1.66 – 8.97), respectively. 
In addition, a sVEGFR-3 baseline value above the population median also had a 
borderline significant effect on PFS, though weaker compared to the same parameter 
for sVEGFR-2 (HR: 2.69, p = 0.050, 95% CI: 1.19 – 6.12). In both cases patients with 
high baseline value of the respective protein had a lower survival independent of 
treatment (see also Kaplan-Meier analysis). Furthermore, age showed a weak effect 
on survival (HR: 0.95, p = 0.036, 95% CI: 0.91 – 0.99). A significant difference between 
suntinib and pazopanib was not detectable (HR: 0.81, p = 0.64). 
Results of the multivariate analysis including all significant covariates from the 
univariate approach are shown in table 4.19. Here, the effect of absolute sVEGFR-2 
baseline concentration as well as the dichotomized covariate were no longer 
significant. However, as both covariates comprise nearly identical information, 
absolute sVEGFR-2 baseline was removed for further testing. As a result, all three 
covariates were significant with the dichotomized sVEGFR-2 and sVEGFR-3 baseline 
concentrations featuring comparable hazard ratios (HR: 3.5 vs 3.13).  
 
Tab. 4.19:  Results of the multivariate Cox regression (sunitinib and pazopanib) 
Covariate Hazard ratio p value 
All significant covariates included 
sVEGFR-2 baseline above pop. median 5.63 0.070 
sVEGFR-3 baseline above pop. median 3.84 0.032 
Absolute sVEGFR-2 baseline 1.00 0.74 
Age 0.97 0.39 
Final covariate model 
sVEGFR-2 baseline above pop. median 3.50 0.016 
sVEGFR-3 baseline above pop. median 3.13 0.037 
Age 0.95 0.045 
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4.4.2  Model-based time-to-event analysis 
Sunitinib 
The PFS could be described by a parametric time-to-event (TTE) model assuming 
exponentially distributed data with a baseline hazard function λ0 of 0.0252 week-1 (90% 
CI: 0.0168 - 0.0336). The inclusion of the measured sVEGFR-2 baseline value led to 
a decrease of the OFV by 4.14 (p < 0.05) with β defined as the natural logarithm of the 
HR. 
The estimated baseline value of sVEGFR-2 showed a slightly increased effect strength 
with an estimated β of 0.341 vs. 0.260 for the measured value (dOFV: -4.67). The 
dichotomized covariate, dividing patients into two groups with baseline values above 
and below the population median of 8814.68 pg/mL, had the strongest effect with a 
decrease of the OFV by -6.40 (p < 0.025). β was estimated with 1.45 (90% CI: 0.71 – 
2.68), which corresponds to a hazard ratio of 4.26. For comparison, when 
dichotomizing the patients regarding the estimated baseline values the effect was no 
longer significant (β: 0.786, dOFV: -1.93), indicating that the resulting groups differ, 
when using model predicted baseline concentrations. sVEGFR-2 plasma 
concentration over time, relative or absolute to the individual baseline, showed no 
significant effect (β: 0.923, dOFV = -0.3; β: 0.237, dOFV = -3.7).  
None of the other covariates including genotypes, sunitinib pharmacokinetics, 
sVEGFR-3 and blood pressure showed a statistically significant effect on PFS. The 
effect of sVEGFR-3 baseline above the population median identified in the Kaplan-
Meier and Cox regression analysis could not be confirmed in the model based 
approach. Inclusion of this parameter did result in a dOFV of -2.42 with an estimated 
β of 0.867. While the central tendency of the effect was comparable it was statistical 
not significant. Hence, the best prediction was achieved by using the dichotomized 
baseline value of sVEGFR-2: 
λ(t)=λr∙eβ∙sVEGFR-2 baseline (dichotomized) (Eq. 4.1) 
Parameter estimates of the final model including bootstrap mean, median and 
confidence intervals can be found in Table 4.20.  
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Tab 4.20:  Final parameter estimates of the time-to-event model for sunitinib 
patients 
Parameter Unit Estimate 
Mean 
(Bootstrap) 
Median 
(Bootstrap) 
90% CI 
(Bootstrap) 
λ0 week-1 0.0118 (46.3) 0.0121 0.0117 0.0038 – 0.0220 
β - 1.45 (43.3) 1.57 1.49 0.71 – 2.68 
 
The observed Kaplan-Meier curve describing the progression-free survival function of 
the mRCC patients was within the 90% prediction interval of 1000 simulations and 
could sufficiently be described by the time-to-event model (Figure 4.25). However, 
stratification naturally shows wider prediction intervals for the respective subgroups, 
due to the small sample size in each cohort. However, the description of the underlying 
data is still acceptable, though difficult for later time-points as a result of censored data 
(Figure 4.26).  
 
  
 
Fig. 4.25: Visual predictive check of the final time-to-event model for sunitinib (no 
stratification). 
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Pazopanib 
A separate model-based TTE analysis for pazopanib alone was not performed due to 
the limited data. However, results after combined analysis, pooling data from both 
treatment groups, are described in the following section. 
 
Pazopanib and Sunitinib 
As for sunitinib alone, PFS was best described by a parametric TTE model with a 
baseline hazard function λ0 of 0.0232 week-1 (90% CI: 0.0160 – 0.0324  
week-1). Estimation of two different baseline hazard parameters for both study drugs 
had no significant effect, confirming the result of the Kaplan-Meier analysis, that 
survival was comparable in both treatment arms (dOFV = -0.18, not significant). 
In a univariate analysis, sVEGFR-2 baseline concentrations showed significant effects 
comparable to the analysis in sunitinib patients alone. Inclusion of absolute sVEGFR-
2 baseline concentration in µg/L led to a significant decrease of the OFV with an 
estimated β of 0.247 (dOFV = -4.6) and 0.315 (dOFV = -5.3), if the measured or 
estimated baseline values were used, respectively. Dividing patients in subgroups 
below and above the population baseline median also showed a statistically significant 
effect and comparable results between measured and estimated baseline values with 
a beta of 0.938 (dOFV = -4.4) and 1.01 (dOFV = -5.0), respectively. In contrast to 
sunitinib alone, absolute sVEGFR-2 concentration over time had the strongest effect 
Fig. 4.26: Visual predictive check of the final time-to-event model for sunitinib 
stratified by covariate with (A) sVEGFR-2 baseline below the population 
median and (B) sVEGFR-2 baseline above the population median. 
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overall with a dOFV of -8.4.β was estimated with 0.296 L/µg (0.237 L/µg for sunitinib 
patients alone).  
Relative increase in systolic and diastolic blood pressure could also be confirmed as 
significant covariate in the univariate analysis. Effect strength was comparable in both 
cases with a β of 12.7 mmHg-1 for systolic and diastolic blood pressure, respectively. 
Introduction of both parameters decreased the OFV significantly each by 6.7 and 6.8, 
respectively. However, the simultaneous inclusion of systolic and diastolic blood 
pressure had no further effect, indicating that both parameters have the same 
predictive value. Both time-dependent covariates, sVEGFR-2 and systolic blood 
pressure over time were tested in a multivariate approach. When sVEGFR-2 over time 
and relative systolic blood pressure over time were included simultaneously the OFV 
decreased by -10.67 (DF = 2, p < 0.005). However, removing blood pressure as 
predictor from the model had no significant effect (dOFV = + 2.27). In contrast, removal 
of sVEGFR-2 over time showed a borderline significant OFV increase (dOFV= 4.01). 
Therefore, for the final model only sVEGFR-2(t) was kept: 
λ(t)=λr∙eβ∙sVEGFR-2 (t) (Eq. 4.2) 
An estimated β of 0.292 L/µg corresponds to a hazard ratio of 1.33. For example, a 
baseline sVEGFR-2 concentration of 10 µg/L is associated to a hazard of 0.069  
week-1. A decrease by 1 µg/L during treatment therefore reduces the hazard by 25.8% 
(0.0512 week-1). Visual predictive checks indicate that the model can describe the 
underlying survival data sufficiently well (Figure 4.26). An overview of the estimated 
parameter values is given in Table 4.21. 
 
Tab 4.21:  Final parameter estimates of the time-to-event model for sunitinib and 
pazopanib patients with absolute sVEGFR-2 concentration over time 
included as predictor 
Parameter Unit Estimate 
Mean 
(Bootstrap) 
Median 
(Bootstrap) 
90% CI 
(Bootstrap) 
λ0 week-1 0.0037 (78.8) 0.0044 0.0036 0.001 – 0.010 
β L/µg 0.292 (30.9) 0.298 0.296 0.153 – 0.458 
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4.4.3 Simulation of treatment effects 
Figure 4.28 shows a simulation using the population estimates for a 4/2 schedule of 
50 mg sunitinib daily (A) and 800 mg pazopanib on a continuously basis (B), 
respectively. As expected the hazard decreases proportionally to the sVEGFR-2 
plasma concentration. For comparison, sVEGFR-2 baseline value was set to 10000 
pg/mL in both simulations. 
In addition, two simulations were performed showing the most common sunitinib 
regimens in comparison over the course of 18 weeks. Usually, as shown above, 
sunitinib is administered in 4/2 cycles. However, 2/1 cycles are also common practice 
in clinical settings. While the total dose is identical in the same time frame, fluctuations 
of sVEGFR-2 plasma concentrations and therefore in hazard, are lower with a 2/1 
regimen (Figure 4.29). 
 
Fig. 4.27: Visual predictive check of the final time-to-event model including 
sVEGFR-2 over time as predictor stratified for both sunitinib and 
pazopanib patients. 
Results  133 
  
 
 
Fig. 4.28 B: Simulated treatment effect during 6 weeks of continuously administered 
pazopanib with a daily dose of 800 mg. The black line represents the 
sVEGFR-2 plasma concentration during treatment and the red one the 
hazard during treatment. 
 
  
 
Fig. 4.28 A: Simulated treatment effect during one cycle of sunitinib with 50 mg daily 
intake (4/2). The black line represents the sVEGFR-2 plasma 
concentration during treatment and the red one the hazard during 
treatment. 
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Fig. 4.29 A: Simulated treatment effect during three cycles of sunitinib with 50 mg 
daily intake (4/2). The black line represents the sVEGFR-2 plasma 
concentration during treatment and the red one the hazard during 
treatment. 
 
Fig. 4.29 B: Simulated treatment effect during six cycles of sunitinib with 50 mg daily 
intake (2/1). The black line represents the sVEGFR-2 plasma 
concentration during treatment and the red one the hazard during 
treatment. 
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4.5 Markov models for toxicity analysis 
Myelosuppression 
Occurrence of myelosuppression of any grade could be described using the 
“catenary”- model approach proposed by Keizer et al. and adapted by Suleiman et al. 
[108,167]. A model estimating all possible transitions between states was also tested; 
however, this approach was not feasible for the data of this study, as it relied on too 
many assumptions regarding non-observed transitions. For a full parameterization rate 
constants for non-observed transitions had to be fixed to plausible values. E.g. if only 
transitions between grade 1 and grade 3 were observed, a rate constant for a change 
from grade 1 to 2 or 2 to 3 could not be estimated and was therefore set equal to the 
constant for a grade 1 to 3 switch.  
The inclusion of a time dependency on worsening rate constants improved the model 
fit significantly (dOFV = -20.8, p < 0.0001). In this case overall probability of developing 
a myelosuppression of any grade decreased exponentially over the course of the first-
line therapy. 
Sunitinib treatment had a small effect on worsening rates when adding the cumulative 
AUC of active, unbound sunitinib and SU12662 (AUCu) as linear covariate  
(dOFV = 4.08, p < 0.05). Active, unbound sunitinib and SU12662 concentration 
showed also an effect on recovery rates, when added as exponential covariate (dOFV 
= 4.59, p < 0.05). Here, higher drug concentrations led to a decrease and therefore a 
lower probability of a transition to a lower grade of the adverse event. However, when 
both effects were included simultaneously, the model was no longer stable and no 
reliable parameter estimates could be obtained. Therefore, visual predictive checks 
were used for decision making. Here, the model which solely relied on the effect of ACu 
on recovery rate constants as predictor was superior compared to the model which 
also included AUCu on the worsening rates. In addition, the bootstrap analysis revealed 
that the estimate for the AUCu effect was unreliable as the 90% CI included zero. 
Hence, only the effect of ACu on the recovery rate kB was kept in the model. 
In the final model, the worsening rates k01, k12 and k23 were parameterized as follows: 
Hr//· =  "Hr//· ∙ ,(u§¸∙k) (Eq. 4.3) 
HJ =  "HJ ∙  ,C@@∙\B¹ (Eq. 4.4) 
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These rate constants describe the probability over time to switch between the 
respective states of the adverse event. kB denotes for the recovery rate constant, which 
describes the probability of decreasing the current grade. kt quantifies the effect of time 
on worsening constants k01, k12 and k23 and EFF the estimated drug effect on recovery 
rate constants scaled by the ACu. In both cases TV denotes for “typical value” and 
represents the base value of the rate constant without any effect included.  
As the incidence of myelosuppression was relatively low and not all patients developed 
this kind of toxicity of any grade a case deletion diagnostic or jackknife was used to 
identify highly influential individuals in the dataset. Worsening rate constant k23, in 
particular, was highly biased as a result of the low adverse event incidence (jackknife 
estimate: 452%). Removal of one specific patient from the data set increased the 
estimated parameter value by 100.3%. As a consequence the bootstrap analysis for 
obtaining standard errors and confidence intervals for each parameter was stratified, 
to ensure that all bootstrap runs included patients with and without an occurrence of 
this adverse event. This was necessary to avoid biased bootstrap results with respect 
to the low number of subjects in this study. 
Final parameter estimates are shown in Table 4.22. Categorical VPCs indicate that the 
final model can describe the underlying data sufficiently well (Figure 4.30) 
 
Tab. 4.22:  Final parameter estimates of the Markov myelosuppression model for 
patients treated with sunitinib 
Parameter Unit 
Estimate 
(RSE, %) 
Mean 
(Bootstrap) 
Median 
(Bootstrap) 
90% CI  
(Bootstrap) 
k01 day-1 0.0149 (45) 0.0165 0.0157 0.0061 – 0.0299 
k12 day-1 0.101 (47) 0.224 0.103 0.044 – 0.408 
k23 day-1 0.438 (84) 0.778 0.453 0.129 – 2.79 
kB day-1 0.058 (44) 0.061 0.059 0.032 – 0.096 
kt day-1 -0.0207 (28) -0.0228 -0.0210 -0.0397 – 0.0120 
EFF - -0.337 (53) -0.305 -0.329 -0.473 – (-0.088) 
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A simulation for one cycle of 50 mg sunitinib daily intake in 4/2 regime is shown in 
Figure 4.31. The effect of sunitinib on recovery rates can especially be seen in the off 
phase, where toxicity of CTCAE grade 2 shows a slight increase due to the transition 
from higher toxicity grades. 
Fig. 4.29: Visual predictive checks for the development of myelosuppression 
under sunitinib treatment with (A) probability of no toxicity, (B) CTCAE 
Grade 1, (C) CTCAE Grade 2, and (D) CTCAE Grade 3/4. 
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Fig. 4.31: Simulation of a standard sunitinib regimen with 50 mg daily drug intake. 
Lines represent the probability over time to develop a myelosuppression 
of the respective grade. The grey rectangle shows the time on treatment. 
 
Fatigue 
Analogously to myelosuppression under sunitinib treatment, the development of 
fatigue of any grade could be described using the “catenary” – model proposed by 
Suleiman et al. [108] and Keizer et al. [167]. A model allowing transitions between all 
CTCAE grades was rejected for the reasons stated above. 
Recovery and worsening rates were parameterized as follows in the final model: 
Hr//· =  "Hr//· ∙ ,(u§¸∙k) (Eq. 4.5) 
HJ =  "HJ (Eq. 4.6) 
Where TV denotes for the “typical value” without any effect included. Initially k12 and 
k23 were estimated separately; however, both parameters were highly correlated and 
could not be estimated with sufficient precision. Hence, those parameter values were 
set equal. The overall model performance did not worsen significantly by removing one 
parameter (dOFV = 1.42). Adding a time-dependent constant kt describing the 
exponential decay of the worsening rates decreased the OFV significantly by -9.04 (p 
< 0.01). The same function was tested on the recovery rates, but did not improve the 
model fit significantly. Recovery rates were set equal (kB) for all transitions. A separate 
estimation did not result in a significant improvement.   
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Of the tested covariates none showed a clinically relevant effect. While inclusion of the 
sVEGFR-3 concentration over the course of the therapy decreased the OFV 
significantly by -6.8, the effect was contradictory, since a stronger decrease of 
sVEGFR-3 led to a decreased probability of suffering from fatigue. This, in reverse, 
would suggest that a higher sunitinib exposition decreases the chance of developing a 
fatigue. Hence, this effect was not included in the final model and considered as an 
artifact due to the low patient number and the low incidence of fatigue. 
Final parameter estimates including mean, median and 90% bootstrap confidence 
intervals can be found in Table 4.23. 
Categorical visual predictive checks indicate that the model is able to describe the 
occurrence of fatigue in this mRCC cohort reasonably well, regardless of the low 
incidence rate during the study period (Figure 4.32) 
 
Tab 4.23:  Final parameter estimates of the Markov fatigue model for patients 
treated with sunitinib 
Parameter Unit 
Estimate 
(RSE, %) 
Mean 
(Bootstrap) 
Median 
(Bootstrap) 
90% CI  
(Bootstrap) 
k01 day-1 0.0094 (41.2) 0.0099 0.0091 0.0046 – 0.0173 
k12/k23 day-1 0.0935 (81.7) 0.1112 0.0909 0.0239 – 0.2599 
kB day-1 0.0704 (29.3) 0.0712 0.0695 0.0415 – 0.1078 
kt day-1 -0.0134 (58.6) -0.0145 -0.0132 -0.0256 – (-0.007) 
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Fig. 4.32: Visual predictive checks for the development of fatigue under sunitinib 
treatment with (A) probability of no toxicity, (B) CTCAE Grade 1, (C) 
CTCAE Grade 2, and (D) CTCAE Grade 3/4. 
Discussion  141 
 
   
5 DISCUSSION 
5.1 PK/PD and Biomarker Analysis 
5.1.1 Pharmacokinetics 
Sunitinib 
The developed pharmacokinetic/pharmacodynamic (PK/PD) models adequately 
describe plasma concentration-time profiles of sunitinib and its active metabolite 
SU12662 in both tumor entities. Covariate analysis on the PK parameters did not 
reveal any significant findings. Differences between both studies were not observed, 
indicating that sunitinib pharmacokinetics are independent of the tumor type. The 
estimated pharmacokinetic parameters are in the same range compared to other 
published population PK analyses [32,165]. Whereas both published semi-mechanistic 
models were able to describe the data, the rigid transit-compartment model developed 
by Lindauer et al. failed to provide accurate estimates without adding a fixed effects 
parameter to account for uncertainties in sampling and dosing times. This problem was 
absent when the model originally developed by Yu et al. was used. Nonetheless, the 
poor documentation is a clear limitation of this study, even though the sensitivity 
analysis proved that parameter estimates are reliable. 
The significant increase of sunitinib clearance in patients with ABCB1 rs2032582 TT  
(-18%, p = 0.02) found in previous studies could not be confirmed [166]. Presumably, 
this may be caused by the relatively small and heterogeneous cohort in this study. 
 
Pazopanib 
Individual PPK parameters for the investigated study population treated with pazopanib 
could be estimated using a Bayesian approach with a population PK model published 
by Yu et al. [110]. 
By using this method, the applicability of the model on new datasets could be verified. 
However, the Bayesian approach limited the pharmacokinetic analysis, as no 
population parameters were estimated for this study cohort. Therefore, a covariate 
analysis was not possible and the estimated individual parameters relied on the fixed 
parameters and their variability based on the original model. With respect to the 
physiological basis of the model, this approach was still considered to be reliable 
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enough to use the resulting individual parameters for further analysis. In particular for 
establishing a link to sVEGFR-2 and sVEGFR-3 plasma concentrations and blood 
pressure.  
As initially stated, absorption of pazopanib is rather complex with respect to extrinsic 
factors. Notably, the simultaneous intake of food can alter the drug exposure 
significantly [64]. A factor which is difficult to control in a routine clinical setting. 
Although patients are usually advised to avoid drug intake right after a meal, this cannot 
be completely ruled out. As the model does not take food effect into account and 
patient’s habits’ were not documented, a potential bias may be introduced. One 
conceivable solution would be to use a mixture model to distinguish between patients 
who took their medication after a meal or in a fasting state. This would allow the 
estimation of different absorption parameters per subgroup, with the advantage that 
grouping is completely data-driven. However, due to the limited data and, in 
consequence, the use of a Bayesian approach, this method was not applicable in this 
study. Furthermore, a mixture model is usually used to distinguish between 
subpopulations with time-independent differences. Theoretically, a food effect could 
occur in multiple occasions over the course of a therapy, which would make it almost 
impossible to account for in a mixture model. Another solution could be the estimation 
of an inter-occasion variability on the respective absorption parameters. This would 
add a time -dependent random effect, to describe the variability of the drug absorption 
within a patient from occasion to occasion. However, the same constraints described 
for the mixture model approach also apply here.  
 
5.1.2  Pharmacodynamic response 
sVEGFR-2 and sVEGFR-3 
Decreasing plasma concentrations of sVEGFR-2 under sunitinib treatment have been 
reported and considered as potential biomarker for several cancer types 
[28,30,126,168,169]. As expected, a slow decrease over the course of 4 weeks on 
treatment followed by a subsequent increase in the off-phase could also be observed 
in this study. However, independent of dose or tumor entity plasma levels did not 
completely recover after the off-phase. Interestingly, intrinsic activity of sunitinib 
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showed a significant difference in both tumor entities, with a stronger decrease in 
sVEGFR-2 plasma concentrations observed for mRCC patients.  
This might be an indicator for a tumor specific resistance mechanism or in general for 
a lower efficacy of sunitinib in mCRC patients. In a double-blind, randomized phase III 
trial where sunitinib was compared to placebo in addition to the standard regimen 
consisting of fluorouracil, folinate and irinotecan (FOLFIRI) no benefit in favor for 
sunitinib could be shown. Quite contrary, median PFS was even lower compared to 
placebo (7.8 vs 9.2 months), which can probably be explained by a higher rate of 
severe adverse events [170]. Similarly, a phase II study with FOLFIRI plus sunitinib as 
first-line therapy in Japanese mCRC patients was prematurely discontinued as no 
additional activity of the combined therapy could be observed [171]. In fact, this could 
well be an isolated problem for sunitinib as other antiangiogenic drugs showed efficacy 
when combined with standard treatment, such as bevacizumab and the TKI 
regorafenib [172,173]. However, it must be noted that regorafenib, even though it was 
approved by FDA and EMA, is no longer available in Germany as no additional benefit 
could be shown according to the Gemeinsamer Bundesausschuss (G-BA) [174]. 
The presence of the variant G-allele in SNP rs6877011 in VEGFR-3 was associated 
with a 56.5% decrease in intrinsic activity on sVEGFR-2 response compared to the 
wild-type in the sunitinib cohort. In a previous study this SNP was shown to be 
associated with a decrease in PFS in mRCC patients (12 vs 4 months) [175]. 
Interestingly, this SNP effect of G-allele carriers of rs6877011 in VEGFR-3 was not 
found for intrinsic activity of sunitinib on sVEGFR-3, but on VEGFR-2. This may be 
explained by a similar binding domain in VEGFR-1, 2 and 3 [176]. A SNP in any of the 
genes encoding these VEGF receptors could result in a conformation change and 
prevent or stimulate binding of the drug ligand to VEGF-receptors, and change the 
ability of sunitinib to decrease the concentration of sVEGFR-2 and sVEGFR-3. This 
assumes that a lower intrinsic activity of sunitinib on sVEGFR-3 also affects  
sVEGFR-2 plasma concentrations. While this could be explained with a higher impact 
of a confirmation change on the binding affinity of sVEGFR-2 compared to sVEGFR-3 
these results have to be interpreted with caution. With respect to the small patient 
cohort, it is still possible that the found relationship is an artifact; hence, it needs to be 
confirmed in a larger study, ideally with a higher number of patients with the respective 
SNP. 
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A similar effect as the 31.1% decrease in intrinsic activity of sunitinib in patients with 
ABCB1 rs2032582 GT/TT compared to wildtype was not reported in the literature so 
far. However, as stated above the same SNP was previously found to be associated 
with an increased sunitinib clearance as well as an increased time-to-dose reduction 
[166,177]. ABCB1 encodes for the transport protein p-glycoprotein (Pgp), which was 
shown to be a principal cause for drug resistance in anticancer treatments [178]. 
Furthermore, a high expression was observed in healthy kidney and colon tissue as 
well as in various tumor tissues including colorectal cancer [179]. Interestingly, van der 
Veldt et al. observed an increased PFS in patients with a TCG copy in the ABCB1 
haplotype (HR 0.52, p = 0.033) [180]. However, similar to the other found influential 
genetic covariates the results need to be validated in a larger cohort.  
The same base model for sVEGFR-2 could also be successfully linked to pazopanib 
pharmacokinetics. Here, the equation for pharmacodynamic effect on sVEGFR-2 
plasma concentrations (INH) (Equation 3.29) was replaced with the active pazopanib 
plasma concentration as it provided a better fit. Using INH as a predictor, resulted in 
poor estimation of lower sVEGFR-2 plasma concentrations. One explanation might be 
the high protein binding of pazopanib which was assumed with 99.9 %, though reports 
vary between > 99% and up to > 99.9% [47,59,151,181]. In fact, no combination of 
binding constant and protein bound fraction tested provided a better fit than plasma 
concentration alone. A possible reason for this could be the high variability of the 
plasma albumin concentration due to various intrinsic and extrinsic factors in cancer 
patients, which is the main binding partner for pazopanib [182,183]. Routine 
determination of this parameter over the course therapy could help to implement a 
dynamic plasma protein binding into the model to capture this process more naturally 
than with a fixed constant leading to improved outcomes. Even though the theoretical 
protein bound fraction of 99.9% was used to calculate the active pazopanib 
concentration in the final model, this parameter only affected the scale of the estimate 
of the intrinsic activity α. Essentially, the implantation of protein binding did no longer 
influence the estimation of the intrinsic activity α, which resulted in a significantly better 
fit. 
Analogously to sVEGFR-2, decreasing concentrations of sVEGFR-3 were reported 
under antiangiogenic treatment with TKI like sunitinib or pazopanib 
[24,28,126,168,169]. The indirect response model originally developed for sVEGFR-2 
was applicable for sVEGFR-3 in both tumor entities and also for both study drugs. 
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Similarly to the model for sVEGFR-2, the INH equation was adapted accordingly for 
pazopanib (see above). 
Observed mean baseline values of sVEGFR-3 were in the same magnitude previously 
reported by Motzer et al. ranging between 22300 and 129200 pg/mL for mRCC 
patients. However, they were significantly higher compared to mCRC patients [184]. 
This finding might indicate a higher expression of this protein in patients with renal cell 
cancer. Unfortunately, data regarding the baseline values of sVEGFR-3 concentration 
in plasma in mCRC patients is sparse, as the first- and second-line treatment usually 
does not involve multi-tyrosine kinase inhibitors [185].  
Interestingly, some patients showed slightly increasing sVEGFR-2 and sVEGFR-3 
plasma concentrations under pazopanib treatment over the course of the study, which 
lead to the assumption that the effect strength of pazopanib may decrease over time. 
Yet, the implementation of any kind of mechanistic approach to describe this behavior, 
e.g. models to account for development of tolerance via feedback response, did not 
result in a model improvement. This may be attributed to the low patient number and 
the fact that only some patients showed this phenomenon. Furthermore, pazopanib 
bioavailability was shown to decrease at steady-state over the course of the therapy, 
which was taken into account by the PK model. If the reduced response was linked to 
steady-state concentrations, it should be observable in all patients. However, dose 
reductions and the possibility of lower adherence in later treatment phases hinder the 
correct interpretation of the results and make further investigations in a larger cohort 
mandatory. 
 
Blood pressure 
Whereas the model is able to describe the mean increase in systolic and diastolic blood 
pressure sufficiently well independent of the study drug, the applicability of the model 
developed based on healthy volunteers is debatable. The main problem is the high 
parameterization of the model. In consequence, parameters for circadian variation had 
to be fixed to the values estimated for healthy volunteers as they could not be reliably 
estimated with the underlying sparse data and missing information on measurement 
times in a few cases. This is particularly problematic when considering that 
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hypertension is a risk factor for mRCC and the circadian rhythm is eventually different 
compared to healthy individuals. 
Although measurements in this study were handled with standardized rules and 
devices, they were still prone to extrinsic distortions of any kind. As all measurements 
were conducted by physicians or study nurses in the respective centers, spikes of 
systolic or diastolic blood pressure can also be the result of the so called “white-coat-
effect” [186]. However, this procedure was necessary to guarantee reliable and 
comparable measurements across all study centers. Self-measurements by the 
patients could be a viable alternative, but require additional measures to ensure 
comparable results, such as journals for documentation, proper instructions by health 
professionals and a certified device [187,188]. Another result of this approach was the 
sparse data especially at later time-points. As a result, the model is able to give 
reasonable predictions for the first cycle, but becomes unreliable in later cycles. 
Interestingly, even though parameters for circadian rhythm of blood pressure could not 
be estimated directly, the effect of blood pressure treatment of any kind could be 
identified as covariate. As the simulations showed (Figure 4.18), this results in a 
smoother course of blood pressure over the day. Due to the lack of data, this covariate 
was dichotomized and the strength of the individual therapy could not be 
acknowledged, which would most likely improve the model fit even further.  
Nevertheless, provided that a large dataset is available, diagnosed hypertension and 
antihypertensive treatment could potentially be implemented as covariates in the 
model. For more reliable estimates of the respective parameters a more dense 
documentation of blood pressure measurements (e.g. a journal given to the patient, 
see above) would be necessary. Even though this would improve the dataset 
significantly, the execution can be challenging as this approach could potentially 
introduce other limitations, e.g. missing values, false documentation or ignoring the 
SOPs for correct measurements by the patient.  
  
Discussion  147 
 
   
5.2 Pharmacometric approaches for modeling outcome 
5.2.1 Model-based time-to-event analysis 
Based on the research of the last few years, after the emergence of antiangiogenic 
therapy, there is strong evidence of a potential relationship between sVEGFR-2 and/or 
sVEGFR-3 plasma concentration, hypertension and clinical outcome 
[24,28,30,32,189,190]. These findings could be further confirmed by the results of this 
study. While the effect of sVEGFR-2 decrease over time was not significant in the 
model-based time-to-event analysis (HR: 1.26, P = 0.06), patients with a substantially 
higher baseline value of sVEGFR-2 showed a significantly worse PFS. The estimated 
HR for patients with a sVEGFR-3 baseline above the population median was 2.38 while 
not statistically significant (P = 0.2). An effect of similar magnitude (HR: 2.4,  
95% CI: 1.13 – 5.11) was reported by Harmon et al. for the same covariate [189]. 
Interestingly, both effects were significant in the univariate Cox regression analysis for 
sunitinib with a HR of 5.60 (CI 90%: 1.82 – 17.24) for sVEGFR-2 baseline above the 
median and 3.74 (CI 90%: 1.36 – 10.27) for sVEGFR-3, but deviated when both were 
included simultaneously into the model. Even though our analysis suggests that the 
effect strength differs based on which biomarker is chosen, the direction is the same 
for both. This can be interpreted as a sign of high correlation between both soluble 
receptors; however, the wide confidence interval limits the validity of the results. Yet, 
these effects could be confirmed in the pooled Cox regression analysis of both 
treatment groups. 
PK/PD models for sunitinib and pazopanib in mRCC patients could be successfully 
linked to the TTE model. The novelty here was the possibility to test the predictive 
performance of the investigated biomarkers sVEGFR-2, sVEGFR-3 and blood 
pressure independent of the study drug. In particular, the modeling framework allows 
the outcome analysis of two drugs with different pharmacokinetics but comparable 
pharmacodynamic response in parallel. Previous analyses with similar approaches 
were mostly limited to one drug, while here the class effects of the TKIs pazopanib and 
sunitinib could be used for a pooled analysis of all patients. As both drugs show 
comparable benefits with respect to survival, this kind of analysis can help to further 
differentiate between non-responders and responders. Interestingly, the absolute 
decrease in sVEGFR-2 in plasma over time was found to be predictive for PFS in 
mRCC while the relative decrease had no comparable effect. In a similar approach in 
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GIST patients the sVEGFR-3 concentration was found to be predictive over time [32]. 
The results of our study suggest that sVEGFR-2 and -3 concentrations are highly 
correlated which is probably the reason that some studies attribute effects to one 
protein and vice versa.  
Furthermore, absolute systolic blood pressure over time showed a similar effect when 
included into the model. Probably, sVEGFR-2 and blood pressure describe the same 
effect, which can be explained by the assumption that increase in blood pressure is 
most likely related to VEGFR-2 inhibition [191]. This is also confirmed by the fact that 
no additional effects could be observed when both parameters were tested in the 
model. With respect to the results for the blood pressure model and its limitation in this 
study population, inclusion of sVEGFR-2 concentration over time as predictor in the 
final model is the more reliable approach. However, as blood pressure can be 
measured non-invasive and is in general more accessible, it could be possible to use 
this approach as well, once a more reliable model for cancer patients, especially with 
treated or untreated hypertension, is developed.  
 
5.2.2 Markov models for toxicity analysis 
Linking pharmacokinetic or pharmacodynamic response with toxicity using continuous-
time Markov models is a quite novel approach, and could successfully be applied to 
the toxicity data from this study. However, overall the incidence of toxicity of any kind 
was rather low in both treatment arms. As expected, fewer patients in the pazopanib 
group were affected compared to sunitinib [74,75]. Since Markov models require a high 
amount of observed transitions, only the two most common adverse events in this 
population, myelosuppression and fatigue, could be analyzed [192]. 
The chosen catenary - model assumes that a patient undergoes all grades of the 
respective toxicity until a maximum is reached and vice versa [108,167]. Hence, rate 
constants have to be estimated for each transition to describe the model completely. 
Whereas this approach is plausible from a biological perspective it also requires a 
dense documentation of adverse events. Otherwise, estimates of rate constants will 
be rather high, which corresponds to a fast transition, to describe switches which skip 
grades, e.g. grade 1 to 3. This and the low overall incidence of adverse events are the 
main limiting factors in this work. In several cases, adverse events were only 
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documented with grade 3 or higher and once an improvement was observed the 
documentation stopped. It is possible that these adverse events were not considered 
clinically significant until they reached a higher grade or were just asymptomatic. 
Another factor that rendered the situation more complicated was that end-dates of 
adverse events were missing in some cases. This was particularly an issue in patients 
who suffered from fatigue during sunitinib treatment. It is quite possible that patients 
mentioned this toxicity once to a physician or study nurse but it was not followed-up 
due to being asymptomatic or just not communicated by the patient. Compared to 
myelosuppression the grading of fatigue is more complicated as it relies on the 
physicians’ discretion or a wide variety of questionnaires for quantification [193]. 
However, the assumption that a fatigue persists at least until the end of a sunitinib 
cycle allowed the analysis of this data, but also requires a careful interpretation of the 
results. 
Nonetheless, the visual predictive checks indicated that the models could adequately 
describe the underlying data despite the sparse documentation. The quantitative 
relationship between myelosuppression and the active sunitinib plasma concentration 
(ACu) is an interesting finding as a higher exposure of sunitinib not necessarily 
increases the probability of a higher CTCAE grade but increases the chance to 
maintain the current grade for a longer period of time. In fact, the model suggests that 
sunitinib prolongs the time period in a certain grade. Interestingly, in a similar approach 
by Hansson et al. the relative decrease of sVEGFR-3 was predictive for a higher 
incidence of myelosuppression in patients with GIST treated with sunitinib [32]. While 
this could not be observed in our study the higher exposure to sunitinib seems likely to 
be related to the occurrence of myelosuppression independent of the tumor entity.  
 
5.3 Clinical relevance and potential applications 
PK/PD models can be a first and important step to develop individualized dosing 
strategies. A hypothesis generated in a smaller scale study might help to plan studies 
with a higher sample size and a design to quantify differences in two treatment arms. 
But even though our study was small in comparison, it was still possible to successfully 
apply models developed based on other populations and in other indications, and to 
construct the basis for a larger modeling framework for TKI. 
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As initially stated, dosing strategies for TKI, especially sunitinib and pazopanib, still 
mainly follow a “one-fits-all” strategy with a rigid regimen and fixed doses [67,68]. 
Although it could be shown that high exposition to sunitinib may be related to increased 
efficacy, it is also associated with a higher risk of toxicity [194]. Similar findings are also 
documented for pazopanib [195]. A trend that could also be verified in our study. In 
particular, the increase in blood pressure is a class effect which could be described for 
both dugs in the underlying population. In addition, the risk of maintaining longer 
periods of myelosuppression of any grade were directly linked to sunitinib 
pharmacokinetics in the respective Markov model.  
However, the implementation of a model-based dosing approach into clinical practice 
highly depends on the quality of the model and the underlying data, especially when 
considering a TDM approach for dose individualization. Ideally residual and inter-
individual variability is explained by informative covariates which can guide the dosing 
procedure.  
In an in silico analysis using Monte Carlo simulations it could be shown that a PK 
guided dosing approach could increase the time-to-progression by 15-31% in GIST 
patients treated with sunitinib. Here, a through plasma concentration of < 50 ng/mL 
was used as target for dose adjustment [196]. Noda et al. showed in a small cohort 
that RCC patients with a median total concentration of ≥ 100 ng/mL are associated 
with a higher incidence of grade 3 toxicity [197]. The quantitative relationship between 
sunitinib exposure and the occurrence of certain types of toxicity may therefore be 
valuable for future adverse event management strategies. 
Pazopanib shows a high inter-individual variability under standard treatment conditions 
with respect to the AUC0-24. In a feasibility study with 13 patients no benefit for 
pharmacokinetically guided dosing compared to a fixed dosage regime could be 
identified. The authors of this study stated that this is possibly due to the lack of 
knowledge on what causes the variability in pazopanib patients [198]. However, a 
through value in steady state above a limit of 20 µg/mL seems to be associated with a 
higher efficacy in renal cell carcinoma patients [195,199] 
Besides the already mentioned factors, adherence can be another crucial cause for 
variability in PK and PD parameters. Indeed, both TKI are a good example on how oral 
anticancer treatments in an ambulant setting shift the responsibility for therapy success 
from the treating physician and other health care professionals to the patient. Since 
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the variability of pazopanib can partly be explained by food effects and variable 
absorption due to solubility issues at higher doses, adherence to the therapy becomes 
an even more important aspect [63–65]. Independent of the drug used, it is necessary 
to have better parameters to assess therapy success and to distinguish non-
responders from non-adherent patients. In a study by Byfield et al. it was shown that 
adherence and persistence is comparable between sunitinib and pazopanib, though 
almost 40% of patients in each group had a surprisingly low persistence of below  
80% [200]. An analysis by Margolis et al. indicates an even worse scenario: In a 
retrospective investigation of 2395 mRCC patients more than 50% of the patients were 
non-adherent based on a mean possession ratio below 80%. Here, sunitinib showed 
the worst results across all investigated treatments [201]. A high inter-individual and 
residual variability in PK and PD parameters was also observed in our study for both 
drugs. Even though the identification of several covariates helped to reduce the 
unknown variability there is still uncertainty left. Partly documentation errors can be 
accounted for this, but as evidence suggests also unrecognized non-adherence may 
play a role in addition to unidentified covariates.   
Determination of sVEGFR-2 and -3 concentrations in plasma is comparatively easy 
and cost-effective due to commercially available ELISA kits [132,133]. In a clinical 
setting this can be crucial as not every hospital has the technical equipment for a fast 
analysis of sunitinib or pazopanib. In addition, sunitinib requires light-protected sample 
handling. Otherwise the analytical results might not be reliable due to degradation 
[130,202]. Furthermore, for a viable monitoring approach it is necessary to define target 
parameters and also ranges for these parameters. Even though sVEGFR-2 and 
sVEGFR-3 were investigated as potential biomarkers for various cancer types in 
several studies, none provided guidance for clinical practice [24,28,32,189,203,204]. 
Although our results suggest that a high baseline value of sVEGFR-2 is associated 
with a lower PFS, the chosen median as threshold value is based on a relatively small 
cohort. Another aspect which needs to be considered beforehand is, if sVEGFR-2 
baseline values serve as a prognostic or predictive biomarker [205]. Here, it is 
necessary to validate the findings of this study in larger patient groups treated with 
various first-line therapies for mRCC. The lack of target parameters is even more 
problematic when considering sVEGFR-2 plasma concentration over time as predictive 
factor. The developed modeling framework can be highly valuable in this case to guide 
dosing in a prospective clinical trial. 
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It was not possible to relate higher sVEGFR levels to tumor load of the individual 
patients, as this information was not available in the majority of subjects. Currently, 
there is sparse evidence of a direct quantitative relationship between tumor burden 
and sVEGFR-2 plasma concentrations in mRCC patients. In a preclinical analysis of 
various tumor models the relationship between sVEGFR-2 and tumor size was found 
to be inverse-linear over time in mice. Here, the plasma concentration of sVEGFR-2 
decreased with disease progression. The authors concluded that this might be related 
to the mediation by VEGF which was overexpressed in the investigated tumor models 
[206]. Comparable in vivo results in cancer patients are not available. However, it is 
well known that various tumor types express the membrane-bound variants of VEGFR-
1 -2 and -3 as well as other angiogenic factors to a higher extent [10,11]. Hansen et al. 
reported a significantly higher VEGFR-2 tissue concentration in colorectal carcinoma 
tumor tissue compared to normal colorectal tissue (127 pg/mL vs 78 pg/mL, p < 10-6) 
[207]. By comparing carcinoid neuroendocrine tumors (NET) with pancreatic NET 
(pNET) Zurita et al. showed that sVEGFR-2 expression is significantly higher in the 
latter tumor type, but did not correlate with tumor burden [203]. In an investigation by 
Bierer et al. two RCC subtypes, pRCC and ccRCC (Section 1.2), were compared 
regarding their expression profile. Interestingly, both subgroups differed in expression 
of VEGF-C, D and VEGFR-3 even though for the latter the difference was not 
statistically significant (ccRCC: 44%, pRCC: 61%, p = 0.11) [208]. We observed a 
difference in sVEGFR-3 baseline values between mCRC and mRCC patients. This 
emphasizes the assumption that tumor mass maybe less important than tumor entity 
or even tumor subtype. Nonetheless, measurement of sVEGFR baseline values could 
provide a reliable and easy approach for additional risk assessment in mRCC patients 
in addition to the already established MSKCC- or Heng-Scores (Section 1.2.2) 
Since it is common knowledge that patients treated with TKI are likely to develop 
hypertension, blood pressure was investigated as potential biomarker for therapy 
response with heterogeneous results across studies [83,191,209–211]. In a 
retrospective analysis by Rini et al. it was shown that mRCC patients under sunitinib 
treatment had an improved PFS when they developed hypertension during therapy 
(HR: 0.603, p < 0.001). These results could not be confirmed in a recent analysis of 
the COMPARZ study, which aimed to compare PFS in sunitinib and pazopanib patients 
[74,208]: here, hypertension was assessed after 4 and 12 weeks of treatment. 
Whereas a trend towards a positive effect of high blood pressure could be observed 
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after 4 weeks in both groups (HR: 0.79 for sunitinib and 0.75 for pazopanib), this was 
not confirmed after week 12. 
In theory, blood pressure would be an ideal biomarker as it can be easily measured, 
even by the patients themselves, without reliance on invasive methods. However, this 
accessibility comes with several major shortcomings. To be a usable biomarker, 
measurements have to be reliable and reproducible, which can be difficult as patients 
and clinicians use different devices and do not necessarily stick to standard 
procedures. Even under perfect (study) conditions it is almost impossible to collect 
unbiased blood pressure data, as already discussed in Section 5.1.2. 
Another crucial factor is the prevalence of hypertension. Peak incidence of mRCC 
ranges between 60 and 70 years [69]. According to the epidemiologic bulletin of the 
Robert-Koch Institute (RKI) prevalence of hypertension is up to 33% in the age group 
of 18 to 79, and 75% between 70 and 80 years in Germany. In total, 70% of these 
patients are treated with antihypertensive drugs [212]. This is an obstacle for the 
applicability of blood pressure as biomarker, as increases are potentially already 
suppressed due to antihypertensive treatment in many patients. 
Therefore, further investigations in a larger cohort of patients are certainly needed. 
With a denser sampling it should then be possible to extend the model with relevant 
information on diagnosis and antihypertensive treatment. But even then it will be quite 
challenging to define parameters which quantify the effect of a co-medication with 
respect to the amount of different antihypertensive drugs and regimens. In addition the 
problems regarding reliability of measurements remain, and need to be carefully 
addressed. Developing a standard operational procedure including relevant steps and 
a list of certified devices to guarantee a minimum of consistency across oncological 
centers could be a possible solution. 
The feasibility of more sophisticated dosing approaches could also be hindered by the 
available dosage strengths of sunitinib and pazopanib [46,47]. With a minimum dose 
of 12.5 mg for sunitinib and 400 mg for pazopanib it is quite difficult to target specific 
ranges of PK or PD parameters. Once a validated approach for individualized dosing 
is accessible a higher flexibility regarding possible doses is essential. 
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6 CONCLUSIONS AND OUTLOOK 
Personalized medicine is considered as a key factor to optimize treatments, especially 
in anticancer drug therapy. In order to achieve individualized therapies, a crucial factor 
is the identification and validation of potential predictors for relevant clinical endpoints. 
Here, pharmacometric approaches are of excellent value as they allow to quantify the 
relationships between influential factors and model parameters. In addition, an 
informed model can be used to extrapolate knowledge to other clinically relevant 
questions or serve as basis for therapeutic drug monitoring. 
In this thesis the basis for a PK/PD modeling framework for mRCC patients was 
developed for two common first-line therapies. Whereas the relationship between 
sunitinib pharmacokinetics and the proteins sVEGFR-2 and sVEGFR-3 in plasma was 
already quantified in healthy volunteers and applied to mCRC patients by Kanefendt 
et al., here, it could be shown that different tumor entities can show different response 
to the same treatment [109,126]. This is particularly evident in the different intrinsic 
activity of sunitinib in mRCC and mCRC patients with regard to sVEGFR-2 plasma 
concentrations. Covariates identified in the PD models are biologically plausible, 
though due to the small cohort especially the genetic influential factors need to be 
validated in a larger study. Although blood pressure has the potential to be a viable 
biomarker, this study revealed some limitations in the applicability of the developed 
model. The highly parameterized model relied on estimates from healthy volunteers 
due to the sparse sampling approach used here. For a more precise prediction of blood 
pressure over time several key factors such as physiological changes due to 
hypertension and active antihypertensive treatment need to be implemented and 
quantified. In addition, the value of a semi-mechanistic model could be compared to 
the Markovian approach used for fatigue and myelosuppression. As the CTCAE 
grading is associated with a potential loss of information, it would be highly intriguing 
to see if more sophisticated semi-mechanistic models for these adverse events would 
be more reliable and more precise with regard to outcome prediction. 
The published PK model for pazopanib by Yu et al. could successfully be used for a 
Bayesian estimation of the individual PK parameters in our study [110]. Furthermore, 
it allowed to establish the link between the measured biomarkers and pazopanib PK, 
which represents a novel approach. Even though the models adequately describe the 
PK/PD relationship of pazopanib, there is still unexplained variability which could not 
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be addressed in this thesis due to the low patient number and sparse data. Hence, the 
application of the models in a larger patient cohort and also other indications would be 
highly informative and may allow the identification of covariates.  
As the model-based time-to-event analysis showed, sVEGFR-2 seems to be a 
potential predictor for PFS in patients with mRCC. This was more evident in the 
analysis of survival data of both drugs combined, where not only the baseline value 
was predictive for outcome but also the absolute decrease sVEGFR-2 concentration 
over time. With commercially available kits for quantification, sVEGFR-2 has a great 
potential to be a valuable and cost-effective biomarker for dose individualization. 
Therefore, the next logical step should be to evaluate the effect in a prospective study 
with a dosing approach based on sVEGFR-2 plasma concentrations compared to 
standard fixed dose treatment. However, even though the quantitative association 
could be established, sVEGFR-2 threshold values for dose increase or reduction need 
to be defined for an adequate clinical application. 
Continuous-time Markov models are an excellent method to link PK/PD models with 
categorical outcome data. The approach used in this study allowed estimating the 
quantitative relationship between sunitinib exposure and the development of toxicity of 
a certain grade. However, due to the data limitations the application in this study has 
to be interpreted as a feasibility analysis. Similar to the other outcome models, the 
interpretation of the results is limited by the low patient number which corresponds to 
an overall very low incidence of adverse events. Despite that, the implementation into 
a modeling framework was successful and provided a first hint on the quantitative 
relationship between sunitinib exposure and myelosuppression. Of particular interest 
would be the application to other TKI, especially pazopanib, as this was not possible 
with our data. 
As shown in other studies, modeling frameworks can be highly informative and provide 
an interesting basis for further analyses. Possible applications can be simulation 
studies to show the effect of different sunitinib or pazopanib dosing regimens on PFS 
and toxicity or whole clinical trial simulations. Furthermore, the framework could be 
extended with other models. Conceivable would be a tumor growth model similar to 
the one developed by Hansson et al. in patients with GIST [32]. Tumor growth has the 
advantage of being a progression parameter on a continuous time scale, which can be 
informative also in respect to resistance mechanisms [213]. In addition, the 
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interconnection of the existing models could be further extended. For example, the link 
between Markov models for adverse events and a time-to-event model could provide 
highly valuable information on the effect of a proper toxicity management on overall 
survival.  
In conclusion, the developed modeling framework gives an insight into the quantitative 
relationship between the pharmacokinetics, the pharmacodynamic response and the 
clinical outcome of sunitinib and pazopanib. As it can be easily extended, it also 
provides a solid basis for further investigations. Additionally, this framework can serve 
as a template for pharmacometric analyses of other antiangiogenic drugs used in 
oncology. 
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7 SUMMARY 
This thesis provides the basis for an extensive modeling framework for patients with 
metastatic renal cell carcinoma (mRCC) treated with two common first-line therapies, 
sunitinib and pazopanib. As part of the European-wide EuroTARGET project, which 
aimed at identifying predictive biomarkers in mRCC patients, a pharmacokinetic phase 
IV study was conducted in Germany and the Netherlands. 
Based on a center-specific schedule up to 12 blood samples per patient were collected 
in conjunction with blood pressure measurements. Plasma concentrations of the 
respective study drug and the soluble VEGF receptors 2 and 3 were quantified for each 
time-point using previously established analytical methods. The generated data was 
pooled with the results from a previous study in mCRC patients treated with sunitinib 
(C-II-005) for a combined pharmacokinetic/pharmacodynamic analysis. 
Published pharmacokinetic and pharmacodynamics (PK/PD) models were used as 
basis for this work. For both sunitinib and pazopanib, reliable individual 
pharmacokinetic parameters could be obtained and successfully linked to 
pharmacodynamic models for the potential biomarkers. An inverse-linear relationship 
provided the overall best fit for sVEGFR-2, sVEGFR-3 and blood pressure. Covariate 
analysis of the PK/PD models revealed two single nucleotide polymorphisms (SNPs) 
with influence on the intrinsic activity of sunitinib on sVEGFR-2 plasma concentrations 
(VEGFR-3 rs6877011 and ABCB1 rs2032582). 
Furthermore, a significant difference in response to sunitinib with respect to sVEGFR-
2 between both investigated tumor entities was estimated, indicating a higher activity 
of sunitinib in mRCC patients. sVEGFR-3 baseline concentrations were significantly 
higher in mRCC compared to mCRC patients. The final PK/PD models were then used 
to establish a link to clinical outcome parameters including progression-free survival 
(PFS) and the two most commonly observed adverse events in the mRCC population. 
In a model-based time-to-event (TTE) analysis, a high sVEGFR-2 baseline plasma 
concentration was associated with a worse prognosis for sunitinib patients. In a 
combined analysis of sunitinib and pazopanib the absolute sVEGFR-2 plasma 
concentration over time was a potentially predictive factor. Hence, this model allows 
the prediction of PFS based on the measured sVEGFR-2 plasma concentration. 
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Myelosuppression and fatigue as treatment-associated adverse events were analyzed 
separately using first-order continuous Markov models. Here, active sunitinib plasma 
concentration proved to be influential as a higher exposition did result in prolonged 
time frames of myelosuppression. However, a similar effect was not observed for 
fatigue. 
The modeling framework presented in this thesis provides a better understanding of 
the relationship between the exposure, pharmacological response, and clinical 
outcome of antiangiogenic drugs and is therefore an important step towards finding 
optimal dosing schedules and identifying potential predictive biomarkers for both 
drugs. However, it also emphasizes, that it is might be difficult to find general 
biomarkers for antiangiogenic therapies, which can be applied across different tumor 
entities.
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A.I Pharmacokinetic models 
 
Covariate Comments 
Gender Categorical 
Age Continuous 
Tumor entity (mRCC or mCRC) Categorical 
ABCB1 rs1128503 Additive and general model (if applicable) 
ABCB1 rs2032582 Additive and general model (if applicable) 
ABCB1 rs1045642 Additive and general model (if applicable) 
VEGF A rs699947 Additive and general model (if applicable) 
VEGF A rs833061 Additive and general model (if applicable) 
VEGF A rs2010963 Additive and general model (if applicable) 
IL8 rs1126647 Additive and general model (if applicable) 
VEGF A Haplotype Additive and general model (if applicable) 
 
  
188  Appendices 
 
  __ 
A.II Pharmacodynamic models 
 
Covariate Comments 
Gender Categorical 
Age Continuous 
Weight Continuous 
BSA Continuous 
Tumor entity (mRCC or mCRC) Categorical 
ABCB1 rs1128503 Additive and general model (if applicable) 
ABCB1 rs2032582 Additive and general model (if applicable) 
ABCB1 rs1045642 Additive and general model (if applicable) 
VEGF A rs699947 Additive and general model (if applicable) 
VEGF A rs833061 Additive and general model (if applicable) 
VEGF A rs2010963 Additive and general model (if applicable) 
IL8 rs1126647 Additive and general model (if applicable) 
VEGF A Haplotype Additive and general model (if applicable) 
Continued  
VEGFR-3 rs6877011 Additive and general model (if applicable) 
VEGFR-3 rs307826 Additive and general model (if applicable) 
VEGFR-3 rs307821 Additive and general model (if applicable) 
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A.III Survival analysis and Markov models for toxicity 
 
Covariate Comments 
Age Continuous 
Weight Continuous 
Gender Categorical 
sVEGFR-2 Baseline value Continuous 
sVEGFR-2 above population 
median 
 
Categorical 
sVEGFR-3 Baseline value Continuous 
sVEGFR-3 above population 
median 
 
Categorical 
Prior Surgery (any type) Categorical 
Prior Nephrectomy Categorical 
Radiotherapy  
before/during treatment 
 
Categorical 
Hypertension diagnosed  
at treatment start 
 
Categorical 
Base BP(systolic) Continuous 
Base BP(diastolic) Continuous 
Total AUCSS Continuous 
Total CSS Continuous 
Active AUCSS Continuous 
Active CSS Continuous 
Total AUCSS > Median Categorical 
Total CSS > Median Categorical 
Active AUCSS > Median Categorical 
Active CSS > Median Categorical 
Number of metastases Categorical 
Toxicity of any kind ≥ Grade 3 Categorical 
CYP3A5*3 rs776746 Additive and general model (if applicable) 
ABCB1 rs1128503 Additive and general model (if applicable) 
ABCB1 rs2032582 Additive and general model (if applicable) 
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Continued  
ABCB1 rs1045642 Additive and general model (if applicable) 
VEGF A rs699947 Additive and general model (if applicable) 
VEGF A rs833061 Additive and general model (if applicable) 
VEGF A rs2010963 Additive and general model (if applicable) 
VEGF A rs3025039 Additive and general model (if applicable) 
VEGFR3 rs307826 Additive and general model (if applicable) 
IL8 rs1126647 Additive and general model (if applicable) 
ABCB1 Haplotype Additive and general model (if applicable) 
VEGF A Haplotype Additive and general model (if applicable) 
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A.IV Time-dependent covariates 
 
These covariates were only tested in the model-based time-to-event analysis and the 
Markov models for selected adverse events. 
 
Covariate Comments 
Active concentration of  
sunitinib and SU12662 
 
Continuous 
AUC of active substance Continuous 
Total concentration of  
sunitinib and SU12662 
 
Continuous 
AUC of total substance Continuous 
Absolute concentration of sVEGFR-2 Continuous 
Relative concentration of sVEGFR-2 Continuous 
AUC of sVEGFR-2 Continuous 
Absolute concentration of sVEGFR-3 Continuous 
Relative concentration of sVEGFR-3 Continuous 
AUC of sVEGFR-3 Continuous 
Systolic blood pressure Continuous 
Diastolic blood pressure Continuous 
Relative change in systolic  
blood pressure 
Continuous 
Relative change in diastolic 
blood pressure 
Continuous 
 
Only genotypes which were preselected based on their percentage of occurrence in 
the population were tested. For the PD models sVEGFR-3 related SNPs were tested 
despite the percentage under the threshold due to the high relevance 
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  __ 
Legend 
AUC(SS) = Area under the curve (steady state), BP = Blood pressure, BSA = Body 
surface area, C(SS) = Concentration (steady state), IL8 = Interleukin 8, mCRC = 
metastasized colorectal carcinoma, mRCC = metastasized renal cell carcinoma, 
(s)VEGF(R) = (soluble) vascular endothelial growth factor (receptor), 
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B.I Blood sampling 
  
 
 Interdisziplinäre 
Arbeitsgruppe 
„Nierentumore“ 
(IAG-N) 
 
 
 
 
Entnahme und Handhabung von Blutproben C-IV-001: EuT-PKPD EUDRACT-No.: 2012-001415-23 
EuroTARGET-Substudie C-IV-001: EuT-PK/PD 
 
Entnahme und Handhabung von Plasmaproben 
 
Blutentnahme 
 
 Entnahmemenge: 7,5 ml 
 
- In EDTA-Monovetten 
 
 
Kontrolle des 
Etiketts 
 
- Studienbezeichnung/Zentrumsnummer 
 
- EuroTARGET-Patientennummer 
 
- Abnahmetag und –zeitpunkt 
 
- „P“ für Pazopanib bzw. „S“ für Sunitinib auf den Deckel des Tubes 
 
- Das Etikett mit Klebefolie schützen! 
 
- Proben entsprechend dem Bestimmungsort mit „Uni Bonn“ kennzeichnen 
 
Zentrifugation 
 
- innerhalb von 30 min nach der Blutabnahme 
 
- 1000 g rel. Zentrifugalbeschleunigung  (bitte Umrechnung beachten, da die 
rpm-Einstellung variiert je nach Art der Zentrifuge (s.u.)) 
 
- Mit Bremsfunktion 
 
- bei 4°C 
 
- für 15 min 
 
 
Abpipettieren 
 
- Abnahmeröhrchen bis zum Pipettieren in der Zentrifuge belassen 
 
- Kontrolle der Pipette (µL-Einstellung, Pipettenspitze) 
 
- 500 µL als Pipetteneinstellung 
 
- Pipettenspitze  nach jeder Probe wechseln 
 
- Es ist darauf zu achten, dass nur Plasma übertragen wird und der unten 
liegende Blutkuchen unangetastet bleibt 
 
- Deckel des Plasmaröhrchens nach dem Pipettieren sofort schließen 
 
- Aufteilung in 6 Aliquote á 500 µL 
 
- Light-protected micro-tubes als Plasmaröhrchen (Sunitinib ist 
lichtempfindlich!) 
 
- Plasmaröhrchen sofort danach einfrieren (aufrecht!) 
 
 
Lagerung 
 
- Bei mind. -80°C 
 
- Sortierung der Proben kontrollieren  
o aufsteigende Reihenfolge der Patientennummern von links nach rechts 
o zeitliche Reihenfolge von vorn nach hinten 
 Interdisziplinäre 
Arbeitsgruppe 
„Nierentumore“ 
(IAG-N) 
 
 
 
 
Entnahme und Handhabung von Blutproben C-IV-001: EuT-PKPD EUDRACT-No.: 2012-001415-23 
 
Zentrifuge: Umrechnung von „g“in „rpm“ 
 
Sollte an der genutzten Zentrifuge keine Einstellung der Geschwindigkeit über die 
Erdbeschleunigung g möglich sein, empfiehlt sich eine Umrechnung in die üblichen 
rpm (rounds per minute). 
 
Dies ist mit folgender Formel möglich: 
                    
 
Bitte beachten Sie, dass der Zentrifugenradius r (in cm) dabei entscheidend ist 
(zu entnehmen aus der Bedienungsanleitung des jeweiligen Gerätes). 
 
 
 
Versand: 
 
Mit „Uni Bonn“ gekennzeichnete Proben werden auf Trockeneis an folgende 
Adresse versandt (die Abholung wird durch die CESAR organisiert): 
 
Prof. Dr. Ulrich Jaehde 
Pharmazeutisches Institut 
Universität Bonn 
An der Immenburg 4 
D-53121 Bonn 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bei Unklarheiten wenden Sie sich bitte an: 
 Achim Fritsch  
(Tel.: 0228-73 5229, E-Mail: a.fritsch@uni-bonn.de). 
 Interdisziplinäre 
Arbeitsgruppe 
„Nierentumore“ 
(IAG-N) 
 
 
 
 
Entnahme und Handhabung von Blutproben C-IV-001: EuT-PKPD EUDRACT-No.: 2012-001415-23 
Dokumentation der Blutprobenentnahme 
 
Klinik:     ______________________ 
EuroTARGET-Patientennummer:  ______________________ 
Zyklus Datum 
[TT.MM.JJ] 
Uhrzeit 
[HH:MM] 
Abstand zur letzten 
Einnahme 
[in Stunden] 
Aktuelle Dosierung 
[in mg]  
(Bitte Datum der 
Dosisanpassung angeben, 
falls zutreffend) 
    
Baseline 
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B.II Blood pressure assessment 
  
 
 Interdisziplinäre 
Arbeitsgruppe 
„Nierentumore“ 
(IAG-N) 
 
 
 
 
[1] Modifiziert nach: Bundesvereinigung Deutscher Apothekerverbände (ABDA). Standardarbeitsanweisung –Blutdruckmessung in 
der Apotheke. Stand:04.2009. Verfügbar auf: http://www.abda.de/leitlinien.html. Letzter Zugriff: 13.04.2012 
Blutdruckmessung C-IV-001: EuT-PK/PD EUDRACT-No.: 2012-001415-23 
 
EuroTARGET-Substudie C-IV-001: EuT-PK/PD 
 
Blutdruckmessung 
Die Messungen erfolgen im Rahmen der klinischen Routineuntersuchung. Sollten während der 
Studienzeit Langzeit-Blutdruckmessungen durchgeführt werden, so ist dies ebenfalls zu 
dokumentieren. 
 
Technische 
Ausstattung 
Die Messungen werden mit einem zertifizierten Gerät der Deutschen 
Hochdruckliga ausgeführt. Ein solches Gerät wird jeder teilnehmenden 
Klinik kostenlos zur Verfügung gestellt.  
Durchführung der 
Messung[1] 
 Messung möglichst zur selben Tageszeit 
 
 Beginn der Messung nach 5 minütiger Ruhepause in sitzender 
Position 
 
 Entsprechende Verlängerung der Ruhephase bei 
außergewöhnlicher Belastung (>5 min) 
 
 Alle Störquellen vermeiden (z.B. Gespräche) 
 
 Bis mindestens eine Stunde vor der Messung sollte der Patient  
auf Coffein-haltige Getränke, Alkohol und Nikotin verzichten 
 
 Der Messarm darf nicht durch zurückgeschobene Kleidung 
abgeschnürt werden (entsprechende Kleidungsstücke, Uhren 
sowie Schmuck vor der Messung ablegen) 
 
 Der untere Rand der Manschette sollte 1-2 cm über der 
Ellenbeuge liegen. Der Messfühler mit dem Schlauch liegt an 
der Arminnenseite 
 
 Den Messarm während der Messung ruhig und leicht 
angewinkelt auf einer Unterlage auflegen und nicht bewegen 
 
 Manschette muss auf Herzhöhe liegen 
 
Dokumentation  Folgende Daten werden auf dem Dokumentationsbogen erfasst. 
 
o Datum und Uhrzeit der Messung 
 
o Systolischer Blutdruck 
 
o Diastolischer Blutdruck 
 
o Puls 
 
o Kommentare/Auffälligkeiten 
 
Bei Unklarheiten wenden Sie sich bitte an Achim Fritsch (0228-73-5229; a.fritsch@uni-bonn.de) 
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B.III Adverse events 
  
 
 
 Interdisziplinäre 
Arbeitsgruppe 
„Nierentumore“ 
(IAG-N) 
 
 
 
AE - Dokumentationsbogen – CIV-001    EUDRACT-No.: 2012-001415-23 Version 1.0 
Studie C-IV-001: EuT-PK/PD: 
 
Dokumentation von „Adverse Events“ 
 
 
Allgemeine Hinweise zur Dokumentation 
 
Dieser Dokumentationsbogen dient der Erfassung von „Adverse Events“. Sollten bei einem 
Ihrer Patienten „Serious Adverse Events“ auftreten, so melden Sie diese zusätzlich  
innerhalb von 24h via Fax an den Sponsor (Weiteres entnehmen Sie bitte dem 
entsprechenden Dokument). 
 
Der Abschnitt „Kommentar“ dient zusätzlichen Informationen, die zum Verständnis der 
erfassten Daten wichtig sind (z.B. Hospitalisierung aufgrund eines AE etc.). 
 
Die häufigsten Nebenwirkungen von Sunitinib (entsprechend der Fachinformation) finden 
sich bereits im ersten Teil der Dokumentationstabelle aufgelistet. Nicht gelistete 
unerwünschte Ereignisse sowie Rezidive tragen Sie bitte in den entsprechenden freien 
Feldern ein. 
 
 
Bitte nutzen Sie zur Dokumentation den folgenden Bewertungsschlüssel: 
1. Kausalität 
Unwahrscheinlich:   
Möglich:    
Wahrscheinlich:   
Gesichert:     
Nicht zutreffend:     
 
 
[1] 
[2] 
[3] 
[4] 
[5] 
 
2. Intervention 
Keine Intervention:  
Studientherapie angepasst: 
Studientherapie kurzzeitig unterbrochen: 
Studientherapie dauerhaft unterbrochen: 
Begleitmedikation verordnet:  
Nichtmedikamentöse Behandlung:  
  
 
 
[0] 
[1] 
[2] 
[3] 
[4] 
[5] 
 
3. Outcome 
Verbesserung: 
Keine Änderung: 
Verschlimmerung (SAE): 
Unbekannt: 
 
 
[1] 
[2] 
[3] 
[4] 
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B.IV Immunoassays 
  
 
Standardarbeitsanweisung (SOP) 
Nr.: SOP 3 09 
Klinsiche Pharmazie 
  Revision:  
Gültig ab: Seite 1 von 7 
SOP-Immunoassays.doc.doc 
 
 
 
 
 
 
 
Gültigkeitsbereich: Klinische Pharmazie 
 
Autor(en): Friederike Kanefendt 
Datum/Unterschrift: 
 
Datum/Prof. Dr. Ulrich Jaehde Datum/Friederike Kanefendt 
 
 
 
 
Überprüfungsvermerk/Qualitätssicherung 
 
 
 
Name/Datum/Unterschrift 
 
 
Verteiler: Laborleiter 
Mitarbeiter Labor 3.110 
Mitarbeiter Labor 3.116 
Mitarbeiter Labor 3.117 
weitere Mitarbeiter:    
 
 
Inhalt 1. Zweck / Prinzip 2 
2. Einsatzbereich 2 
3. Messprinzip / Grundlagen 2 
4. Verfahrenskenndaten / Validierung 3 
5. Geräte/Geräteeinstellungen und Material 3 
6. Chemikalien und herzustellende Lösungen 4 
7. Durchführung der Analyse 5 
8. Mitgeltende Unterlagen 7 
 
Titel: Proteinbestimmung mittels ELISA 
Standardarbeitsanweisung (SOP) 
Nr.: SOP 3 09 
Klinsiche Pharmazie 
  Revision:  
Gültig ab: Seite 2 von 7 
SOP-Immunoassays.doc.doc 
 
 
 
 
 
 
 
 
Diese SOP regelt die Bestimmung von proteinogenen Analyten in humanem 
Kalium-EDTA-Plasma mit Hilfe von Enzyme-linked Immunosorbent Assays 
(ELISAs) 
Sie sichert ein einheitliches Vorgehen bei der Vorbereitung der Proben, der 
Durchführung der Assays, die Qualität der Messungen und die Vergleichbarkeit 
der Ergebnisse. 
  2. Einsatzbereich  
 
Die hier beschriebenen Methoden werden angewendet für die Bestimmung der 
proteinogenen Wachstumsfaktoren VEGF-A und VEGF-C und deren löslichen 
Rezeptoren sVEGFR-2 und sVEGFR-3 in humanem Kalium-EDTA- Plasma. 
  3. Messprinzip / Grundlagen  
 
Der ELISA ist ein immunologisches Nachweisverfahren, das auf einer Antigen-
Antikörper-Reaktion beruht. Generell unterscheidet man direkte und indirekte 
ELISA sowie Sandwich- und kompetitive ELISA. Das Messprinzip beruht auf der 
Bindung eines Analyten (Antigen) an freie (kompetitiv) oder immobilisierte für 
diesen Analyten spezifische Antikörper. Anschließend zugegebene Substrate 
werden von Enzymen zu farbigen Produkten umgesetzt oder führen durch die 
katalysierte chemische Umsetzung zu Lumineszenz, deren Intensität 
entsprechend mit einem  UV-Spektrometer oder einem Luminometer gemessen 
werden kann. Diese Enzyme befinden sich entweder auf Zweitantikörpern 
(Sandwich-ELISA), die in einem weiteren Schritt den auf der Platte gebundenen 
Analyten binden, oder sind an das kompetitive Antigen (kompetitiver ELISA), 
das in definierter Menge hinzugefügt wird, gebunden. Anhand parallel 
vermessener Standards und einer entsprechenden Kalibrierkurve kann der 
Analyt quantifiziert werden. 
1. Zweck / Prinzip 
Standardarbeitsanweisung (SOP) 
Nr.: SOP 3 09 
Klinsiche Pharmazie 
  Revision:  
Gültig ab: Seite 3 von 7 
SOP-Immunoassays.doc.doc 
 
 
 
 
 4. Verfahrenskenndaten / Validierung  
 
Die zurzeit verwendeten Testkits für VEGF-A, VEGF-C und sVEGFR-2 wurden 
von der Firma R&D Systems validiert; die Validierungsparameter befinden 
sich im Herstellerprotokoll zum entsprechenden Test. Die Handhabung der 
Tests verläuft nach Protokoll (mitgeltende Unterlagen). Dieses entstammt 
den Anweisungen für die Verwendung der Testkits. Zur Bestimmung von 
sVEGFR-3 wird ein vom humanen VEGFR-3 DuoSet ELISA ausgehender, für 
humanes Plasma validierter, ELISA verwendet [Kanefendt et al. 201X]. Für 
die Validierungskriterien, wie Präzision und Richtigkeit werden nach 
geltenden Vorschriften für Immunoassays Akzeptanzkriterien von ≤ 20 % 
angenommen [DeSilva et al. 2003]. 
5. Geräte/Geräteeinstellungen und Material  
 
5.1 Geräte 
 
• Pipetten/ Mehrkanalpipetten 
• UV-Spektrometer (Thermo Electron Corporation Multiscan EX) 
• Luminometer (Fluostar Optima) 
• Schüttler (Heidolph Instruments Unimax 1010 (d=10mm)) 
5.2 Chemikalien und Reagenzien 
 
• QuantiGlo human VEGF-A Immunoassay (#QVE00B) 
• Quantikine human sVEGFR-2 Immunoassay (#DVR200) 
• Quantikine human VEGF-C Immunoassay (#DVEC00) 
• Materialien zur Bestimmung von VEGF-A, VEGF-C und sVEGFR-2 sind 
im entsprechenden Testkit enthalten 
sVEGFR-3 (R&D Systems, Abingdon, UK) 
• Human sVEGFR-3 (Flt-4) DuoSet ELISA (#DY349) 
• Purelab® Wasser 
• Wash Buffer 0,05 % Tween® 20 in PBS, pH 7,2 – 7,4 (#WA126) 
• Reagent Diluent Concentrate 2 – 1 % (#DY995) 
Standardarbeitsanweisung (SOP) 
Nr.: SOP 3 09 
Klinsiche Pharmazie 
  Revision:  
Gültig ab: Seite 4 von 7 
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• Substrate Solution (#DY999) 
• Stop Solution – 2N H2SO4 (#DY994) 
• CrossDown Buffer (AppliChem, A6485) 
• Fetales Kälberserum (FKS) (Sigma, F7524) 
5.3 Verbrauchsmaterialien 
 
• Clear Polystyrene MicroPlates (#DY990) 
• Parafilm 
• Eppendorf Caps (0,5; 1,5; 2,0 mL) 
• Polypropylen (PP)-Röhrchen (15, 50 mL) 
• Pipettenspitzen 
5.4 Geräteeinstellungen 
 
• Die Geräte sind nach Angaben des Herstellers (Herstellerprotokoll) 
einzustellen. 
• Zu beachten ist bei Verwendung des Schüttlers, dass die Angaben in rpm 
entsprechend auf den verwendeten Schüttler umgerechnet  werden 
müssen. 
 rcf = 1,118 . 10-5 r . rpm2 
rcf: relative centrifugal force [x g]; r: Radius [cm]; rpm: rotations per 
minute [1/min]  1 inch = 2,54 cm 
6. Chemikalien und herzustellende Lösungen  
 
VEGF-A, VEGF-C und sVEGFR-2: 
Sämtliche Chemikalien, die verwendet werden, werden vom Hersteller mit 
jedem Testkit mitgeliefert. Hergestellt werden müssen Waschpuffer und 
Substratmischungen jeweils nach Anweisung des Herstellerprotokolls. 
sVEGFR-3 
• PBS Puffer 
137 mM NaCl 8,0 g 
2,7 mM KCl 0,2 g 
Standardarbeitsanweisung (SOP) 
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8,1 mM Na2HPO4 1,15 g 
1,5 mM KH2PO4 0,204 g 
Purelab Plus® Wasser ad 1000,0 ml 
pH 7,2 – 7,4; 0,2 μm filtriert 
• Reagent Diluent (1:10) 
Reagent Diluent Concentrate 2 1 T 
Purelab Plus® Wasser 9 T 
• Capture Antikörper Verdünnung (1:180) 
Capture Antikörper Konzentrat 1 T 
PBS 179 T 
• Detection Antikörper Verdünnung (1:225) 
Detection Antikörper Konzentrat 1 T 
Reagent Diluent 224 T 
• Streptavidin-HRP (1:200) 
Streptavidin-HRP Konzentrat 1 T 
Reagent Diluent 199 T 
• Substrat-Mischung (1:1) 
Reagent A 1 T 
Reagent B 1 T 
• FCS: 30 min bei 50 °C inaktivieren 
7. Durchführung der Analyse  
 
7.1 Probenentnahme 
 
Vollblut wird durch entsprechend qualifizierte Personen in Kalium-EDTA 
enthaltende Monovetten entnommen und innerhalb von 30 Minuten bei 4 °C, 
1029 x g für 15 min zentrifugiert. Das gewonnene Plasma wird  aliquotiert  und 
bei -80 °C eingefroren und gelagert. 
7.2 Probenvorbereitung 
 
Die Proben und alle weiteren Reagenzien, die für einen Test benötigt werden, 
werden auf Raumtemperatur gebracht. Das Plasma wird gegebenenfalls 
Standardarbeitsanweisung (SOP) 
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verdünnt (Angaben in den entsprechenden Versuchsprotokollen oder wenn 
Plasmakonzentrationen oberhalb des oberen Kalibrierbereiches zu erwarten 
sind). 
Während der Inkubation kann es erforderlich sein, die Platten zu schütteln. Um 
Temperaturschwankungen während der Inkubationszeit durch die Erwärmung 
des Schüttlers zu vermeiden, wird eine Styroporplatte in entsprechender Größe 
zur Isolation zwischen Schütteloberfläche und Versuchsplatte gelegt. 
7.3 Kalibrierung 
 
Die Kalibrierung verläuft ebenfalls nach Herstellerprotokoll. Sie basiert auf 
einer Surrogatmatrix auf Basis von FCS. Humanes Plasma kann nicht als 
Kalibriermatrix verwendet werden, da die Analyten endogen in humanem 
Plasma vorkommen und keine humane Leermatrix existiert. Als 
Kalibriermodell dient in der Regel die 4-Parameter logistische Funktion (1) 
für Messungen, bei denen die UV-Absorption gemessen wird, und ein Cubic 
Spline bei der Messung der Lumineszenz. Entsprechende Angaben werden 
ebenfalls in den entsprechenden Versuchsprotokollen gemacht. Zur 
Verifizierung der Kalibrierung werden Qualitätskontrollproben (QCs) auf 
jeder Platte mit vermessen, die vom Hersteller geliefert werden. Diese 
müssen den Herstellerspezifikationen entsprechen. Im Falle der Messung 
von sVEGFR-3 werden die QCs selbst hergestellt und müssen eine Präzision 
(CV,%) und Richtigkeit (RE, %) von ≤ ± 20 % aufweisen. 
 
 
4-Parameter logistische Funktion 
 
X: Konzentration 
Y: Absorption 
A1: untere Asymptote 
A2: obere Asymptote 
X0: Konzentration bei der halber Absorption 
p: Steigungsparameter 
Der Cubic Spline interpoliert Messsignale innerhalb der Kalibrierkurve und 
schätzt somit die Analyt-Konzentrationen entsprechend der Lumineszenz ab. 
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7.4 Messung 
 
Die Proben werden auf der 96-Well-Platte entweder  im  UV-Spektrometer oder 
im Luminometer vermessen. Gemessen wird nach entsprechend vorgegebener 
Inkubationszeit nach Zugabe des Stopp-Reagenzes oder des zur Lumineszenz 
befähigtem Substratgemisches. Erhalten werden die entsprechenden Rohdaten 
für Absorption oder Lumineszenz für jedes Well im Excel-Format. 
7.5 Auswertung 
 
Ausgewertet wird durch entsprechende Berechnung der Konzentrationen des 
Analyten mit Hilfe der abgeschätzten Parameter der Kalibrierkurve. Durch 
die parallel vermessenen QCs, die innerhalb der Akzeptanzkriterien liegen 
müssen, kann überprüft werden, ob die Messungen akzeptiert werden 
können. 
8. Mitgeltende Unterlagen  
 
• Herstellerprotokoll QuantiGlo VEGF-A ELISA (#QVE00B) 
• Herstellerprotokoll Quantikine VEGF-C ELISA (#DVEC00) 
• Herstellerprotokoll Quantikine sVEGFR-2 ELISA (#DVR200) 
• Herstellerprotokoll VEGFR-3 DuoSet (#DV349) 
• Versuchsprotokoll zur VEGF-A-Bestimmung 
• Versuchsprotokoll zur VEGF-C-Bestimmung 
• Versuchsprotokoll zur sVEGFR-2-Bestimmung 
• Versuchsprotokoll zur sVEGFR-3-Bestimmung 
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C.I sVEGFR-2 
 
 
 
 
 
 
 
 
  
 
  
 
Mitgeltende Unterlagen SOP 3 09
Versuchsprotokoll zur sVEGFR-2 Bestimmung Datum
1. Herstellen der Reagenzlösungen
alle Reagenzien vor dem Gebrauch auf Raumtemperatur bringen
Waschpuffer
Wash Buffer Concentrate 20 mL
Purelab Wasser ad 500 mL
VEGFR-2 Standard
Rekonstitution mit 1 mL Purelab Wasser
15 min unter leichtem Schütteln stehen lassen
Kalibratoren
Vorgegangen wird nach folgenden Schema ausgehend von dem im Kit enthaltenen Standard 
C7 C6 C5 C4 C3 C2 C1
Probe
Lösung Cx+1
[μL]
Calibrator Diluent
RD6-31 [μL]
Konzentration
[pg/mL]
C7 100 900 5000.0
C6 500 500 2500.0
C5 500 500 1250.0
C4 500 500 625.0
C3 500 500 312.5
C2 500 500 156.3
C1 500 500 78.1
C0 500 0.0 Leerprobe
Qualitätskontrollproben
unverdünnt auftragen
Probe
Konz.-Bereich 
[pg/mL]
QC1 216-370
QC2 1171-1920
QC3 2340-3413
Probenherstellung
Plasma muss 1:5 verdünnt werden 
60 μL Plasma und 240 μL Calibrator Diluent RD6-31
Mitgeltende Unterlagen SOP 3 09
2. ELISA Durchführung
100 μL Assay Diluent RD1W in jedes Well pipettieren
100 μL Standard, QC oder Probe in die entsprechenden Wells pipettieren
mit der adhäsiven Folie abkleben 
Inkubation für 2 h bei Raumtemperatur Start: Temp.:
Ende: Temp.:
Waschen mit Waschpuffer (4 x 400 μL)
Platte ausklopfen und nach dem letzten Schritt absaugen
200 μL sVEGFR-2 Conjugate in jedes Well pipettieren
mit der adhäsiven Folie abkleben 
Inkubation für 2 h bei Raumtemperatur Start: Temp.:
Ende: Temp.:
Waschen mit Waschpuffer (4 x 400 μL)
Platte ausklopfen und nach dem letzten Schritt absaugen
200 μL Substrate Solution in jedes Well pipettieren
Reagenz A 10 mL
Reagenz B 10 mL
Inkubation für 30 min bei Raumtemparatur Start: Temp.:
Lichtschutz!!! Ende: Temp.:
50 μL Stop Solution in jedes Well pipettieren
innerhalb von 30 min Messung der Absorption bei 450 nm und bei 570 nm zur Korrektur
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C.II sVEGFR-3 
   
 
 
Mitgeltende Unterlagen SOP 3 09
Versuchsprotokoll zur sVEGFR-3 Bestimmung Datum
1. Herstellen der Reagenzlösungen
alle Reagenzien vor dem Gebrauch auf Raumtemperatur bringen
Waschpuffer
Wash Buffer Concentrate 20 mL
Purelab Wasser ad 500 mL
sVEGFR-3 Standard
Rekonstitution mit 1 mL Purelab Wasser
15 min unter leichtem Schütteln stehen lassen
Reagent Diluent (1:10)
Reagent Diluent Concentrate 2 5.2 mL
Purelab Wasser 46.8 mL
Kalibratoren
Begonnen wird die Verdünnungsreihe mit C7 bestehend aus 45 μL Standard und 1530 μL FKS
für alle weiteren Verdünnungen Cx wird die jeweil vorherige Cx+1 verwendet
Probe
Lösung Cx+1 
[μL]
FKS* 
[μL]
Verdünnungs-
 faktor
Konzentration 
[pg/mL]
C7 45 1530 35 10571.4
C6 700 200 45 8222.2
C5 600 200 60 6166.7
C4 480 240 90 4111.1
C3 300 300 180 2055.6
C2 300 300 360 1027.8
C1 300 300 720 513.9
C0 250 0.0
* inaktiviert 30 min bei 50°C
Qualitätskontrollproben
Gleiches Vorgehen gilt für die Herstellung der QCs, es werden 3 QCs für den Assay verwendet
Probe
Lösung Cx+1 
[μL] FKS [μL]
Verdünnungs-
 faktor
Konzentration 
[pg/mL]
QC2 300 300 360 1027.8
300 300 180 2055.6
QC4 480 240 90 4111.1
600 200 60 6166.7
QC6 700 200 45 8222.2
45 1530 35 10571.4
Probenvorbereitung
Verdünnung 1:10 mit CrossDown Buffer
Mitgeltende Unterlagen SOP 3 09
2. Plattenvorbereitung 1. Tag
pH-Wert bestimmen pH: (Soll: 7,2 - 7,4)
Sterilfiltration der PBS (Sterilfilter 0,2 μm)
Bubble-point-Test 
100 μL Capture-Antikörper Verdünnung in jedes Well pipettieren
4,0 μg/mL Capture-AB 57 μL
PBS 10.2 mL
100 μL in jedes Well pipettieren
Inkubation über Nacht Start: Temp: 
bei Raumtemperatur (RT) Ende: Temp: 
in Dunkelheit
2. Tag Datum
Waschen mit Waschpuffer
3 x mit jeweils 340 μL pro Well
ausklopfen und nach dem letzten Schritt absaugen
300 μL Reagent Diluent in jedes Well (Reagent Diluent immer frisch herstellen)
Inkubation für 2 h bei RT Start: Temp.:
Ende: Temp.:
Waschen mit Waschpuffer
3 x mit jeweils 340 μL pro Well
ausklopfen und nach dem letzten Schritt absaugen
Mitgeltende Unterlagen SOP 3 09
3. ELISA-Durchführung
Datum
100 μL Proben-Lösung in jedes Well pipettieren
Abdecken mit Parafilm
Inkubation für 2 h bei 30 °C Start: Temp.:
cave: Verdunstung!!! Ende: Temp.:
Waschen mit Waschpuffer
3 x mit jeweil (2x 170μL)
ausklopfen und nach dem letzten Schritt absaugen
100 μL Detection-Antikörper Verdünnung in jedes Well pipettieren
0,4 μg/mL Detection-AB 48 μL
Reagent Dil. 10.75 mL
Abdecken mit Parafilm
Inkubation für 2 h bei RT Start: Temp.:
Schütteln bei 272 rpm Ende: Temp.:
Waschen mit Waschpuffer
100 μL Streptavidin-HRP Strept-HRP 52 μL
innerhalb von 60 min Reagent Dil. 10.35 mL
Abdecken mit Parafilm und Alufolie --> Lichtausschluss
Inkubation für 20 min bei RT Start: Temp.:
Schütteln bei 272 rpm Ende: Temp.:
Waschen mit Waschpuffer
100 μL Substrat Verdünnung in jedes Well pipettieren
innerhalb von 15 min Reagenz A 5.1 mL
Reagenz B 5.1 mL
Abdecken mit Parafilm und Alufolie --> Lichtausschluss
Inkubation für 20 min bei RT Start: Temp.:
Ende: Temp.:
50 μL Stop Solution in jedes Well pipettieren
sofortige Messung 
1.  2 x Schüttelschritt
2. Messung der Absorption bei 450 nm und bei 570 nm
 > Differenz: Abs.(450 nm) - Abs.(570 nm)

Appendices  229 
 
     
Appendix D  
Goodness-of-fit plots and visual predictive checks 
 
D.I Pharmacokinetics (Sunitinib and SU12662) ................................................ 231 
D.II PK/PD – sVEGFR-2 (Sunitinib) ................................................................... 234 
D.III PK/PD – sVEGFR-3 (Sunitinib) ................................................................... 235 
D.IV PK/PD – Blood pressure (Sunitinib) ............................................................ 236 
D.V PK/PD – sVEGFR-2 (Pazopanib) ................................................................ 238 
D.VI PK/PD – sVEGFR-3 (Pazopanib) ................................................................ 239 
D.VII PK/PD – Blood pressure (Pazopanib) ......................................................... 240 
D.VIII VPC - Sunitinib pharmacokinetics ............................................................... 242 
D.IX VPC - PK/PD – sVEGFR-2 and sVEGFR-3 (Sunitinib) ............................... 243 
D.X VPC - PK/PD – Blood pressure (Sunitinib) .................................................. 245 
D.XI VPC - PK/PD – sVEGFR-2 and sVEGFR-3 (Pazopanib) ............................ 246 
D.XII VPC - PK/PD – Blood pressure (Pazopanib) ............................................... 247 
  
 
Appendices   231 
 
  __ 
D.I Pharmacokinetics (Sunitinib and SU12662) 
 
Sunitinib 
  
  
 
OBS vs IPRED (A), OBS vs PRED (B), CWRES vs PRED (C), CWRES vs Time (D) , |IWRES| vs 
IPRED (E) 
OBS = Observed values, IPRED = Individual predictions, PRED = Population predictions, CWRES = 
Conditional weighted residuals, IWRES = Individual weighted residuals 
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  __ 
SU12662 
  
  
 
OBS vs IPRED (A), OBS vs PRED (B), CWRES vs PRED (C), CWRES vs Time (D) , |IWRES| vs 
IPRED (E) 
OBS = Observed values, IPRED = Individual predictions, PRED = Population predictions, CWRES = 
Conditional weighted residuals, IWRES = Individual weighted residuals 
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  __ 
Comparison between the two different pharmacokinetic models for sunitinib by  
Yu et al. [110] and Lindauer et al. [109] 
OBS vs IPRED (Lindauer et al) (A), OBS vs PRED (Lindauer et al)  (B), CWRES vs Scatter plot if 
individual predictions (Sunitinib) (C), Scatter plot if population predictions (Sunitinib) (D) 
OBS = Observed values, IPRED = Individual predictions, PRED = Population predictions, CWRES = 
Conditional weighted residuals, IWRES = Individual weighted residuals 
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  __ 
D.II PK/PD – sVEGFR-2 (Sunitinib) 
  
  
 
OBS vs IPRED (A), OBS vs PRED (B), CWRES vs PRED (C), CWRES vs Time (D) , |IWRES| vs 
IPRED (E) 
OBS = Observed values, IPRED = Individual predictions, PRED = Population predictions, CWRES = 
Conditional weighted residuals, IWRES = Individual weighted residuals 
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  __ 
D.III PK/PD – sVEGFR-3 (Sunitinib) 
  
  
 
OBS vs IPRED (A), OBS vs PRED (B), CWRES vs PRED (C), CWRES vs Time (D) , |IWRES| vs 
IPRED (E) 
OBS = Observed values, IPRED = Individual predictions, PRED = Population predictions, CWRES = 
Conditional weighted residuals, IWRES = Individual weighted residuals 
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  __ 
D.IV PK/PD – Blood pressure (Sunitinib) 
 
Systolic blood pressure 
  
  
 
OBS vs IPRED (A), OBS vs PRED (B), CWRES vs PRED (C), CWRES vs Time (D) , |IWRES| vs 
IPRED (E) 
OBS = Observed values, IPRED = Individual predictions, PRED = Population predictions, CWRES = 
Conditional weighted residuals, IWRES = Individual weighted residuals 
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  __ 
Diastolic blood pressure  
  
 
 
 
OBS vs IPRED (A), OBS vs PRED (B), CWRES vs PRED (C), CWRES vs Time (D) , |IWRES| vs 
IPRED (E) 
OBS = Observed values, IPRED = Individual predictions, PRED = Population predictions, CWRES = 
Conditional weighted residuals, IWRES = Individual weighted residuals 
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  __ 
D.V PK/PD – sVEGFR-2 (Pazopanib) 
  
  
 
OBS vs IPRED (A), OBS vs PRED (B), CWRES vs PRED (C), CWRES vs Time (D) , |IWRES| vs 
IPRED (E) 
OBS = Observed values, IPRED = Individual predictions, PRED = Population predictions, CWRES = 
Conditional weighted residuals, IWRES = Individual weighted residuals 
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  __ 
D.VI PK/PD – sVEGFR-3 (Pazopanib) 
  
  
 
OBS vs IPRED (A), OBS vs PRED (B), CWRES vs PRED (C), CWRES vs Time (D) , |IWRES| vs 
IPRED (E) 
OBS = Observed values, IPRED = Individual predictions, PRED = Population predictions, CWRES = 
Conditional weighted residuals, IWRES = Individual weighted residuals 
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  __ 
D.VII PK/PD -  Blood pressure (Pazopanib) 
 
Systolic blood pressure 
  
  
 
OBS vs IPRED (A), OBS vs PRED (B), CWRES vs PRED (C), CWRES vs Time (D) , |IWRES| vs 
IPRED (E) 
OBS = Observed values, IPRED = Individual predictions, PRED = Population predictions, CWRES = 
Conditional weighted residuals, IWRES = Individual weighted residuals 
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  __ 
Diastolic blood pressure 
  
  
 
OBS vs IPRED (A), OBS vs PRED (B), CWRES vs PRED (C), CWRES vs Time (D) , |IWRES| vs 
IPRED (E) 
OBS = Observed values, IPRED = Individual predictions, PRED = Population predictions, CWRES = 
Conditional weighted residuals, IWRES = Individual weighted residuals 
  
242   Appendices 
 
  __ 
D.VIII Visual predicitive check – Sunitinib/SU12662 pharmacokinetics 
 
Sunitinib 
 
 
 
SU12662  
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  __ 
D.IX Visual predictive check - PK/PD – sVEGFR-2 and sVEGFR-3 (Sunitinib) 
 
sVEGFR-2 
 
 
sVEGFR-3 
 
 
 
The black solid lines indicate the mean model prediction and the 90 % prediction 
interval. Dotted lines show the measured mean and interval, respectively. Dark and 
light grey areas represent the respective confidence bands. The dark-grey rectangle 
represents the time on treatment. 
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  __ 
sVEGFR-3 – Stratified by tumor entity 
 
 
mRCC (A) and mCRC (B). 
The black solid lines indicate the mean model prediction and the 90 % prediction 
interval. Dotted lines show the measured mean and interval, respectively. Dark and 
light grey areas represent the respective confidence bands. The dark-grey rectangle 
represents the time on treatment. 
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  __ 
D.X Visual predictive check - PK/PD – Blood pressure (Sunitinib) 
 
 
Systolic (A) and diastolic (B) blood pressure  
The black solid lines indicate the mean model prediction and the 90 % prediction 
interval. Dotted lines show the measured mean and interval, respectively. Dark and 
light grey areas represent the respective confidence bands. The dark-grey rectangle 
represents the time on treatment. 
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  __ 
D.XI Visual predictive check - PK/PD – sVEGFR-2 and sVEGFR-3 (Pazopanib) 
 
sVEGFR-2 
 
 
 
sVEGFR-3  
 
The black solid lines indicate the mean model prediction and the 90 % prediction 
interval. Dotted lines show the measured mean and interval, respectively. Dark and 
light grey areas represent the respective confidence bands. The dark-grey rectangle 
represents the time on treatment. 
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  __ 
D.XII Visual predictive check - PK/PD – Blood pressure (Pazopanib) 
 
 
Systolic (A) and diastolic (B) blood pressure  
The black solid lines indicate the mean model prediction and the 90 % prediction 
interval. Dotted lines show the measured mean and interval, respectively. Dark and 
light grey areas represent the respective confidence bands. The dark-grey rectangle 
represents the time on treatment. 
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  _ 
E.I Overview on documented events  
 
Registered events in patients treated with sunitinib first-line (n = 24) 
ID Comment Event TTE [months] 
NM S1 Died as result of malignancy 1 4.83 
NM S2 Lost to follow-up 0 0.43 
NM S3 Lost to follow-up 0 1.45 
NM S4 Lost to follow-up 0 0.3 
NM S5 
Started new treatment,  
w/o reason 0 
4.17 
NM S6 Lost to follow-up 0 10.09 
NM S13 
Started new treatment,  
w/o reason 0 
12.42 
NM S15 PD documented 1 12.65 
NM S17 Died as result of malignancy 1 5.35 
NM S19 Died as result of malignancy 1 6.87 
NM S21 Censored on 01.07.2015 0 6.6 
NM S22 New lesion during first-line 1 9.07 
NM S24 New lesion during first-line 1 5.88 
NM S25 Died as result of malignancy 1 3.45 
NM S27 Lost to follow-up 0 0.23 
NM S28 Lost to follow-up 0 15.24 
NM S29 PD documented 1 0.76 
NM S30 Died as result of malignancy 1 7.03 
NM S31 Censored (brainmetastases) 0 0.36 
NM S32 Therapy stop due to progression 1 4.11 
NM S33 Died as result of malignancy 1 0.46 
NM S39 New lesion during first-line 1 2.96 
NM S42 Lost to follow-up 0 4.2 
NM S43 Died as result of malignancy 1 0.99 
ID = Dataset Identifier, PD = Progressive disease, TTE = Time-to-event 
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Registered events in patients treated with pazopanib first-line (n = 16) 
ID Comment Event TTE [months] 
NM P7 PD documented 1 12.1 
NM P8 PD documented 1 12.5 
NM P9 
New lesion during first-line 
therapy 
1 5.3 
NM P10 
New lesion during first-line 
therapy 
1 2.6 
NM P11 Censored on 01.07.2015 0 3.8 
NM P12 Censored on 01.07.2015 0 1.5 
NM P16 
Started second-line treatment w/o 
documented PD 
0 5.2 
NM P18 PD documented 1 6.0 
NM P20 Censored on 01.07.2015 0 13.1 
NM P23 Changed treatment due to toxicity 0 8.3 
NM P26 Censored on 01.07.2015 0 3.9 
NM P34 Censored on 01.07.2015 0 7.7 
NM P35 New lesion during first-line 1 1.1 
NM P36 Censored on 01.07.2015 0 5.6 
NM P38 
New lesion during first-line 
therapy 
1 0.7 
NM P40 
Patient died during first-line 
therapy 
1 0.8 
ID = Dataset Identifier, PD = Progressive disease, TTE = Time-to-event 
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F.I PK model Sunitinib/SU12662 
   
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL  
NCOMP =5 
COMP = (DEPOT, DEFDOSE)    
COMP = (OBSLIV)                      
COMP = (CENTRALM)         
COMP = (PERIM)              
COMP = (PERISUN)            
 
$PK 
 
WT = WEIGHT 
IF(WEIGHT.EQ.-99.AND.SEX.EQ.1) WT = 83  ; ET Population mean - male 
IF(WEIGHT.EQ.-99.AND.SEX.EQ.0) WT = 75  ; ET Population mean - female 
ASCL   = (WT/70)**0.75 
ASV    = WT/70 
 
KA  = THETA(1)      
V2  = THETA(2)*ASV * EXP(ETA(1)) 
QH  = THETA(3)*ASCL 
CLP  = THETA(4)*ASCL* EXP(ETA(3)) 
CLM     = THETA(5)*ASCL 
V3      = THETA(6)*ASV * EXP(ETA(2)) 
Q34     = THETA(7)*ASCL  
V4      = THETA(8)*ASV  
FM      = THETA(9)      * EXP(ETA(4)) 
Q25     = THETA(10)*ASCL     
V5      = THETA(11)*ASV     
 
K34 = Q34/V3 
K43 = Q34/V4 
K25 = Q25/V2 
K52 = Q25/V5 
 
S2 = V2 
S3 = V3 
 
$DES 
 
CLIV = (KA*A(1) + QH/V2*A(2))/(QH+CLP) 
 
DADT(1) = -KA*A(1) 
DADT(2) = QH*CLIV-QH/V2*A(2) - K25*A(2) + K52*A(5) 
DADT(3) = FM*CLP*CLIV-CLM/V3*A(3)-K34*A(3) + K43*A(4) 
DADT(4) = K34*A(3)-K43*A(4) 
DADT(5) = K25*A(2) - K52*A(5) 
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PK model Sunitinib/SU12662 – continued  
 
$ERROR 
TY = LOG(F) 
IF(F.LT.0.001) TY = 0.001 
IPRED = TY 
 
IF (CMT.EQ.2) THEN   
W = SQRT(THETA(12)**2)  
Y = IPRED+W*EPS(1) 
ENDIF 
    
IF (CMT.EQ.3) THEN  ; DV log-transformed 
W = SQRT(THETA(13)**2)  
Y = IPRED+W*EPS(2)   
ENDIF 
  
IRES = DV-IPRED 
DEL = 0 
IF(W.EQ.0) DEL = 0.0001 
IWRES = IRES/(W+DEL) 
 
$THETA 
(0, 0.133)   ;1 = KA  
(0, 1820)   ; 2 = V2  
(80) FIX   ; 3 = QH  
(0, 33.9)   ;4 = CLP  
(0, 16.5)   ;5 = CLM  
(0, 730)   ;6 = V3  
(0, 2.75)   ;7 = Q34  
(0, 592)   ;8 = V4  
(0.21) FIX   ;9 = FM  
(0, 0.371)   ;10 = Q25   
(588) FIX   ;11 = V5  
(0,0.367)   ;12 = Prop. Error Suni 
(0,0.281)   ;13 = Prop. Error Metab 
 
$OMEGA BLOCK(4) 
 0.0621    ;1 IIV V2  
 0.0473 0.169   ;2 IIV V3  
 0 -0.0613 0.088   ;3 IIV CLP  
 0 0 -0.0421 0.113   ;4 IIV FM 
 
$SIGMA 
 1 FIX 
 1 FIX 
 
$ESTIMATION SIG=2 SIGL=4 PRINT=1 METHOD=1 INTER MAXEVAL=9999 
NOABORT  
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F.II PK/PD model – sVEGFR-2 (Sunitinib) 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL       
NCOMP=6  
COMP =(DEPOT,DEFDOSE)   
COMP =(OBSLIV)    
COMP =(CENTRALM)   
COMP =(PERIM)    
COMP =(PERISUN)   
COMP =(VEGFR2)    
 
$PK  
 
; Covariate relationships 
 
;;; ALFAABCR2-DEFINITION START 
IF(ABCR2.EQ.1) ALFAABCR2 = 1     
IF(ABCR2.EQ.-99) ALFAABCR2 = 1    
IF(ABCR2.EQ.0) ALFAABCR2 = ( 1 + THETA(8)) 
;;; ALFAABCR2-DEFINITION END 
 
 
;;; ALFASTUDY-DEFINITION START 
IF(STUDY.EQ.1) ALFASTUDY = 1     
IF(STUDY.EQ.2) ALFASTUDY = ( 1 + THETA(7)) 
;;; ALFASTUDY-DEFINITION END 
 
 
;;; ALFAFLT1-DEFINITION START 
IF(FLT1.EQ.0) ALFAFLT1 = 1    
IF(FLT1.EQ.-99) ALFAFLT1 = 1     
IF(FLT1.EQ.1) ALFAFLT1 = ( 1 + THETA(6)) 
;;; ALFAFLT1-DEFINITION END 
 
;;; ALFA-RELATION START 
ALFACOV=ALFAFLT1*ALFASTUDY*ALFAABCR2 
;;; ALFA-RELATION END 
 
 
;PHARMACODYNAMICS  
         
TVBLV2 = THETA(1 
BLV2   = TVBLV2*EXP(ETA(1)) 
  
TVALFA = THETA(2)              
 
ALFA   = TVALFA*ALFVACOV*EXP(ETA(2))    
  
258  Appendices 
   
PK/PD model – sVEGFR-2 (Sunitinib) - continued 
 
TVKOUT  = THETA(3)              
KOUT  = TVKOUT*EXP(ETA(3))   
  
A_0(6) = BLV2 
 
KIN = BLV2*KOUT 
                                              
TVKD = THETA(4 
KD  = TVKD*EXP(ETA(4)) 
  
;PHARMACOKINETICS      
 
KA = 0.133    
V2 = V2X 
QH = QHX 
CLP = CLPX 
CLM = CLMX 
V3 = V3X 
Q34 = Q34X 
V4 = V4X 
FM = FMX 
Q25 = Q25X   
V5 = V5X    
 
K34  = Q34/V3 
K43  = Q34/V4 
K25  = Q25/V2 
K52  = Q25/V5 
 
S2  = V2 
S3  = V3 
 
$DES  
 
CLIV = (KA*A(1) + QH/V2*A(2))/(QH+CLP) 
 
DADT(1) = -KA*A(1) 
DADT(2) = QH*CLIV-QH/V2*A(2) - K25*A(2) + K52*A(5) 
DADT(3) = FM*CLP*CLIV-CLM/V3*A(3)-K34*A(3) + K43*A(4) 
DADT(4) = K34*A(3)-K43*A(4) 
DADT(5) = K25*A(2) - K52*A(5) 
 
 
CONC = A(3)/V3+A(2)/V2  
 
FC= A(3)/V3*(1-0.90)+A(2)/V2*(1-0.95) 
 
IF(FC.LE.0) THEN 
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PK/PD model – sVEGFR-2 (Sunitinib) - continued  
 
BND=0 
  ELSE  
 BND=FC/(KD+FC)         
  ENDIF  
 
INH = BND    
 
SF=1/(1+ALFA*INH) 
 
 DADT(6)= KIN*SF-KOUT*A(6)   
 
$ERROR  
 
IPRE = A(6) 
RBL = IPRE/BLV2            
IRES = DV-IPRE    
W      = THETA(5)*IPRE        
Y       = IPRE+EPS(1)*W 
 DVRL = DV/BLV2            
 
 DEL = 0 
 IF(W.EQ.0) DEL = 1 
 IWRE = IRES/(W+DEL) 
 
$THETA 
(0, 9030)   ; TVBLV2   
(0, 2.31)   ; TValfa   
(0, 0.00428)   ; THKOUT   
(4) FIX   ; THKD     
(0, 0.124)   ; CV      
(-1, -0.565,5)  ; ALFAFLT11 
(-1, -0.328,5)            ; ALFASTUDY1 
(-1, -0.311,5)  ; ALFAABCR21 
 
$OMEGA 0.0388  ; ETABLVR2 
$OMEGA 0 FIX   ; ETAalfa 
$OMEGA 0 FIX   ; ETAKOUT 
$OMEGA 0 FIX   ; ETAKD 
 
$SIGMA 1 FIX  
 
$ESTIMATION SIG=2 PRINT=1 METHOD=1 INTER MAXEVAL=9999 NOABORT 
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F.III PK/PD model – sVEGFR-3 (Sunitinib) 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL       
 
COMP=6 
COMP =(DEPOT,DEFDOSE)   
COMP =(OBSLIV)    
COMP =(CENTRALM)    
COMP =(PERIM)   
COMP =(PERISUN)   
COMP =(VEGFR3)    
 
$PK  
 
; Covariate relationships 
 
;;; BLV3STUDY-DEFINITION START 
IF(STUDY.EQ.1) BLV3STUDY = 1  
IF(STUDY.EQ.2) BLV3STUDY = ( 1 + THETA(6)) 
;;; BLV3STUDY-DEFINITION END 
 
;;; BLV3-RELATION START 
BLV3COV=BLV3STUDY 
;;; BLV3-RELATION END 
 
 
TVBLV3 = THETA(1)               
BLV3   = TVBLV3*BLV3COV*EXP(ETA(1)) 
  
TVALFA = THETA(2)              
ALFA   = TVALFA*EXP(ETA(2))    
 
TVKOUT = THETA(3)               
KOUT   = TVKOUT  
  
A_0(6)=BLV3 
 
KIN = BLV3*KOUT 
                   
TVKD = THETA(4)             ; 
KD = TVKD 
  
K12 = 0.133    
V2      = V2X 
QH     = QHX 
CLP   = CLPX 
CLM  = CLMX 
V3     = V3X   
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PK/PD model – sVEGFR-3 (Sunitinib) – continued  
 
Q34 = Q34X 
V4 = V4X 
FM  = FMX 
Q25 = Q25X   
V5   = V5X    
 
K34  = Q34/V3 
K43  = Q34/V4 
K25  = Q25/V2 
K52  = Q25/V5 
 
S2  = V2 
S3  = V3 
 
$DES  
 
CLIV = (K12*A(1) + QH/V2*A(2))/(QH+CLP) 
 
DADT(1) = -K12*A(1) 
DADT(2) = QH*CLIV-QH/V2*A(2) - K25*A(2) + K52*A(5) 
DADT(3) = FM*CLP*CLIV-CLM/V3*A(3)-K34*A(3) + K43*A(4) 
DADT(4) = K34*A(3)-K43*A(4) 
DADT(5) = K25*A(2) - K52*A(5) 
 
CONC = A(3)/V3+A(2)/V2  
   
FC= A(3)/V3*(1-0.90)+A(2)/V2*(1-0.95) 
 
IF(FC.LE.0) THEN 
 BND=0 
  ELSE  
 BND=FC/(KD+FC)        ; 
  ENDIF  
 
INH = BND     
 
SF=1/(1+ALFA*INH) 
   
DADT(6)= KIN*SF-KOUT*A(6)   
 
$ERROR  
 
IPRE  = A(6) 
RBL    = IPRE/BLV3            
IRES   = DV-IPRE    
W    = THETA(5)*IPRE        
Y       = IPRE+EPS(1)*W 
DVRL  = DV/BLV3   
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PK/PD model – sVEGFR-3 (Sunitinib) – continued  
 
DEL = 0 
IF(W.EQ.0) DEL = 1 
IWRE = IRES/(W+DEL) 
 
$THETA 
(0, 63500)  ; TVBLV3   
(0, 1.74)  ; TValfa   
(0, 0.0054)  ; TVKOUT   
(4) FIX  ; TVKD     
(0, 0.15)  ; CV       
( -0.642) ; BLV3TUMOR 
 
$OMEGA  BLOCK(2) 
0.167   ; ETABLVR3 
0.124 0.258   ; ETAalfa 
 
$SIGMA 1 FIX  
 
$ESTIMATION SIG=2 PRINT=1 METHOD=1 INTER MAXEVAL=9999 NOABORT 
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F.IV PK/PD model – Blood pressure (Sunitinib) 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL 
NCOMP=8 
COMP = (DEPOT, DEFDOSE)    
COMP = (OBSLIV)            
COMP = (PERISUN)            
COMP = (CENTRALM)          
COMP = (PERIM)             
COMP = (SYS)                
COMP = (DIA)                
COMP = (SST)               
 
$PK 
 
TREAT = 1 
IF(BPTRT.EQ.1) TREAT = (1+THETA(14)) 
IF(BPTRT.EQ.2) TREAT = (1+THETA(14)) 
IF(BPTRT.EQ.-99) TREAT = 1 
 
TVBLS   = THETA(1) 
TVBLD   = THETA(2) 
TVALDI  = THETA(3)  
TVALSY  = THETA(4) 
TVKD    = THETA(5) 
TVTAU  = THETA(6) 
TVPS1   = THETA(7) 
TVPS2   = THETA(8) 
TVAMP1  = THETA(9) 
TVAMP2 = THETA(10) * TREAT 
PROP    = THETA(13) 
  
BLS  = TVBLS  *EXP(ETA(1)) 
BLD  = TVBLD  *EXP(ETA(2)) 
ALDI = TVALDI *EXP(ETA(3)) 
ALSY = TVALSY *EXP(ETA(3)*PROP) 
TAU  = TVTAU 
  
KD = TVKD 
  
; PS1  = TVPS1 
AMP1 = TVAMP1*EXP(ETA(4)) 
 
PS2  = TVPS2 
AMP2 = TVAMP2*EXP(ETA(5)) 
 
K12     = 0.133    
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PK/PD model – Blood pressure (Sunitinib) - continued 
 
V2 = V2X 
QH = QHX 
CLP = CLPX 
CLM = CLMX 
V3 = V3X 
Q34 = Q34X 
V4 = V4X 
FM = FMX 
Q25 = Q25X   
V5 = V5X    
 
K34  = Q34/V3 
K43  = Q34/V4 
K25  = Q25/V2 
K52  = Q25/V5 
 
S2  = V2 
S3  = V3 
  
A_0(8)=0 
   
$DES 
;PK MODEL 
CLIV = (K12*A(1) + QH/V2*A(2))/(QH+CLP) 
 
DADT(1) = -K12*A(1) 
DADT(2) = QH*CLIV-QH/V2*A(2) - K25*A(2) + K52*A(5) 
DADT(3) = FM*CLP*CLIV-CLM/V3*A(3)-K34*A(3) + K43*A(4) 
DADT(4) = K34*A(3)-K43*A(4) 
DADT(5) = K25*A(2) - K52*A(5) 
 
CONC = A(3)/V3+A(2)/V2  
   
FC= A(3)/V3*(1-0.90)+A(2)/V2*(1-0.95) 
  
DADT(6) = BLS*(1+(AMP1*COS((TIME+6)*6.283/24-
PS1)+AMP2*COS((TIME+6)*6.283/12-PS2))) 
DADT(7) = BLD*(1+(AMP1*COS((TIME+6)*6.283/24-
PS1)+AMP2*COS((TIME+6)*6.283/12-PS2))) 
 
IF(FC.LE.0) FC=0  
 
 INH     = FC/(KD+FC)                 
 DADT(8) = 1/TAU*INH-1/TAU*A(8)     
  
 
$ERROR 
 FCx  = A(3)/V3*(1-0.90)+A(2)/V2*(1-0.95)   
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PK/PD model – Blood pressure (Sunitinib) - continued 
 
INHx = FCx/(KD+FCx)                         
 
CBLS =BLS*(1+(AMP1*COS((TIME+6)*6.283/24-
PS1)+AMP2*COS((TIME+6)*6.283/12-PS2))) 
CBLD =BLD*(1+(AMP1*COS((TIME+6)*6.283/24-
PS1)+AMP2*COS((TIME+6)*6.283/12-PS2))) 
  
IF(CMT.EQ.6) THEN 
 IPRE = CBLS*(1+ALSY*(INHx+A(8)))    
IRES = DV - IPRE                                    
 W = THETA(11) * IPRE                           
 Y = IPRE+ERR(1)*W 
 DVRL  = DV/BLS 
 RESP  = 1  
 ENDIF 
 
IF(CMT.EQ.7) THEN 
IPRE = CBLD*(1+ALDI*(INHx+A(8 
IRES = DV - IPRE                                  
W = THETA(12) * IPRE                         
Y = IPRE+ERR(1)*W 
DVRL  = DV/BLD                    
RESP  = 2 
ENDIF 
 
 
 DEL = 0 
 IF(W.EQ.0) DEL = 1   
 IWRE = IRES/(W+DEL)    
   
$THETA 
(0, 138)   ; TVBLS  
(0, 82.8)   ; TVBLD  
(0.0637)    ; TVALSY  
(0.0482)   ; TVALDI  
(4) FIX   ; TVKD  
(121) FIX   ; TVTAU  
(0) FIX   ; TVPS1  
(1.4) FIX   ; TVPS2  
(0.025) FIX   ; TVAMP1  
(-0.016) FIX   ; TVAMP2  
(0.0938)   ; PROP_SYS  
(0.0791)   ; PROP_DIA  
(1.21)    ; THSPROP 
(-2.02)  ; BPAMP2 
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PK/PD model – Blood pressure (Sunitinib) - continued 
 
$OMEGA 0.00854  ; ETABLS 
$OMEGA 0.00551  ; ETABLD  
$OMEGA 0.751  ; ETA ALSY/ALDI 
$OMEGA 0 FIX   ; ETAAMP1  
$OMEGA 0 FIX   ; ETAAMP2  
 
$SIGMA 1 FIX  
 
$ESTIMATION SIG=3 PRINT=1 METHOD=1 INTER MAXEVAL=9999 NOABORT  
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F.V PK model Pazopanib 
$SUBROUTINE ADVAN6 TRANS1 TOL=4 
$MODEL 
COMP=(PAZD1)    
COMP=(CENTSN,DEFOBS)  
COMP=(PAZD2)    
COMP=(PERIPH)   
 
$PK  
DOSE = DOS 
 
CL  = THETA(1)*EXP(ETA(1)) 
V2  = THETA(2) 
KAF  = THETA(3)*EXP(ETA(3)) 
KAS  = THETA(4) 
ALAG3 = THETA(5) 
Q24  = THETA(6) 
V4  = THETA(7)*EXP(ETA(2)) 
 
ED50  = THETA(8) 
EMAX  = THETA(9) 
LAMBDA  =THETA(10)/24 
DCRP    = THETA(11) 
TVFD    = (1-(DOSE-200)*EMAX/(ED50+DOSE-200)) 
TVFT    = 1-DCRP+DCRP*EXP(-LAMBDA*TIME) 
TVF     = TVFD*TVFT *EXP(ETA(4)) 
FR      = THETA(12) 
F1      = FR*TVF 
F3      = TVF-F1 
 
K20 = CL/V2 
K24 = Q24/V2 
K42 = Q24/V4 
S2 = V2 
 
$DES  
 
DADT(1) = -KAF*A(1) 
DADT(2) = KAF*A(1)+KAS*A(3)-K20*A(2)-K24*A(2)+K42*A(4) 
DADT(3) = -KAS*A(3) 
DADT(4) = K24*A(2)-K42*A(4) 
 
$ERROR  
 
TY=F 
 
IF(F.LT.0.001) THEN 
TY=0.001 
ENDIF  
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PK model Pazopanib – continued 
 
IPRE = TY 
 
W = THETA(13)*IPRE + THETA(14) 
Y = IPRE + W*EPS(1) 
  
IRES           = DV-IPRE   
DEL            = 0 
IF(W.EQ.0) DEL = 0.0001 
IWRE           = IRES/(W+DEL)  
 
$THETA   
(0.27) FIX ; 1  CL 
(2.43) FIX  ; 2  V2 
(0.40)   FIX ; 3  KAF 
(0.12)   FIX  ; 4  KAS 
(0.98) FIX  ; 5  ALAG3 
(0.99) FIX   ; 6  Q24 
(25.1) FIX   ; 7  V4 
(480) FIX    ; 8  ED50 
(1 FIX)  ; 9  EMAX 
(0.15) FIX ; 10 LAMBDA  (1/day in 1/h) 
(0.501) FIX  ; 11 DCRP 
(0.63) FIX ; 12 FR 
0.064 FIX  ;13 proportional error 
3.1 FIX          ;14 addtive error 
 
$OMEGA   
0.095 FIX  ; 1 CL 
0.96 FIX  ; 2 V4 
1.96 FIX  ; 3 KAF 
0.13 FIX  ; 4 FREL 
 
$SIGMA   
1 FIX 
 
$ESTIMATION METHOD=1 INTER NOABORT MAXEVAL=0 SIG=3 PRINT=1 
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F.VI PK/PD model – sVEGFR-2 (Pazopanib) 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL 
COMP =(PAZD1)           
COMP =(CENTSN,DEFOBS)   
COMP =(PAZD2)           
COMP =(PERIPH)   
COMP = (VEGFR2 
COMP = (AUCV2 
    
$ABBREVIATED COMRES = 2 
 
$PK 
 
TVBLV2 = THETA(1)             
BLV2  = TVBLV2*EXP(ETA(1)) 
  
TVALFA  = THETA(2) 
ALFA    = TVALFA*EXP(ETA(2))    
 
TVKOUT  = THETA(3)             
 KOUT    = TVKOUT  
  
A_0(5) = BLV2 
 
KIN = BLV2*KOUT 
 
CL  = YCLX 
V2      = 2.43 
KAF     = YKAFX 
KAS     = 0.12 
ALAG3   = 0.98 
Q24     = 0.99 
V4      = YV4X 
 
TVF     = YF1X 
FR      = 0.63 
F1      = FR*TVF 
F3      = TVF-F1 
 
K20    = CL/V2 
K24    = Q24/V2 
K42   = Q24/V4 
S2     = V2 
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PK/PD model – sVEGFR-2 (Pazopanib) – continued  
 
$DES 
 
DADT(1) =  -KAF*A(1) 
DADT(2) =   KAF*A(1)+KAS*A(3)-K20*A(2)-K24*A(2)+K42*A(4) 
DADT(3) =  -KAS*A(3) 
DADT(4) =   K24*A(2)-K42*A(4) 
CONC = A(2)/V2  
 
FC= A(2)/V2*(1-0.999)   
 
IF(FC.LE.0) THEN 
 BND=0 
  ELSE  
 BND=FC         
  ENDIF  
INH = BND     
 
SF=1/(1+ALFA*INH) 
   
DADT(5)= KIN*SF-KOUT*A(5)   
DADT(6)= A(3)/1000 
  
$ERROR 
 
AUCV2 = A(6) 
   
IPRE = A(5) 
RB = IPRE/BLV2                  
IRES  = DV-IPRE    
W = THETA(5)        
Y = IPRE+EPS(1)*W 
DVRL = DV/BLV2              
   
DEL= 0 
IF(W.EQ.0) DEL = 1 
IWRE = IRES/(W+DEL) 
 
$THETA 
(0, 9820)  ; TVBLV2   
(0, 22.1)  ; TVALFA   
(0, 0.00377)  ; TVKOUT   
(-846)  ; RES_ADD     
 
$OMEGA 0.0159  ; ETABLVR2 
$OMEGA 0.192  ; ETAalfa 
 
$SIGMA 1 FIX  
$ESTIMATION SIG=2 PRINT=1 METHOD=1 INTER MAXEVAL=9999 NOABORT  
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F.VII PK/PD model – sVEGFR-3 (Pazopanib) 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL 
COMP =(PAZD1)          
COMP =(CENTSN,DEFOBS)   
COMP =(PAZD2)           
COMP =(PERIPH)     
COMP = (VEGFR3) 
COMP = (AUCV2)         
    
$ABBREVIATED COMRES = 2 
 
$PK 
            
TVBLV3  = THETA(1)             
BLV3    = TVBLV3*EXP(ETA(1)) 
  
TVALFA  = THETA(2)             
ALFA    = TVALFA*EXP(ETA(2))    
 
TVKOUT  = THETA(3)            ; 
KOUT    = TVKOUT  
  
A_0(5) = BLV3 
 
KIN = BLV3*KOUT 
                   
 
CL  = YCLX 
V2  = 2.43 
KAF    = YKAFX 
KAS  = 0.12 
ALAG3 = 0.98 
Q24    = 0.99 
V4     = YV4X 
 
TVF    = YF1X 
FR      = 0.63 
F1      = FR*TVF 
F3      = TVF-F1 
 
K20    = CL/V2 
K24    = Q24/V2 
K42    = Q24/V4 
S2     = V2 
  
272  Appendices 
   
PK/PD model – sVEGFR-3 (Pazopanib) -continued 
 
$DES 
 
DADT(1) =  -KAF*A(1) 
DADT(2) =   KAF*A(1)+KAS*A(3)-K20*A(2)-K24*A(2)+K42*A(4) 
DADT(3) =  -KAS*A(3) 
DADT(4) =   K24*A(2)-K42*A(4) 
 
CONC = A(2)/V2  
   
FC= A(2)/V2*(1-0.999) 
 
IF(FC.LE.0) THEN 
 BND=0 
  ELSE  
 BND=FC       
  ENDIF  
 
INH = BND     
;Signal Function 
SF=1/(1+ALFA*INH) 
 
DADT(5)= KIN*SF-KOUT*A(5)   
DADT(6)= A(5)/1000 
  
$ERROR 
 
AUCV3  = A(6) 
IPRE = A(5) 
RBL = IPRE/BLV3         
IRES = DV-IPRE    
W = THETA(5)*IPRE        
Y = IPRE+EPS(1)*W 
DVRL = DV/BLV3                
 
DEL = 0 
IF(W.EQ.0) DEL = 1 
IWRE = IRES/(W+DEL) 
 
$THETA 
(0, 64300)  ; TVBLVR3 
(0, 17.5)  ; TVALFA 
(0, 0.00471)  ; TVKOUT 
0, 0.142)  ; RES_PROP 
 
$OMEGA 0.0543  ; ETABLVR3 
$OMEGA 0.324  ; ETAalfa 
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PK/PD model – sVEGFR-3 (Pazopanib) -continued 
 
$SIGMA 1 FIX  
 
$ESTIMATION SIG=2 PRINT=1 METHOD=1 INTER MAXEVAL=9999 NOABORT  
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F.VIII PK/PD model – Blood pressure (Pazopanib) 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL 
NCOMP=8 
COMP = (PAZD1)          
COMP = (CENTSN,DEFOBS)   
COMP = (PAZD2)           
COMP = (PERIPH)   
COMP = (AUC)   
COMP = (SYS)             
COMP = (DIA)             
COMP = (SST)             
 
$PK 
 
IF(BPDIAG.EQ.1)THEN 
DIAG = (1+THETA(10)) 
ELSE 
DIAG = 1 
ENDIF 
 
TVBLS   = THETA(1) * DIAG 
TVBLD   = THETA(2) 
TVALSY  = THETA(3) 
TVTAU   = THETA(4) 
TVPS1   = THETA(5) 
TVPS2   = THETA(6) 
TVAMP1  = THETA(7) 
TVAMP2  = THETA(8)  
  
 
BLS   = TVBLS *EXP(ETA(1)) 
BLD   = TVBLD *EXP(ETA(2)) 
ALSY  = TVALSY *EXP(ETA(4)) 
ALDI  = TVALSY *EXP(ETA(3)) 
TAU   = TVTAU 
  
PS1   = TVPS1 
AMP1 = TVAMP1*EXP(ETA(5)) 
 
PS2  = TVPS2 
AMP2 = TVAMP2*EXP(ETA(6)) 
  
CL      = YCLX 
V2      = 2.43 
KAF     = YKAFX 
KAS     = 0.12 
ALAG3 = 0.98   
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PK/PD model – Blood pressure (Pazopanib) – continued  
 
Q24   = 0.99 
V4    = YV4X 
 
TVF   = YF1X 
FR  = 0.63 
F1    = FR*TVF 
F3     = TVF-F1 
 
K20   = CL/V2 
K24   = Q24/V2 
K42   = Q24/V4 
S2    = V2 
  
A_0(8) = 0 
   
$DES 
 
DADT(1) = -KAF*A(1) 
DADT(2) =  KAF*A(1)+KAS*A(3)-K20*A(2)-K24*A(2)+K42*A(4) 
DADT(3) = -KAS*A(3) 
DADT(4) =  K24*A(2)-K42*A(4) 
 
CONC = A(2)/V2  
   
FC= A(2)/V2*(1-0.999) 
 
DADT(5) = FC 
 
AUCF    = A(5) 
     
DADT(6) = BLS*(1+(AMP1*COS((TIME+6)*6.283/24 
PS1)+AMP2*COS((TIME+6)*6.283/12-PS2))) 
 
DADT(7) = BLD*(1+(AMP1*COS((TIME+6)*6.283/24-
PS1)+AMP2*COS((TIME+6)*6.283/12-PS2))) 
    
IF(FC.LE.0) FC=0  
 
INH     = FC              
 
DADT(8) = 1/TAU*INH-1/TAU*A(8)     
  
$ERROR 
 
 FCx  = A(2)/V2*(1-0.999) 
 INHx = FCx                      
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PK/PD model – Blood pressure (Pazopanib) – continued  
 
CBLS =BLS*(1+(AMP1*COS((TIME+6)*6.283/24-
PS1)+AMP2*COS((TIME+6)*6.283/12-PS2))) 
CBLD =BLD*(1+(AMP1*COS((TIME+6)*6.283/24-
PS1)+AMP2*COS((TIME+6)*6.283/12-PS2))) 
  
IF(CMT.EQ.6) THEN 
 IPRE  = CBLS*(1+ALSY*(INHx+A(8)))     
 IRES  = DV - IPRE                     
 W  = THETA(9) * IPRE                ; 
 Y  = IPRE+ERR(1)*W 
 DVRL = DV/BLS 
 RESP= 1  
ENDIF 
 
IF(CMT.EQ.7) THEN 
 IPRE  = CBLD*(1+ALDI*(INHx+A(8)))    
 IRES  = DV - IPRE                    
 W  = THETA(9) * IPRE                
 Y  = IPRE+ERR(1)*W 
 DVRL= DV/BLD                       
ENDIF 
 
DEL = 0 
IF(W.EQ.0) DEL = 1   
IWRE = IRES/(W+DEL)  
   
$THETA 
(0, 130)  ; TVBLS  
(0, 80.2)  ; TVBLD  
(0.907)  ; TVALSY  
(121) FIX  ; TVTAU  
(0) FIX  ; TVPS1  
(1.4) FIX  ; TVPS2  
(0.025) FIX  ; TVAMP1  
(-0.016) FIX  ; TVAMP2  
(0.0948)  ; PROP_SYS  
(0.0907)  ; COV effect 
 
$OMEGA 0.00456  ; ETABLS 
$OMEGA 0.00613  ; ETABLD  
$OMEGA 0 FIX  ; ETA ALSY 
$OMEGA 0 FIX   ; ETA ALDI 
$OMEGA 0 FIX   ; ETAAMP1  
$OMEGA 0 FIX   ; ETAAMP2  
 
$SIGMA 1 FIX  
 
;$ESTIMATION SIG=3 PRINT=1 METHOD=1 INTER MAXEVAL=9999 NOABORT  
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F.IX Time-to-event models 
 
Sunitinib patients (mRCC) 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL 
NCOMP  =1 
COMP  = (CUMHAZ)           
 
$PK 
               
TVBLHAZ  = THETA(1)          
BLHAZ  = TVBLHAZ*EXP(ETA(1))       
 
TVBETA   = THETA(2) 
BETA   = TVBETA*EXP(ETA(2))   
  
PMN = 8814.3      
IF(VG2B.GT.PMN)THEN 
VGB = 1 
ELSE 
VGB = 0 
ENDIF 
 
$DES     
 
DADT(1) = BLHAZ*EXP(BETA*VGB)              
  
$ERROR   
                 
CHZ   = A(1) 
  
SUR    = EXP(-CHZ  
HAZNOW = BLHAZ*EXP(BETA*VGB)        
                       
IF(DV.EQ.1) THEN  
 Y = HAZNOW*SUR                   
ELSE  
 Y = SUR                       
ENDIF                
   
$THETA 
(0, 0.00007)  ;  TVBLHAZ   
(1.45)   ;  TVBETA    
 
$OMEGA 0 FIX   ;  ETA_HAZ 
$OMEGA 0 FIX   ;  ETA_BETA 
 
$ESTIMATION SIG=2 SIGL=6 MAXEVAL=9999 METHOD=COND LAPLACE LIKE  
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Sunitinib and pazopanib patients (mRCC) 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL 
NCOMP=12 
COMP = (SUND)              
COMP = (OBSLIV)            
COMP = (PERISUN)           
COMP = (CENTRALM)          
COMP = (PERIM)             
COMP = (PAZD1)            
COMP = (CENTSN)           
COMP = (PAZD2)           
COMP = (PERIPH)   
COMP = (VEGFR2)            
COMP = (AUCV2)             
COMP = (CUMHAZ)            
 
$PK 
 
TVBLHAZ = THETA(1)          
BLHAZ = TVBLHAZ*EXP(ETA(1))       
 
TVBETA  = THETA(2) 
BETA  = TVBETA*EXP(ETA(2))   
 
;PHARMACOKINETICS SUNITINIB 
 
K12_S  = 0.133    
V2_S  = V2X 
QH_S  = QHX 
CLP_S  = CLPX 
CLM_S = CLMX 
V3_S      = V3X 
Q34_S     = Q34X 
V4_S      = V4X 
FM_S      = FMX 
Q25_S     = Q25X   
V5_S      = V5X    
 
K34_S = Q34_S/V3_S 
K43_S = Q34_S/V4_S 
K25_S = Q25_S/V2_S 
K52_S = Q25_S/V5_S 
 
S2 = V2_S 
S3 = V3_S 
 
;PHARMACOKINETIC PAZOPANIB     
 
CL_P      = YCLX 
V2_P     = 2.43 
KAF_P   = YKAFX 
KAS_P    = 0.12  
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Sunitinib and pazopanib patients (mRCC) – continued  
 
ALAG8   = 0.98 
Q24_P   = 0.99 
V4_P      = YV4X 
TVF_P   = YF1X 
FR_P        = 0.63 
F6       = FR_P*TVF_P 
F8      = TVF_P-F6 
 
K20_P   = CL_P/V2_P 
K24_P   = Q24_P/V2_P 
K42_P   = Q24_P/V4_P 
S7       = V2_P     
 
;PHARMACODYNAMICS  sVEGFR2 
 
BLV2   = BSL2X 
ALFA   = AL2X    
 
IF(TRTM.EQ.1)THEN   ; Sunitinib  
KOUT    = 0.0043 
ENDIF 
 
IF(TRTM.EQ.2)THEN   ; Pazopanib  
KOUT    = 0.0038 
ENDIF 
 
KD      = 4 
 
BASE   = BLV2/1000 
   
A_0(10) = BLV2 
 
KIN    = BLV2*KOUT 
 
$DES   
   
;PHARMACOKINETICS SUNITINIB 
 
IF(TRTM.EQ.1) THEN 
 
CLIV = (K12_S*A(1) + QH_S/V2_S*A(2))/(QH_S+CLP_S) 
 
DADT(1) = -K12_S*A(1) 
DADT(2) = QH_S*CLIV-QH_S/V2_S*A(2) - K25_S*A(2) + K52_S*A(5) 
DADT(3) = FM_S*CLP_S*CLIV-CLM_S/V3_S*A(3)-K34_S*A(3) + K43_S*A(4) 
DADT(4) = K34_S*A(3)-K43_S*A(4) 
DADT(5) = K25_S*A(2) - K52_S*A(5) 
 
DADT(6) = 0 
DADT(7) = 0 
DADT(8) = 0 
DADT(9) = 0  
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Sunitinib and pazopanib patients (mRCC) 
 
ENDIF 
 
;;;;TOTAL DRUG PLASMA CONCENTRATION   
CONCS = A(3)/V3_S+A(2)/V2_S  
   
;;;;FREE DRUG CONCENTRATION 
FCS  = A(3)/V3_S*(1-0.90)+A(2)/V2_S*(1-0.95) 
 
;PHARMACOKINETICS PAZOPANIB 
 
IF(TRTM.EQ.2) THEN 
 
DADT(1) = 0 
DADT(2) = 0 
DADT(3) = 0 
DADT(4) = 0 
DADT(5) = 0 
 
DADT(6) =  -KAF_P*A(6) 
DADT(7) =   KAF_P*A(6)+KAS_P*A(8)-K20_P*A(7)-K24_P*A(7)+K42_P*A(9) 
DADT(8) =  -KAS_P*A(8) 
DADT(9) =   K24_P*A(7)-K42_P*A(9) 
 
ENDIF 
 
CONCP = A(7)/V2_P  
   
FCP= A(7)/V2_P*(1-0.999) 
 
; PHARMACODYNAMIC MODEL 
 
BND=0 
 
;Sunitinib 
IF(TRTM.EQ.1.AND.FCS.GT.0)THEN 
BND=FCS/(KD+FCS)        
ENDIF  
 
;Pazopanib 
IF(TRTM.EQ.2.AND.FCP.GT.0)THEN 
BND=FCP        
ENDIF  
 
INH = BND     
 
SF=1/(1+ALFA*INH)   ; Inverse linear model 
   
DADT(10) = KIN*SF-KOUT*A(10)   
DADT(11) = A(10)/1000 
 
CV2     = A(10)/1000 
RV2     = A(10)/BLV2 
  
Appendices  281 
 
   
Sunitinib and pazopanib patients (mRCC) 
 
DADT(12) = BLHAZ*EXP(BETA*CV2)              
  
$ERROR   
CV2x   = A(10)/1000                                
CHZ    = A(12)                    
                                    
SUR     = EXP(-CHZ)               
 
IF(DV.EQ.1) THEN  
 HAZNOW = BLHAZ*EXP(BETA*CV2x)        
 Y = HAZNOW*SUR                  
ELSE  
 Y = SUR                          
ENDIF                
   
$THETA 
(0, 0.00002)  ; TVBLHAZ   
(0.292)  ; TVBETA    
 
$OMEGA 0 FIX  ; ETA_HAZ 
$OMEGA 0 FIX  ; ETA_BETA 
 
$ESTIMATION SIG=2 SIGL=6 MAXEVAL=9999 METHOD=COND LAPLACE LIKE  
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F.X Adverse event models 
 
Myelosuppression (Sunitinib only, mRCC) 
 
$ABBREVIATED COMRES = 1 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL 
NCOMP = 9 
COMP=(DEPOTD)  
COMP=(CENTRAL)  
COMP=(PERIPH)  
COMP=(METC) 
COMP=(METP) 
COMP=(G0) 
COMP=(G1) 
COMP=(G2) 
COMP=(G3) 
 
$PK    
 
IF(NEWIND.NE.2) THEN 
PSDV   = 0 
COM(1) = 0 
ENDIF 
 
IF(NEWIND.NE.2.AND.TIME.EQ.0) F6 =1 
 
PRDV = PSDV 
 
IF(PRDV.EQ.1) COM(1) = 0 
IF(PRDV.EQ.2) COM(1) = 1 
IF(PRDV.EQ.3) COM(1) = 2 
IF(PRDV.EQ.4) COM(1) = 3 
 
;;-------- PK Model ---------- 
 
KA  = 0.133 * 24    
V2  = V2X  
QH  = QHX   * 24 
CLP   = CLPX  * 24 
CLM  = CLMX  * 24 
V3  = V3X 
Q34  = Q34X  * 24 
V4  = V4X 
FM  = FMX 
Q25  = Q25X  * 24 
V5  = V5X    
 
K34   = Q34/V3 
K43   = Q34/V4 
K25   = Q25/V2 
K52   = Q25/V5   
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Myelosuppression (Sunitinib only, mRCC) – continued  
 
S2   = V2 
S3   = V3 
 
;;-------- AE Model ---------- 
 
F6 = 0 
F7 = 0 
F8 = 0 
F9 = 0 
 
IF(COM(1).EQ.0) F6 = 1 
IF(COM(1).EQ.1) F7 = 1 
IF(COM(1).EQ.2) F8 = 1 
IF(COM(1).EQ.3) F9 = 1 
 
 
; Typical values for rate constants / probabilities 
 
TVK01  = THETA(1)  
TVK12  = THETA(2) 
TVK23  = THETA(3)  
TVKB  = THETA(4) 
 
TVGAM = THETA(5) 
TVEFF  = THETA(6) 
 
; Individual Parameters 
 
K01   = TVK01  * EXP(ETA(1))  
K12   = TVK12 
K23   = TVK23 
 
KB    = TVKB 
GAM   = TVGAM 
EFF   = TVEFF 
   
$DES 
 
;;-------- PK Model ---------- 
 
CLIV = (KA*A(1) + QH/V2*A(2))/(QH+CLP) 
 
DADT(1) = -KA*A(1) 
DADT(2) = QH*CLIV-QH/V2*A(2) - K25*A(2) + K52*A(5) 
DADT(3) = FM*CLP*CLIV-CLM/V3*A(3)-K34*A(3) + K43*A(4) 
DADT(4) = K34*A(3)-K43*A(4) 
DADT(5) = K25*A(2) - K52*A(5) 
  
CONC = A(3)/V3+A(2)/V2  
   
FC= A(3)/V3*(1-0.90)+A(2)/V2*(1-0.95) 
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Myelosuppression (Sunitinib only, mRCC) 
 
;;-------- AE Model ---------- 
 
K01_F = K01 * EXP(GAM*T)  
K12_F = K12 * EXP(GAM*T)   
K23_F = K23 * EXP(GAM*T)   
 
KB10  = KB   * EXP(FC*EFF) 
KB21  = KB   * EXP(FC*EFF) 
KB32  = KB   * EXP(FC*EFF) 
 
DADT(6) = A(7)*KB10                   - A(6) * K01_F                    ; No Grade 
DADT(7) = A(6)*K01_F  + A(8)*KB21     - A(7) * (KB10 + K12_F)     ; Grade 1 
DADT(8) = A(7)*K12_F  + A(9)*KB32     - A(8) * (KB21 + K23_F)     ; Grade 2 
DADT(9) = A(8)*K23_F                  - A(9) *  KB32                     ; Grade 3/4 
 
$ERROR        
      
Y = 1 
IF(DV.EQ.1.AND.CMT.EQ.0) Y = A(6) 
IF(DV.EQ.2.AND.CMT.EQ.0) Y = A(7) 
IF(DV.EQ.3.AND.CMT.EQ.0) Y = A(8) 
IF(DV.EQ.4.AND.CMT.EQ.0) Y = A(9) 
 
PB0 = A(6) 
PB1 = A(7) 
PB2 = A(8) 
PB3 = A(9) 
 
; Cumulative Probabilities 
 
CUP0 = PB0 
CUP1 = PB0 + PB1 
CUP2 = PB0 + PB1 + PB2 
CUP3 = PB0 + PB1 + PB2 + PB3 
 
IF(ICALL.EQ.4) THEN 
 IF(CMT.EQ.0)THEN 
  CALL RANDOM (2,R) 
     IF(R.LE.CUP0)                  DV = 1     ;grade 0 
     IF(R.GT.CUP0.AND.R.LE.CUP1)    DV = 2   ;grade 1 
     IF(R.GT.CUP1.AND.R.LE.CUP2)    DV = 3   ;grade 2 
     IF(R.GT.CUP2)                  DV = 4    ;grade 3/4 
 ENDIF 
ENDIF 
 
PSDV = DV 
$THETA 
(0, 0.0149)  ;1 TVK01 
(0, 0.101)  ;2 TVK12 
(0, 0.438)  ;3 TVK23 
(0, 0.058)  ;4 TVKB    
(-0.0207)  ;5 TVGAM    
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(-0.337) ;6 EFF 
 
$OMEGA  
 0 FIX  ; OM_K01 
 
$ESTIMATION SIG=2 MAXEVAL=9999 PRINT=1 METHOD=1 LAPLACIAN LIKE  
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Fatigue (Sunitinib only, mRCC) 
 
$ABBREVIATED COMRES = 1 
 
$SUBROUTINE ADVAN6 TOL=4 
 
$MODEL 
NCOMP = 9 
COMP=(DEPOTD)  
COMP=(CENTRAL)  
COMP=(PERIPH)  
COMP=(METC) 
COMP=(METP) 
COMP=(G0) 
COMP=(G1) 
COMP=(G2) 
COMP=(G3) 
 
$PK    
 
IF(NEWIND.NE.2) THEN 
PSDV   = 0 
COM(1) = 0 
ENDIF 
 
IF(NEWIND.NE.2.AND.TIME.EQ.0) F6 =1 
 
 
PRDV = PSDV 
 
IF(PRDV.EQ.1) COM(1) = 0 
IF(PRDV.EQ.2) COM(1) = 1 
IF(PRDV.EQ.3) COM(1) = 2 
IF(PRDV.EQ.4) COM(1) = 3 
 
;;-------- PK Model ---------- 
 
KA      = 0.133    
V2       = V2X 
QH       = QHX 
CLP  = CLPX 
CLM  = CLMX 
V3  = V3X 
Q34  = Q34X 
V4  = V4X 
FM  = FMX 
Q25  = Q25X   
V5  = V5X    
 
K34   = Q34/V3 
K43   = Q34/V4 
K25   = Q25/V2 
K52   = Q25/V5 
 
S2   = V2 
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Fatigue (Sunitinib only, mRCC) – continued  
 
S3   = V3 
 
;;-------- AE Model ---------- 
 
F6 = 0 
F7 = 0 
F8 = 0 
F9 = 0 
 
IF(COM(1).EQ.0) F6 = 1 
IF(COM(1).EQ.1) F7 = 1 
IF(COM(1).EQ.2) F8 = 1 
IF(COM(1).EQ.3) F9 = 1 
 
 
; Typical values for rate constants / probabilities 
 
TVK01     = THETA(1)  
TVK12     = THETA(2) 
TVKB      = THETA(3) 
 
TVGAM     = THETA(4) 
 
; Individual Parameters 
 
K01  = TVK01  * EXP(ETA(1))  
K12  = TVK12 
K23  = TVK12 
 
KB   = TVKB 
GAM  = TVGAM 
   
$DES 
;;-------- PK Model ---------- 
 
  CLIV = (KA*A(1) + QH/V2*A(2))/(QH+CLP) 
 
DADT(1) = -KA*A(1) 
DADT(2) = QH*CLIV-QH/V2*A(2) - K25*A(2) + K52*A(5) 
DADT(3) = FM*CLP*CLIV-CLM/V3*A(3)-K34*A(3) + K43*A(4) 
DADT(4) = K34*A(3)-K43*A(4) 
DADT(5) = K25*A(2) - K52*A(5) 
 
CONC = A(3)/V3+A(2)/V2  
   
FC= A(3)/V3*(1-0.90)+A(2)/V2*(1-0.95) 
 
;;-------- AE Model ---------- 
 
K01_F = K01 * EXP(GAM*T)  
K12_F = K12 * EXP(GAM*T)  
K23_F = K23 * EXP(GAM*T)  
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Fatigue (Sunitinib only, mRCC) – continued  
 
KB10  = KB   
KB21  = KB 
KB32  = KB 
 
DADT(6) = A(7)*KB10                   - A(6) * K01_F                       ; No Grade 
DADT(7) = A(6)*K01_F  + A(8)*KB21     - A(7) * (KB10 + K12_F)   ; Grade 1 
DADT(8) = A(7)*K12_F  + A(9)*KB32     - A(8) * (KB21 + K23_F)          ; Grade 2 
DADT(9) = A(8)*K23_F                  - A(9) *  KB32                   ; Grade 3/4 
 
$ERROR        
      
Y = 1 
IF(DV.EQ.1.AND.CMT.EQ.0) Y = A(6) 
IF(DV.EQ.2.AND.CMT.EQ.0) Y = A(7) 
IF(DV.EQ.3.AND.CMT.EQ.0) Y = A(8) 
IF(DV.EQ.4.AND.CMT.EQ.0) Y = A(9) 
 
PB0 = A(6) 
PB1 = A(7) 
PB2 = A(8) 
PB3 = A(9) 
 
; Cumulative Probabilities 
 
CUP0 = PB0 
CUP1 = PB0 + PB1 
CUP2 = PB0 + PB1 + PB2 
CUP3 = PB0 + PB1 + PB2 + PB3 
  
PSDV = DV 
$THETA 
(0, 0.00938) ;1 TVK01 
(0, 0.0937) ;2 TVK12 
(0, 0.0704) ;4 TVKB    
(-0.0134) ;5 TVGAM    
 
$OMEGA  
 0 FIX  ; OM_K01 
 
$ESTIMATION SIG=2 MAXEVAL=9999 PRINT=1 METHOD=1 LAPLACIAN LIKE  
 
